Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
30500.0 | 2013-11-15 00:00:00 UTC | Baxter Advances on Pivotal Study - Analyst Blog | ABR | https://www.nasdaq.com/articles/baxter-advances-on-pivotal-study-analyst-blog-2013-11-15 | nan | nan | Baxter International Inc. ( BAX ) revealed that it has completed enrolling patients in its Phase III PROLOG-ATE clinical trial evaluating the efficacy of BAX 855, an extended half-life, recombinant factor VIII (rFVIII) protein used for hemophilia A treatment. Following the announcement of the news, BAX shares moved up 2.6% to $67.60 on Nov 14.
Built on the same protein used in Advate [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method], BAX 855 has been modified to include the PEGylation technology from Nektar Therapeutics ( NKTR ). The PEGylation technology is designed to extend the duration of activity of proteins in the body.
This pivotal trial intends to study the efficiency of the BAX 855 compound in lowering annualized bleed rates (ABR) when administered on prophylaxis and on-demand treatment schedules. Additionally, the trial will also assess its safety and pharmacokinetic profile. Management claims that no inhibitors or safety issues have been registered till date.
Upon successful completion of the trial, Baxter intends to file for regulatory approvals in late 2014 and plans to start a continuation study for all patients who will complete the Phase II/III study. Moreover, the company also plans to initiate a BAX 855 study among pediatric patients in 2014.
The Phase I trial analyzed the safety, tolerability and pharmacokinetics of the BAX 855 compound. Results demonstrated that the duration of activity of the drug in the body was roughly 1.5 times higher than the Advate. Moreover, no adverse clinical events were reported during the course of the trial.
Baxter's BioScience business processes recombinant and plasma-based proteins to treat hemophilia. Milestone achievement for pipeline products represents a significant opportunity for top-line growth for BAX.
In the last reported quarter, revenues from the BioScience segment increased 6% year over year to $1.6 billion. Hemophilia, the largest sub-unit, generated revenues of $851 million, up 9% from the prior-year quarter. Growth was driven by higher demand for Advate used in Hemophilia and Feiba, along with benefits from apt timings of international tenders.
Currently, Baxter carries a Zacks Rank #3 (Hold). Stocks that are performing relatively better in the medical products industry include Hill-Rom Holdings, Inc. ( HRC ), and NuVasive, Inc. ( NUVA ). Both of them carry a Zacks Rank #1 (Strong Buy).
BAXTER INTL (BAX): Free Stock Analysis Report
HILL-ROM HLDGS (HRC): Free Stock Analysis Report
NEKTAR THERAP (NKTR): Free Stock Analysis Report
NUVASIVE INC (NUVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This pivotal trial intends to study the efficiency of the BAX 855 compound in lowering annualized bleed rates (ABR) when administered on prophylaxis and on-demand treatment schedules. Built on the same protein used in Advate [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method], BAX 855 has been modified to include the PEGylation technology from Nektar Therapeutics ( NKTR ). Growth was driven by higher demand for Advate used in Hemophilia and Feiba, along with benefits from apt timings of international tenders. | This pivotal trial intends to study the efficiency of the BAX 855 compound in lowering annualized bleed rates (ABR) when administered on prophylaxis and on-demand treatment schedules. Currently, Baxter carries a Zacks Rank #3 (Hold). Stocks that are performing relatively better in the medical products industry include Hill-Rom Holdings, Inc. ( HRC ), and NuVasive, Inc. ( NUVA ). | This pivotal trial intends to study the efficiency of the BAX 855 compound in lowering annualized bleed rates (ABR) when administered on prophylaxis and on-demand treatment schedules. Baxter International Inc. ( BAX ) revealed that it has completed enrolling patients in its Phase III PROLOG-ATE clinical trial evaluating the efficacy of BAX 855, an extended half-life, recombinant factor VIII (rFVIII) protein used for hemophilia A treatment. Upon successful completion of the trial, Baxter intends to file for regulatory approvals in late 2014 and plans to start a continuation study for all patients who will complete the Phase II/III study. | This pivotal trial intends to study the efficiency of the BAX 855 compound in lowering annualized bleed rates (ABR) when administered on prophylaxis and on-demand treatment schedules. Baxter International Inc. ( BAX ) revealed that it has completed enrolling patients in its Phase III PROLOG-ATE clinical trial evaluating the efficacy of BAX 855, an extended half-life, recombinant factor VIII (rFVIII) protein used for hemophilia A treatment. Upon successful completion of the trial, Baxter intends to file for regulatory approvals in late 2014 and plans to start a continuation study for all patients who will complete the Phase II/III study. |
30501.0 | 2013-08-09 00:00:00 UTC | Arbor Realty Trust (ABR) Ex-Dividend Date Scheduled for August 12, 2013 | ABR | https://www.nasdaq.com/articles/arbor-realty-trust-abr-ex-dividend-date-scheduled-august-12-2013-2013-08-09 | nan | nan | Arbor Realty Trust ( ABR ) will begin trading ex-dividend on August 12, 2013. A cash dividend payment of $0.13 per share is scheduled to be paid on September 03, 2013. Shareholders who purchased ABR stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 8.33% increase over the prior quarter. At the current stock price of $7.54, the dividend yield is 6.9%.
The previous trading day's last sale of ABR was $7.54, representing a -12.33% decrease from the 52 week high of $8.60 and a 59.75% increase over the 52 week low of $4.72.
ABR is a part of the Consumer Services sector, which includes companies such as Simon Property Group, Inc. ( SPG ) and Public Storage ( PSA ). ABR's current earnings per share, an indicator of a company's profitability, is $.32. Zacks Investment Research reports ABR's forecasted earnings growth in 2013 as -3.39%, compared to an industry average of -6.1%.
For more information on the declaration, record and payment dates, visit the ABR Dividend History page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABR stock prior to the ex-dividend date are eligible for the cash dividend payment. ABR is a part of the Consumer Services sector, which includes companies such as Simon Property Group, Inc. ( SPG ) and Public Storage ( PSA ). Zacks Investment Research reports ABR's forecasted earnings growth in 2013 as -3.39%, compared to an industry average of -6.1%. | Shareholders who purchased ABR stock prior to the ex-dividend date are eligible for the cash dividend payment. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Arbor Realty Trust ( ABR ) will begin trading ex-dividend on August 12, 2013. | Shareholders who purchased ABR stock prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of ABR was $7.54, representing a -12.33% decrease from the 52 week high of $8.60 and a 59.75% increase over the 52 week low of $4.72. For more information on the declaration, record and payment dates, visit the ABR Dividend History page. | Shareholders who purchased ABR stock prior to the ex-dividend date are eligible for the cash dividend payment. Arbor Realty Trust ( ABR ) will begin trading ex-dividend on August 12, 2013. The previous trading day's last sale of ABR was $7.54, representing a -12.33% decrease from the 52 week high of $8.60 and a 59.75% increase over the 52 week low of $4.72. |
30502.0 | 2013-08-02 00:00:00 UTC | Sector Update: Financial | ABR | https://www.nasdaq.com/articles/sector-update-financial-2013-08-02 | nan | nan | Financial shares are mixed in today's pre-market session as investors are braced for another indicator on today's jobs climate. The July nonfarm payrolls are due out at 8:30 a.m. and economists expect about 180,000 new jobs with a jobless rate falling to 7.5% from 7.6%. If payrolls are significantly above that number, investors will likely start to anticipate tapering in September.
In financial stocks news, Arbor Realty Trust, Inc. ( ABR ) reported Q2 2013 net income of $3 million, or $0.07 per share, compared to a net income of $15.5 million, or $0.62 per share, in the same period last year. No analyst estimates were available for comparison.
The company's Board of Directors also declared a quarterly cash dividend of $0.13 per share of common stock for the second quarter, payable on September 3, 2013 to common shareholders of record on August 14, 2013. The ex-dividend date is August 12, 2013. The Q2 dividend represents an increase of 8% from first quarter 2013. ABR is flat at $7.51 in pre-market.
And, North Star Realty Finance ( NRF ) reports a surpirse Q2 net loss to common stockholders for Q2 2013 was $12.6 million, or $0.06 per diluted share, compared to a net loss of $77.5 million, or $0.62 per diluted share for Q2 2012.
Analysts expected a gain of $0.22 per share on $168 million in revenue for Q2. NRF is flat at $9.78 in pre-market trade, with a 52-week range of $5.35 to $10.30.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In financial stocks news, Arbor Realty Trust, Inc. ( ABR ) reported Q2 2013 net income of $3 million, or $0.07 per share, compared to a net income of $15.5 million, or $0.62 per share, in the same period last year. ABR is flat at $7.51 in pre-market. The July nonfarm payrolls are due out at 8:30 a.m. and economists expect about 180,000 new jobs with a jobless rate falling to 7.5% from 7.6%. | In financial stocks news, Arbor Realty Trust, Inc. ( ABR ) reported Q2 2013 net income of $3 million, or $0.07 per share, compared to a net income of $15.5 million, or $0.62 per share, in the same period last year. ABR is flat at $7.51 in pre-market. And, North Star Realty Finance ( NRF ) reports a surpirse Q2 net loss to common stockholders for Q2 2013 was $12.6 million, or $0.06 per diluted share, compared to a net loss of $77.5 million, or $0.62 per diluted share for Q2 2012. | In financial stocks news, Arbor Realty Trust, Inc. ( ABR ) reported Q2 2013 net income of $3 million, or $0.07 per share, compared to a net income of $15.5 million, or $0.62 per share, in the same period last year. ABR is flat at $7.51 in pre-market. The company's Board of Directors also declared a quarterly cash dividend of $0.13 per share of common stock for the second quarter, payable on September 3, 2013 to common shareholders of record on August 14, 2013. | ABR is flat at $7.51 in pre-market. In financial stocks news, Arbor Realty Trust, Inc. ( ABR ) reported Q2 2013 net income of $3 million, or $0.07 per share, compared to a net income of $15.5 million, or $0.62 per share, in the same period last year. The company's Board of Directors also declared a quarterly cash dividend of $0.13 per share of common stock for the second quarter, payable on September 3, 2013 to common shareholders of record on August 14, 2013. |
30503.0 | 2013-02-27 00:00:00 UTC | Arbor Realty Trust (ABR) Ex-Dividend Date Scheduled for March 01, 2013 | ABR | https://www.nasdaq.com/articles/arbor-realty-trust-abr-ex-dividend-date-scheduled-march-01-2013-2013-02-27 | nan | nan | Arbor Realty Trust ( ABR ) will begin trading ex-dividend on March 01, 2013. A cash dividend payment of $0.12 per share is scheduled to be paid on March 12, 2013. Shareholders who purchased ABR stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 9.09% increase over the prior quarter.
The previous trading day's last sale of ABR was $7.53, representing a -7.27% decrease from the 52 week high of $8.12 and a 64.41% increase over the 52 week low of $4.58.
ABR is a part of the Consumer Services sector, which includes companies such as Simon Property Group, Inc. ( SPG ) and American Tower Corporation (REIT) ( AMT ). ABR's current earnings per share, an indicator of a company's profitability, is $.85. Zacks Investment Research reports ABR's forecasted earnings growth in 2013 as -11.02%, compared to an industry average of -10.5%.
For more information on the declaration, record and payment dates, visit the ABR Dividend History page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABR stock prior to the ex-dividend date are eligible for the cash dividend payment. ABR is a part of the Consumer Services sector, which includes companies such as Simon Property Group, Inc. ( SPG ) and American Tower Corporation (REIT) ( AMT ). Zacks Investment Research reports ABR's forecasted earnings growth in 2013 as -11.02%, compared to an industry average of -10.5%. | Shareholders who purchased ABR stock prior to the ex-dividend date are eligible for the cash dividend payment. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Arbor Realty Trust ( ABR ) will begin trading ex-dividend on March 01, 2013. | Shareholders who purchased ABR stock prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of ABR was $7.53, representing a -7.27% decrease from the 52 week high of $8.12 and a 64.41% increase over the 52 week low of $4.58. For more information on the declaration, record and payment dates, visit the ABR Dividend History page. | Shareholders who purchased ABR stock prior to the ex-dividend date are eligible for the cash dividend payment. Arbor Realty Trust ( ABR ) will begin trading ex-dividend on March 01, 2013. The previous trading day's last sale of ABR was $7.53, representing a -7.27% decrease from the 52 week high of $8.12 and a 64.41% increase over the 52 week low of $4.58. |
30504.0 | 2013-02-08 00:00:00 UTC | Leon Cooperman Buys 2 Real Estate-Related Stocks | ABR | https://www.nasdaq.com/articles/leon-cooperman-buys-2-real-estate-related-stocks-2013-02-08 | nan | nan | Leon Cooperman , chairman and CEO of New York-based Omega Advisors, has purchased shares of two new companies: Arbor Realty Trust ( ABR ) and Home Loan Servicing Solutions Ltd. ( HLSS ), according to GuruFocus Real Time Picks .
Cooperman took an 8.23% stake in Arbor Realty Trust, equal to 2,572,136 shares, at an average purchase price of $7.14, in a transaction that took place on Feb. 8.
New York-based Arbor Realty Trust focuses on a variety of real estate-related investments, from mortgage-based loans to equity investments. In the last year, its market value has increased by nearly 57%.
The trust released its third quarter results on Nov. 2, in which it reported net income of $2.1 million, or $0.07 per share, compared to a net loss of $2.4 million, or $0.10 per share, the previous year. It also had interest income of $20.03 million, compared to $18.52 million the previous year.
The trust was also the first to bring a collateralized debt obligation (CDO), a risky asset that played a key role in the global financial meltdown of 2007, to market in 2013, according to Reuters. It is offering $260 million worth of the securities.
Arbor Realty Trust, a real estate investment trust (REIT), pays a dividend of $0.11 quarterly. Its P/E stands at 2.1, P/B at 0.9 and P/S of 1.8.
His second buy was a 2.03% stake in Home Loan Servicing Solutions Ltd. on Dec. 31. He purchased 620,000 shares for $18.78 on average. The stock, up 17% since then, is trading for $22 per share on Friday afternoon.
Home Loan Servicing Solutions, based in the Cayman Islands, owns non-agency mortgage servicing assets collateralized by residential real estate and has been in operation for about a year. In its fourth quarter results released Feb. 7, the company reported $14.3 million in net income, or $0.44 per ordinary share, in the fourth quarter, compared to a loss of $191 million, or a loss of $9.55 per ordinary share, in the fourth quarter of 2011. Fourth quarter revenue totaled $27.64 million.
The company has paid a dividend since its first quarter of operations. On Feb. 7, its board declared a monthly dividend of $0.13 per ordinary share for February and March 2013.
"Reflecting on our first year of operations, I believe that we have delivered on our plan to provide our shareholders with earnings and dividends that are particularly attractive given the stability and low risk of our assets which the ABS markets are starting to reward," said Home Loan Servicing Solutions Chairman William Erbey.
GuruFocus Real Time Picks alerts you for the stock purchases and sales that Gurus have made within the last two days. Follow your favorite Gurus closely with GuruFocus' Premium Membership! If you are not a Premium Member, we invite you for a 7-Day Free Trial .About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Leon Cooperman , chairman and CEO of New York-based Omega Advisors, has purchased shares of two new companies: Arbor Realty Trust ( ABR ) and Home Loan Servicing Solutions Ltd. ( HLSS ), according to GuruFocus Real Time Picks . The trust was also the first to bring a collateralized debt obligation (CDO), a risky asset that played a key role in the global financial meltdown of 2007, to market in 2013, according to Reuters. "Reflecting on our first year of operations, I believe that we have delivered on our plan to provide our shareholders with earnings and dividends that are particularly attractive given the stability and low risk of our assets which the ABS markets are starting to reward," said Home Loan Servicing Solutions Chairman William Erbey. | Leon Cooperman , chairman and CEO of New York-based Omega Advisors, has purchased shares of two new companies: Arbor Realty Trust ( ABR ) and Home Loan Servicing Solutions Ltd. ( HLSS ), according to GuruFocus Real Time Picks . The trust released its third quarter results on Nov. 2, in which it reported net income of $2.1 million, or $0.07 per share, compared to a net loss of $2.4 million, or $0.10 per share, the previous year. In its fourth quarter results released Feb. 7, the company reported $14.3 million in net income, or $0.44 per ordinary share, in the fourth quarter, compared to a loss of $191 million, or a loss of $9.55 per ordinary share, in the fourth quarter of 2011. | Leon Cooperman , chairman and CEO of New York-based Omega Advisors, has purchased shares of two new companies: Arbor Realty Trust ( ABR ) and Home Loan Servicing Solutions Ltd. ( HLSS ), according to GuruFocus Real Time Picks . The trust released its third quarter results on Nov. 2, in which it reported net income of $2.1 million, or $0.07 per share, compared to a net loss of $2.4 million, or $0.10 per share, the previous year. In its fourth quarter results released Feb. 7, the company reported $14.3 million in net income, or $0.44 per ordinary share, in the fourth quarter, compared to a loss of $191 million, or a loss of $9.55 per ordinary share, in the fourth quarter of 2011. | Leon Cooperman , chairman and CEO of New York-based Omega Advisors, has purchased shares of two new companies: Arbor Realty Trust ( ABR ) and Home Loan Servicing Solutions Ltd. ( HLSS ), according to GuruFocus Real Time Picks . The trust released its third quarter results on Nov. 2, in which it reported net income of $2.1 million, or $0.07 per share, compared to a net loss of $2.4 million, or $0.10 per share, the previous year. If you are not a Premium Member, we invite you for a 7-Day Free Trial .About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. |
30505.0 | 2013-01-09 00:00:00 UTC | Zacks #1 Rank Additions for Wednesday - Tale of the Tape | ABR | https://www.nasdaq.com/articles/zacks-1-rank-additions-for-wednesday-tale-of-the-tape-2013-01-09 | nan | nan | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today:
Addus Homecare Corp. ( ADUS )
The Allstate Corp. ( ALL )
American States Water Co. ( AWR )
AngloGold Ashanti Limited (ADR) ( AU )
Arbor Realty Trust, Inc. ( ABR )
View the entire Zacks #1 Rank List .
ARBOR RLTY TRST (ABR): Free Stock Analysis Report
ADDUS HOMECARE (ADUS): Free Stock Analysis Report
ALLSTATE CORP (ALL): Free Stock Analysis Report
ANGLOGOLD LTD (AU): Free Stock Analysis Report
AMER STATES WTR (AWR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Addus Homecare Corp. ( ADUS ) The Allstate Corp. ( ALL ) American States Water Co. ( AWR ) AngloGold Ashanti Limited (ADR) ( AU ) Arbor Realty Trust, Inc. ( ABR ) View the entire Zacks #1 Rank List . ARBOR RLTY TRST (ABR): Free Stock Analysis Report ADDUS HOMECARE (ADUS): Free Stock Analysis Report ALLSTATE CORP (ALL): Free Stock Analysis Report ANGLOGOLD LTD (AU): Free Stock Analysis Report AMER STATES WTR (AWR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Addus Homecare Corp. ( ADUS ) The Allstate Corp. ( ALL ) American States Water Co. ( AWR ) AngloGold Ashanti Limited (ADR) ( AU ) Arbor Realty Trust, Inc. ( ABR ) View the entire Zacks #1 Rank List . ARBOR RLTY TRST (ABR): Free Stock Analysis Report ADDUS HOMECARE (ADUS): Free Stock Analysis Report ALLSTATE CORP (ALL): Free Stock Analysis Report ANGLOGOLD LTD (AU): Free Stock Analysis Report AMER STATES WTR (AWR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Addus Homecare Corp. ( ADUS ) The Allstate Corp. ( ALL ) American States Water Co. ( AWR ) AngloGold Ashanti Limited (ADR) ( AU ) Arbor Realty Trust, Inc. ( ABR ) View the entire Zacks #1 Rank List . ARBOR RLTY TRST (ABR): Free Stock Analysis Report ADDUS HOMECARE (ADUS): Free Stock Analysis Report ALLSTATE CORP (ALL): Free Stock Analysis Report ANGLOGOLD LTD (AU): Free Stock Analysis Report AMER STATES WTR (AWR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Addus Homecare Corp. ( ADUS ) The Allstate Corp. ( ALL ) American States Water Co. ( AWR ) AngloGold Ashanti Limited (ADR) ( AU ) Arbor Realty Trust, Inc. ( ABR ) View the entire Zacks #1 Rank List . ARBOR RLTY TRST (ABR): Free Stock Analysis Report ADDUS HOMECARE (ADUS): Free Stock Analysis Report ALLSTATE CORP (ALL): Free Stock Analysis Report ANGLOGOLD LTD (AU): Free Stock Analysis Report AMER STATES WTR (AWR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
30506.0 | 2012-11-11 00:00:00 UTC | Weekly CEO Buys Highlight: GDOT, VOCS, PES, IRWD, ABR | ABR | https://www.nasdaq.com/articles/weekly-ceo-buys-highlight-gdot-vocs-pes-irwd-abr-2012-11-11 | nan | nan | According to GuruFocus Insider Data , these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below:
Green Dot Corp. ( GDOT ): Chairman, President, CEO and 10% Owner Steven W. Streit Bought 178,000 Shares
Chairman, President, CEO and 10% Owner of Green Dot Corp. ( GDOT ) Steven W. Streit bought 178,000 shares during the past week at an average price of $11.25. Green Dot Corp. is a prepaid financial services company providing money management solutions to a broad base of U.S. consumers. Green Dot Corp. has a market cap of $403.7 million; its shares were traded at around $11.25 with a P/E ratio of 9.15 and a P/S ratio of 0.86.
George Soros bought 800,000 shares in the quarter that ended on 6/30/2012, which is 0.26% of the $6.92 billion portfolio of Soros Fund Management LLC. Joel Greenblatt bought 92,880 shares in the quarter that ended on 6/30/2012, which is 0.15% of the $1.36 billion portfolio of Gotham Capital. Ron Baron owns 1,960,119 shares as of 6/30/2012, an increase of 27.75% from the previous quarter. This position accounts for 0.27% of the $15.83 billion portfolio of Baron Funds.
GDOT recently reported its third quarter 2012 financial results. For the third quarter of 2012, Green Dot reported a 14% year-over-year increase in non-GAAP total operating revenues to $135.6 million and non-GAAP diluted earnings per share of $0.29. GAAP results for the third quarter were $134.3 million in revenues and $0.24 in diluted earnings per share.
Director Ross E. Kendell bought 1,500 shares of GDOT stock on 11/06/2012 at the average price of 10.95. Ross E. Kendell owns at least 2,885 shares after this. The price of the stock has increased by 2.74% since.
Vocus, Inc. ( VOCS ): Chairman, CEO and President Richard E. Rudman Bought 70,000 Shares
Chairman, CEO and President of Vocus, Inc. ( VOCS ) Richard E Rudman bought 70,000 shares on 11/08/2012 at an average price of $14.73. Vocus Inc. is a provider of on-demand software for public relations management. Vocus Inc. has a market cap of $304.91 million; its shares were traded at around $14.73 with a P/S ratio of 2.65.
VOCS recently reported its third quarter 2012 financial results. GAAP revenue for the third quarter of 2012 was $45.2 million, a 57% increase over the comparable period in 2011.
Director Kevin J. Burns bought 10,000 shares of VOCS stock on 5/30/2012 at the average price of $15.27. Kevin J. Burns owns at least 45,602 shares after this. The price of the stock has decreased by 3.54% since. Other insiders have decreased their positions in the company.
Pioneer Energy Services Corp ( PES ): President & CEO Stacy Locke Bought 100,000 Shares
President & CEO of Pioneer Energy Services Corp ( PES ) Stacy Locke bought 100,000 shares on 11/06/2012 at an average price of $0. Pioneer Energy Services Corp. provides land contract drilling services and production services to independent and major oil and gas exploration and production companies. with a P/E ratio of 11.73 and P/S ratio of 0.56. Pioneer Energy Services Corp had an annual average earnings growth of 43.1% over the past 10 years. GuruFocus rated Pioneer Energy Services Corp the business predictability rank of 3-star.
Pioneer Energy Services recently reported its third quarter 2012 financial results. Revenues for the third quarter of 2012 were $229.8 million, flat with revenue in the second quarter of 2012, but a 22% increase over $187.7 million for the third quarter of 2011.
John Burbank bought 16,605 shares in the quarter that ended on 6/30/2012, which is 0.0045% of the $2.95 billion portfolio of Passport Capital. Third Avenue Management owns 3,015,573 shares as of 6/30/2012, which accounts for 0.57% of the $4.21 billion portfolio of Third Avenue Management.
Director Dean A. Burkhardt bought 5,000 shares of PES stock on 6/14/2012 at the average price of $7. Dean A. Burkhardt owns at least 80,703 shares after this.
Ironwood Pharmaceuticals Inc. ( IRWD ): CEO Peter M. Hecht Bought 50,000 Shares
CEO of Ironwood Pharmaceuticals, Inc. ( IRWD ) Peter M. Hecht bought 50,000 shares on 11/05/2012 at an average price of $11.97. Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company that discovers, develops, and intends to commercialize innovative human medicines. Ironwood Pharmaceuticals Inc. has a market cap of $1.29 billion; its shares were traded at around $11.97 with a P/S ratio of 19.57.
Edward Owens owns 2,000,000 shares as of 9/30/2012, which accounts for 0.12% of the $22.09 billion portfolio of Vanguard Health Care Fund. Lee Ainslie owns 2,101,695 shares as of 6/30/2012, which accounts for 0.42% of the $6.85 billion portfolio of Maverick Capital.
FMR LLC sold 212,875 shares of IRWD stock on 10/15/2012 at the average price of 13.25. FMR LLC owns at least 1,235,904 shares after this. The price of the stock has decreased by 9.66% since.
Arbor Realty Trust Inc. ( ABR ): Chief of Business, CEO, President and 10% Owner Ivan Kaufman Bought 75,000 Shares
Chief of business, CEO, President and 10% Owner of Arbor Realty Trust, Inc. ( ABR ) Ivan Kaufman bought 75,000 shares on 11/08/2012 at an average price of $0.6. Arbor Realty Trust is a specialized real estate finance company investing in real estate-related bridge and mezzanine loans, preferred equity, mortgage-related securities and other real estate-related assets. Arbor Realty Trust, Inc. has a market cap of $149.29 million; its shares were traded at around $5.38 with and P/S ratio of 1.52. The dividend yield of Arbor Realty Trust, Inc. stocks is 7.43%.
Arbor Realty Trust recently reported its third quarter 2012 financial results. The company reported net income for the quarter of $2.1 million, or $0.07 per diluted common share, compared to net loss for the quarter ended Sept. 30, 2011 of $2.4 million, or $0.10 per diluted common share.
Director William C. Green bought 5,000 shares of ABR stock on 6/19/2012 at the average price of $5.09. William C. Green owns at least 20,000 shares after this. The price of the stock has increased by 5.7% since.About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbor Realty Trust Inc. ( ABR ): Chief of Business, CEO, President and 10% Owner Ivan Kaufman Bought 75,000 Shares Chief of business, CEO, President and 10% Owner of Arbor Realty Trust, Inc. ( ABR ) Ivan Kaufman bought 75,000 shares on 11/08/2012 at an average price of $0.6. Director William C. Green bought 5,000 shares of ABR stock on 6/19/2012 at the average price of $5.09. Green Dot Corp. is a prepaid financial services company providing money management solutions to a broad base of U.S. consumers. | Arbor Realty Trust Inc. ( ABR ): Chief of Business, CEO, President and 10% Owner Ivan Kaufman Bought 75,000 Shares Chief of business, CEO, President and 10% Owner of Arbor Realty Trust, Inc. ( ABR ) Ivan Kaufman bought 75,000 shares on 11/08/2012 at an average price of $0.6. Director William C. Green bought 5,000 shares of ABR stock on 6/19/2012 at the average price of $5.09. The overall trend of CEOs is illustrated in the chart below: Green Dot Corp. ( GDOT ): Chairman, President, CEO and 10% Owner Steven W. Streit Bought 178,000 Shares Chairman, President, CEO and 10% Owner of Green Dot Corp. ( GDOT ) Steven W. Streit bought 178,000 shares during the past week at an average price of $11.25. | Arbor Realty Trust Inc. ( ABR ): Chief of Business, CEO, President and 10% Owner Ivan Kaufman Bought 75,000 Shares Chief of business, CEO, President and 10% Owner of Arbor Realty Trust, Inc. ( ABR ) Ivan Kaufman bought 75,000 shares on 11/08/2012 at an average price of $0.6. Director William C. Green bought 5,000 shares of ABR stock on 6/19/2012 at the average price of $5.09. The overall trend of CEOs is illustrated in the chart below: Green Dot Corp. ( GDOT ): Chairman, President, CEO and 10% Owner Steven W. Streit Bought 178,000 Shares Chairman, President, CEO and 10% Owner of Green Dot Corp. ( GDOT ) Steven W. Streit bought 178,000 shares during the past week at an average price of $11.25. | Arbor Realty Trust Inc. ( ABR ): Chief of Business, CEO, President and 10% Owner Ivan Kaufman Bought 75,000 Shares Chief of business, CEO, President and 10% Owner of Arbor Realty Trust, Inc. ( ABR ) Ivan Kaufman bought 75,000 shares on 11/08/2012 at an average price of $0.6. Director William C. Green bought 5,000 shares of ABR stock on 6/19/2012 at the average price of $5.09. The overall trend of CEOs is illustrated in the chart below: Green Dot Corp. ( GDOT ): Chairman, President, CEO and 10% Owner Steven W. Streit Bought 178,000 Shares Chairman, President, CEO and 10% Owner of Green Dot Corp. ( GDOT ) Steven W. Streit bought 178,000 shares during the past week at an average price of $11.25. |
30507.0 | 2012-11-05 00:00:00 UTC | Donald Yacktman Buys 4 New Stocks in Q3 | ABR | https://www.nasdaq.com/articles/donald-yacktman-buys-4-new-stocks-q3-2012-11-05 | nan | nan | Donald Yacktman of Yacktman Asset Management reported his third quarter portfolio on Monday, which his largest new buys were WellPoint Inc. ( WLP ), CH Robinson Worldwide ( CHRW ), Liberty Ventures ( LVNTA ) and Abbott Laboratories ( ABR ).
Yacktman and his associates, who are long-term focused investors, produced a 10.8% return over the last 10 years, beating the 5.33% returned by the S&P 500 over the same period.
WellPoint ( WLP )
Yacktman purchased 3,518,467 shares of WellPoint for $59 per share on average in the third quarter. He owned the stock previously, but sold out in the fourth quarter of 2010 after the price appreciated.
In the first three quarters of the year, WellPoint's stock declined about 12.5%, with a significant decrease in the third quarter, when Yacktman purchased it.
WellPoint is the largest health benefits company in the U.S. and offers a wide variety of medical and specialty products. Its affiliate health plans have nearly 34 million members and its subsidiaries serve about 65 million clients.
The company's stock dipped in the third quarter when it reported its second quarter results on July 25. WellPoint's net income was $643.6 million, or $1.94 per share, down from $701.6 million, or $1.86 per share, in the second quarter of 2011. The results were negatively affected by lower enrollment due to competition, and slightly higher medical cost trends, which caused the company to reduce its full-year 2012 outlook.
Wellpoint has a market cap of $19.93 billion; its shares were traded at around $60.83 with a P/E ratio of 8.6 and P/S ratio of 0.3. The dividend yield of Wellpoint stocks is 1.9%. Wellpoint had an annual average earnings growth of 17.2% over the past 10 years. GuruFocus rated Wellpoint the business predictability rank of 4-star .
WLP data by GuruFocus.com
CH Robinson Worldwide ( CHRW )
Yacktman purchased 700,000 shares of CH Robinson Worldwide for $57 per share on average in the third quarter. CH Robinson stock declined 11% year to date.
CH Robinson is a global third-party logistics company founded in 1905. It works with 53,000 transportation providers around the world.
For its nine months ended Sept. 30, net income increased 4.7% year over year to 337.4 million from $322.4 billion. Revenue increased 3.4% to $1.3 billion from $1.2 billion.
CH Robinson Worldwide has a market cap of $9.59 billion; its shares were traded at around $61.95 with a P/E ratio of 21.6 and P/S ratio of 0.9. The dividend yield of CH Robinson Worldwide stocks is 2.2%. CH Robinson Worldwide had an annual average earnings growth of 19% over the past 10 years. GuruFocus rated CH Robinson Worldwide the business predictability rank of 4-star.
CHRW data by GuruFocus.com
Liberty Ventures ( LVNTA )
Yacktman purchased 206,321 shares of Liberty Ventures in the third quarter. Its stock has gained 28% year to date.
Liberty Ventures is made of Liberty Interactive Corp's interests in AOL, Expedia, Interval Leisure Group and other web sites, other non-consolidated assets, and green energy investments. Liberty Ventures has a market cap of $1.99 billion; its shares were traded at around $57.89.
In the company's second quarter earnings, released Aug. 8, it reported a 5% year-over-year increase in revenue to $2.37 billion from $2.25 billion, on strong results at its QVC and eCommerce companies. OIBDA increased 1% to $455 million on strong WVC results, offset by weaker results at its eCommerce companies.
During the quarter, the company received approval from China's government for a joint venture with China National Radio. It also repurchased $257 million of its stock. In total, is has repurchased approximately 24.6% of its shares since May 2006, and has approximately $429 million remaining under its present stock repurchase authorization.
Abbott Laboratories ( ABT )
Yacktman purchased 3,000 shares of his smallest new position, Abbott Laboratories, for $66 per share on average, which is a 0.0012% weighting of his portfolio. Abbott Laboratories' stock has increased 16% year to date.
Abbott Laboratories is a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health.
Abbott's earnings for the first nine months of 2012 increased 57.9% year over year to $4.9 billion from $3.1 billion. Net sales improved 2%, to $29.1 billion from $28.5 billion. The company narrowed its earnings per share guidance for 2012 to $5.06 to $5.08 from $5.00 to $5.10, due to strong performance for the year and product launches that will contribute to growth.
Abbott will split into two health care companies on Jan. 1, 2013.
Abbott Laboratories has a market cap of $102.77 billion; its shares were traded at around $65.04 with a P/E ratio of 13.1 and P/S ratio of 2.6. The dividend yield of Abbott Laboratories stocks is 3.1%. Abbott Laboratories had an annual average earnings growth of 7.9% over the past 10 years. GuruFocus rated Abbott Laboratories the business predictability rank of 4.5-star.
ABT data by GuruFocus.com
See more of Donald Yacktman's portfolio updates here. Also check out his undervalued stocks, top growth companies and high yield stocks.About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Donald Yacktman of Yacktman Asset Management reported his third quarter portfolio on Monday, which his largest new buys were WellPoint Inc. ( WLP ), CH Robinson Worldwide ( CHRW ), Liberty Ventures ( LVNTA ) and Abbott Laboratories ( ABR ). WellPoint is the largest health benefits company in the U.S. and offers a wide variety of medical and specialty products. The results were negatively affected by lower enrollment due to competition, and slightly higher medical cost trends, which caused the company to reduce its full-year 2012 outlook. | Donald Yacktman of Yacktman Asset Management reported his third quarter portfolio on Monday, which his largest new buys were WellPoint Inc. ( WLP ), CH Robinson Worldwide ( CHRW ), Liberty Ventures ( LVNTA ) and Abbott Laboratories ( ABR ). WLP data by GuruFocus.com CH Robinson Worldwide ( CHRW ) Yacktman purchased 700,000 shares of CH Robinson Worldwide for $57 per share on average in the third quarter. CHRW data by GuruFocus.com Liberty Ventures ( LVNTA ) Yacktman purchased 206,321 shares of Liberty Ventures in the third quarter. | Donald Yacktman of Yacktman Asset Management reported his third quarter portfolio on Monday, which his largest new buys were WellPoint Inc. ( WLP ), CH Robinson Worldwide ( CHRW ), Liberty Ventures ( LVNTA ) and Abbott Laboratories ( ABR ). WLP data by GuruFocus.com CH Robinson Worldwide ( CHRW ) Yacktman purchased 700,000 shares of CH Robinson Worldwide for $57 per share on average in the third quarter. Abbott Laboratories ( ABT ) Yacktman purchased 3,000 shares of his smallest new position, Abbott Laboratories, for $66 per share on average, which is a 0.0012% weighting of his portfolio. | Donald Yacktman of Yacktman Asset Management reported his third quarter portfolio on Monday, which his largest new buys were WellPoint Inc. ( WLP ), CH Robinson Worldwide ( CHRW ), Liberty Ventures ( LVNTA ) and Abbott Laboratories ( ABR ). WellPoint's net income was $643.6 million, or $1.94 per share, down from $701.6 million, or $1.86 per share, in the second quarter of 2011. Abbott's earnings for the first nine months of 2012 increased 57.9% year over year to $4.9 billion from $3.1 billion. |
30508.0 | 2012-10-05 00:00:00 UTC | Arbor Realty Offers Shares - Analyst Blog | ABR | https://www.nasdaq.com/articles/arbor-realty-offers-shares-analyst-blog-2012-10-05 | nan | nan | Arbor Realty Trust, Inc. (ABR) , a real estate investment trust (REIT), recently announced a public offering of 3.5 million shares to increase its liquidity. To cover up for over allotments, Arbor Realty also plans to offer an option to the underwriters for purchase of an additional tranche in excess of 0.5 million shares.
Deutsche Bank Securities Inc, part of Deutsche Bank AG (DB) , is the sole book running manager for the offering.
Arbor Realty intends to use the net proceeds from the equity offer to increase its investment portfolio and for general corporate purposes.
Earlier in June 2012, Arbor Realty had issued 3.5 million shares in a public offering to raise net proceeds of approximately $17.5 million. At the end of June 2012, cash and cash equivalents stood at $64.3 million with outstanding borrowings for its loan and investment portfolio totalling approximately $1.3 billion. The company diligently manages its portfolio to maintain steady cash reserves. At the same time, it ensures capital appreciation to maximize returns for its shareholders.
Headquartered in Uniondale, New York, Arbor Realty invests in a diversified portfolio of multi-family and commercial real estate-related bridge and mezzanine loans, preferred equity investments, mortgage-related securities and other real estate related assets. The company provides structured finance products to a diverse group of asset classes across a wide geographic region.
Arbor Realty Trust currently retains a Zacks #3 Rank, which translates into a short-term Hold rating. We also have a long-term Neutral recommendation on the stock. One of its competitors, Redwood Trust, Inc. ( RWT ) currently retains a Zacks #2 Rank, which implies a Buy rating.
ARBOR RLTY TRST (ABR): Free Stock Analysis Report
DEUTSCHE BK AG (DB): Free Stock Analysis Report
REDWOOD TRUST (RWT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbor Realty Trust, Inc. (ABR) , a real estate investment trust (REIT), recently announced a public offering of 3.5 million shares to increase its liquidity. ARBOR RLTY TRST (ABR): Free Stock Analysis Report DEUTSCHE BK AG (DB): Free Stock Analysis Report REDWOOD TRUST (RWT): Free Stock Analysis Report To read this article on Zacks.com click here. To cover up for over allotments, Arbor Realty also plans to offer an option to the underwriters for purchase of an additional tranche in excess of 0.5 million shares. | Arbor Realty Trust, Inc. (ABR) , a real estate investment trust (REIT), recently announced a public offering of 3.5 million shares to increase its liquidity. ARBOR RLTY TRST (ABR): Free Stock Analysis Report DEUTSCHE BK AG (DB): Free Stock Analysis Report REDWOOD TRUST (RWT): Free Stock Analysis Report To read this article on Zacks.com click here. Earlier in June 2012, Arbor Realty had issued 3.5 million shares in a public offering to raise net proceeds of approximately $17.5 million. | Arbor Realty Trust, Inc. (ABR) , a real estate investment trust (REIT), recently announced a public offering of 3.5 million shares to increase its liquidity. ARBOR RLTY TRST (ABR): Free Stock Analysis Report DEUTSCHE BK AG (DB): Free Stock Analysis Report REDWOOD TRUST (RWT): Free Stock Analysis Report To read this article on Zacks.com click here. Headquartered in Uniondale, New York, Arbor Realty invests in a diversified portfolio of multi-family and commercial real estate-related bridge and mezzanine loans, preferred equity investments, mortgage-related securities and other real estate related assets. | Arbor Realty Trust, Inc. (ABR) , a real estate investment trust (REIT), recently announced a public offering of 3.5 million shares to increase its liquidity. ARBOR RLTY TRST (ABR): Free Stock Analysis Report DEUTSCHE BK AG (DB): Free Stock Analysis Report REDWOOD TRUST (RWT): Free Stock Analysis Report To read this article on Zacks.com click here. Earlier in June 2012, Arbor Realty had issued 3.5 million shares in a public offering to raise net proceeds of approximately $17.5 million. |
30509.0 | 2012-10-01 00:00:00 UTC | DISH Network Exploring Online TV - Analyst Blog | ABR | https://www.nasdaq.com/articles/dish-network-exploring-online-tv-analyst-blog-2012-10-01 | nan | nan | DISH Network Corp. ( DISH ), the second largest satellite TV operator in the U.S., is currently exploring its opportunities in the over-the-top TV streaming segment. In its recent report, Bloomberg stated that the company is negotiating with several media companies, including Viacom Inc. ( VIAB ), Scripps Networks Interactive Inc. ( SNI ) and Univision Communications Inc. regarding online TV services.
Offering online TV services will transform DISH Network as a virtual MSO that will broadcast pay-TV services for several devices including TV, smartphones and tablets. DISH Network's technology spin-off EchoStar Corp. ( SATS ) has developed an adaptive bit rate (ABR) video platform, which will enable DISH Network to offer over-the-top services. Currently, DISH Network uses EchoStar's satellites and equipments to provide TV services.
Using EchoStar's ABR platform, DISH Network can provide a managed, over-the-top video service supporting live TV streaming, on-demand movies, and a network-based DVR. DISH Network can also offer movies from its Blockbuster stores for over-the-top streaming services.
Just a few days ago, DISH Network started offering bundled satellite TV and Internet services to its customers and became a formidable challenger to large cable pay-TV and telecom service providers, which also offers triple-play video, voice and data services. Moreover, DISH Network is currently waiting for the FCC nod to launch a nationwide high-speed wireless broadband network to offer mobile Internet and phone services to its customers.
The newly acquired spectrums from TerreStar Networks Inc. and DBSD North America Inc. provide most valuable assets to the wireless industry. Using these slots of airwaves, the company can form a formidable video-on-demand service over a wireless network of mobile handsets, such as smartphones and tablets.
DISH NETWORK CP (DISH): Free Stock Analysis Report
ECHOSTAR CORP (SATS): Free Stock Analysis Report
SCRIPPS NETWRKS (SNI): Free Stock Analysis Report
VIACOM INC-B (VIAB): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Using EchoStar's ABR platform, DISH Network can provide a managed, over-the-top video service supporting live TV streaming, on-demand movies, and a network-based DVR. DISH Network's technology spin-off EchoStar Corp. ( SATS ) has developed an adaptive bit rate (ABR) video platform, which will enable DISH Network to offer over-the-top services. The newly acquired spectrums from TerreStar Networks Inc. and DBSD North America Inc. provide most valuable assets to the wireless industry. | Using EchoStar's ABR platform, DISH Network can provide a managed, over-the-top video service supporting live TV streaming, on-demand movies, and a network-based DVR. DISH Network's technology spin-off EchoStar Corp. ( SATS ) has developed an adaptive bit rate (ABR) video platform, which will enable DISH Network to offer over-the-top services. In its recent report, Bloomberg stated that the company is negotiating with several media companies, including Viacom Inc. ( VIAB ), Scripps Networks Interactive Inc. ( SNI ) and Univision Communications Inc. regarding online TV services. | DISH Network's technology spin-off EchoStar Corp. ( SATS ) has developed an adaptive bit rate (ABR) video platform, which will enable DISH Network to offer over-the-top services. Using EchoStar's ABR platform, DISH Network can provide a managed, over-the-top video service supporting live TV streaming, on-demand movies, and a network-based DVR. Just a few days ago, DISH Network started offering bundled satellite TV and Internet services to its customers and became a formidable challenger to large cable pay-TV and telecom service providers, which also offers triple-play video, voice and data services. | Using EchoStar's ABR platform, DISH Network can provide a managed, over-the-top video service supporting live TV streaming, on-demand movies, and a network-based DVR. DISH Network's technology spin-off EchoStar Corp. ( SATS ) has developed an adaptive bit rate (ABR) video platform, which will enable DISH Network to offer over-the-top services. In its recent report, Bloomberg stated that the company is negotiating with several media companies, including Viacom Inc. ( VIAB ), Scripps Networks Interactive Inc. ( SNI ) and Univision Communications Inc. regarding online TV services. |
30510.0 | 2012-06-23 00:00:00 UTC | Weekly CEO Buys Highlight: UTHR, PMC, ABR, AIR, SCHS | ABR | https://www.nasdaq.com/articles/weekly-ceo-buys-highlight-uthr-pmc-abr-air-schs-2012-06-23 | nan | nan | According to GuruFocus Insider Data , these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Utd Therapeutic ( UTHR ): CEO Martine A Rothblatt Bought 20,858 Shares
CEO of Utd Therapeutic ( UTHR ) Martine A Rothblatt bought 20,858 shares during the past week at an average price of $47.94. UTD THERAPEUTIC is a biotechnology company focused on combating cardiovascular, inflammatory, and infectious diseases with unique therapeutic products. Utd Therapeutic has a market cap of $2.57 billion; its shares were traded at around $47.94 with a P/E ratio of 10.8 and P/S ratio of 3.5.
UTHR recently reported its first quarter 2012 financial results. Total revenues for the quarter ended March 31, 2012 were $204.2 million, up from $162.5 million for the quarter ended March 31, 2011. Net income for the quarter ended March 31, 2012 was $70.8 millionor $1.32 per basic share, compared to $16.4 million or $0.28 per basic share for the same quarter in 2011.
Richard Perry bought 15,300 shares in the quarter that ended on 03/31/2012, which is 0.035% of the $2.08 billion portfolio of Perry Capital. Joel Greenblatt owns 165,063 shares as of 03/31/2012, an increase of 82.68% from the previous quarter. This position accounts for 0.68% of the $1.15 billion portfolio of Gotham Capital.
Director Christopher Patusky sold 2,500 shares of UTHR stock on 04/04/2012 at the average price of 45.55. Christopher Patusky owns at least 1,300 shares after this. The price of the stock has increased by 5.25% since.
Pharmerica Corp ( PMC ): CEO Gregory S Weishar Bought 35,500 Shares
CEO of Pharmerica Corp ( PMC ) Gregory S Weishar bought 35,500 shares on 06/14/2012 at an average price of $10.71. PharMerica Corporation is an institutional pharmacy services provider dedicated to providing quality customer service and innovative pharmacy solutions to institutional customers and patients in long-term care settings. Pharmerica Corp has a market cap of $300.3 million; its shares were traded at around $10.71 with a P/E ratio of 7.7 and P/S ratio of 0.1. Pharmerica Corp had an annual average earnings growth of 18.6% over the past 5 years.
Phamerica recently reported its first quarter 2012 results. Net income for the first quarter of 2012 was $5.6 million, or $0.19 per diluted common share, compared with $3.3 million, or$0.11 per diluted common share, for the same period in 2011. Adjusted earnings per diluted common share were $0.30 in 2012 compared with $0.20 per diluted common share in 2011, an increase of 50%.
HOTCHKIS & WILEY owns 768,800 shares as of 03/31/2012, which accounts for 0.057% of the $16.79 billion portfolio of Hotchkis & Wiley Capital Management LLC. Jean-Marie Eveillard sold out his holdings in the quarter that ended on 03/31/2012.
EVP and CFO Michael J Culotta bought 15,000 shares of PMC stock on 06/14/2012 at the average price of 9.51. Michael J Culotta owns at least 158,208 shares after this. The price of the stock has increased by 12.62% since.
Arbor Rlty Trst ( ABR ): COB, CEO and President, 10% Owner Ivan Kaufman Bought 55,000 Shares
COB, CEO and President, 10% Owner of Arbor Rlty Trst ( ABR ) Ivan Kaufman bought 55,000 shares during the past week at an average price of $5.13. Arbor Realty Trust is a specialized real estate finance company investing in real estate-related bridge and mezzanine loans, preferred equity, mortgage-related securities and other real estate-related assets. Arbor Rlty Trst has a market cap of $140.1 million; its shares were traded at around $5.13 with and P/S ratio of 1.4. The dividend yield of Arbor Rlty Trst stocks is 5.9%.
Arbor Realty Trust recently reported net income attributable to Arbor Realty Trust, Inc. for the quarter of $4.2 million, or $0.17 per diluted common share, compared to net income attributable to Arbor Realty Trust, Inc. for the quarter ended March 31, 2011 of $0.3 million, or $0.01 per diluted common share.
Director William C Green bought 5,000 shares of ABR stock on 06/19/2012 at the average price of 5.09. William C Green owns at least 20,000 shares after this. The price of the stock has increased by 0.79% since. Other insiders have also increased their positions in hte company.
Aar Corp ( AIR ): Chairman & CEO David P Storch Bought 20,000 Shares
Chairman & CEO of Aar Corp ( AIR ) David P Storch bought 20,000 shares on 06/19/2012 at an average price of $12.04. AAR Corp. is a worldwide leader in supplying aftermarket products and services to the global aerospace/aviation industry. Aar Corp has a market cap of $416.6 million; its shares were traded at around $12.04 with a P/E ratio of 5.7 and P/S ratio of 0.2. The dividend yield of Aar Corp stocks is 2.9%. Aar Corp had an annual average earnings growth of 13.4% over the past 5 years.
AAR Corp. recently reported preliminary unaudited fourth quarter results for the period ending ending May 31, 2012, as well as its outlook for fiscal year 2013. Consolidated sales for the fourth quarter ended May 31, 2012 are expected to be between $560 million to $565 million.
Mario Gabelli owns 75,000 shares as of 03/31/2012, which accounts for 0.0098% of the $13.95 billion portfolio of GAMCO Investors. Arnold Schneider owns 180,034 shares as of 03/31/2012, which accounts for 0.27% of the $1.23 billion portfolio of Schneider Capital Management.
President & COO Timothy J Romenesko bought 5,000 shares of AIR stock on 06/19/2012 at the average price of 10.47. Timothy J Romenesko owns at least 269,500 shares after this. The price of the stock has increased by 15% since.
School Specialty ( SCHS ): President / CEO Michael P. Lavelle Bought 67,100 Shares
President / CEO of School Specialty ( SCHS ) Michael P. Lavelle bought 67,100 shares on 06/15/2012 at an average price of $2.92. School Specialty, Inc. is one of the largest marketers of non- textbook educational supplies and furniture to schools for pre-kindergarten through twelfth grade. School Specialty has a market cap of $54.5 million; its shares were traded at around $2.92 with and P/S ratio of 0.1.
Chris Davis owns 594,117 shares as of 03/31/2012, which accounts for 0.0044% of the $0 million portfolio of Davis Selected Advisers.
Director Edward C Emma bought 5,000 shares of SCHS stock on 06/15/2012 at the average price of 2.89. Edward C Emma owns at least 19,850 shares after this. The price of the stock has increased by 1.04% since.About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbor Rlty Trst ( ABR ): COB, CEO and President, 10% Owner Ivan Kaufman Bought 55,000 Shares COB, CEO and President, 10% Owner of Arbor Rlty Trst ( ABR ) Ivan Kaufman bought 55,000 shares during the past week at an average price of $5.13. Director William C Green bought 5,000 shares of ABR stock on 06/19/2012 at the average price of 5.09. EVP and CFO Michael J Culotta bought 15,000 shares of PMC stock on 06/14/2012 at the average price of 9.51. | Arbor Rlty Trst ( ABR ): COB, CEO and President, 10% Owner Ivan Kaufman Bought 55,000 Shares COB, CEO and President, 10% Owner of Arbor Rlty Trst ( ABR ) Ivan Kaufman bought 55,000 shares during the past week at an average price of $5.13. Director William C Green bought 5,000 shares of ABR stock on 06/19/2012 at the average price of 5.09. Arbor Realty Trust recently reported net income attributable to Arbor Realty Trust, Inc. for the quarter of $4.2 million, or $0.17 per diluted common share, compared to net income attributable to Arbor Realty Trust, Inc. for the quarter ended March 31, 2011 of $0.3 million, or $0.01 per diluted common share. | Arbor Rlty Trst ( ABR ): COB, CEO and President, 10% Owner Ivan Kaufman Bought 55,000 Shares COB, CEO and President, 10% Owner of Arbor Rlty Trst ( ABR ) Ivan Kaufman bought 55,000 shares during the past week at an average price of $5.13. Director William C Green bought 5,000 shares of ABR stock on 06/19/2012 at the average price of 5.09. Arbor Realty Trust recently reported net income attributable to Arbor Realty Trust, Inc. for the quarter of $4.2 million, or $0.17 per diluted common share, compared to net income attributable to Arbor Realty Trust, Inc. for the quarter ended March 31, 2011 of $0.3 million, or $0.01 per diluted common share. | Arbor Rlty Trst ( ABR ): COB, CEO and President, 10% Owner Ivan Kaufman Bought 55,000 Shares COB, CEO and President, 10% Owner of Arbor Rlty Trst ( ABR ) Ivan Kaufman bought 55,000 shares during the past week at an average price of $5.13. Director William C Green bought 5,000 shares of ABR stock on 06/19/2012 at the average price of 5.09. Arbor Realty Trust recently reported net income attributable to Arbor Realty Trust, Inc. for the quarter of $4.2 million, or $0.17 per diluted common share, compared to net income attributable to Arbor Realty Trust, Inc. for the quarter ended March 31, 2011 of $0.3 million, or $0.01 per diluted common share. |
30511.0 | 2012-06-22 00:00:00 UTC | Arbor Realty Trust CEO Ivan Kaufman Bought 30,000 Shares | ABR | https://www.nasdaq.com/articles/arbor-realty-trust-ceo-ivan-kaufman-bought-30000-shares-2012-06-22 | nan | nan | COB, CEO and President, 10% Owner of Arbor Rlty Trst ( ABR ) Ivan Kaufman bought 30,000 shares on 06/19/2012 at an average price of $5.06. The total transaction amount is $151,800. Arbor Realty Trust is a specialized real estate finance company investing in real estate-related bridge and mezzanine loans, preferred equity, mortgage-related securities and other real estate-related assets. Arbor Rlty Trst has a market cap of $140.1 million; its shares were traded at around $5.07 with and P/S ratio of 1.4. The dividend yield of Arbor Rlty Trst stocks is 5.9%.
President and CEO of Arbor Realty Trust has recently increased his positions several times in the company. On 3/19/2012, he bought 20,000 shares of the company at an average price of $5.37. On 6/14/2012, he bought an additional 25,000 shares of the company. On 6/19/2012, Ivan Kaufman further purchased 30,000 shares of ABR at the average price of $5.06.
Various other insiders have also increased their positions in the company. Director William Geren bought 5,000 shares of the company on 6/19/2012. Director Melvin Lazar bought purchased 50,000 shares of the company throughout the course of two weeks in the first quarter of 2012. No gurus currently hold any positions in ABR.
President and CEO Ivan Kaufman holds various other positions aside from his work at Arbor Realty Trust. He serves as the chair of the independent judicial election qualification commission for the 10th Judicial District of New York. Additionally, he also founded the North Shore Hebrew Academy High School. Kaufman is also a featured presenter at Columbia University and Wharton Business School.
ABR has an average revenue growth average of -5.6% per year in the last 10 years. The company's revenue was showing steady growth from 2004 until 2007, as outlined by the chart below. However, after 2007 the company's revenue continually decreased until showing a little improvement in 2011.
Earnings per share have also been unsteady for the company, negative for 3 out of the past 8 years. In 2011, the company posted a net loss of $1.61 per share. ABR holds about $153 million in cash, but owes over $1 billion in long-term debt. Aside from cash, the rest of the company's assets are from accounts receivable.
In 2011, ABR bought back $5.74 million worth of shares. The last net issuance of stock was back in 2007, when the company issued $73.65 worth of new shares.
Read More:
About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | COB, CEO and President, 10% Owner of Arbor Rlty Trst ( ABR ) Ivan Kaufman bought 30,000 shares on 06/19/2012 at an average price of $5.06. On 6/19/2012, Ivan Kaufman further purchased 30,000 shares of ABR at the average price of $5.06. No gurus currently hold any positions in ABR. | COB, CEO and President, 10% Owner of Arbor Rlty Trst ( ABR ) Ivan Kaufman bought 30,000 shares on 06/19/2012 at an average price of $5.06. In 2011, ABR bought back $5.74 million worth of shares. On 6/19/2012, Ivan Kaufman further purchased 30,000 shares of ABR at the average price of $5.06. | COB, CEO and President, 10% Owner of Arbor Rlty Trst ( ABR ) Ivan Kaufman bought 30,000 shares on 06/19/2012 at an average price of $5.06. On 6/19/2012, Ivan Kaufman further purchased 30,000 shares of ABR at the average price of $5.06. No gurus currently hold any positions in ABR. | COB, CEO and President, 10% Owner of Arbor Rlty Trst ( ABR ) Ivan Kaufman bought 30,000 shares on 06/19/2012 at an average price of $5.06. ABR has an average revenue growth average of -5.6% per year in the last 10 years. In 2011, ABR bought back $5.74 million worth of shares. |
30512.0 | 2011-02-04 00:00:00 UTC | Stocks Mixed at Mid-Session After Employment Data Disappoints; Corporate Earnings Continue | ABR | https://www.nasdaq.com/articles/stocks-mixed-mid-session-after-employment-data-disappoints-corporate-earnings-continue | nan | nan | Stocks are mixed at mid-session as investors digest a relatively disappointing jobs report that added far fewer jobs than analysts had predicted. The data comes after a speech yesterday afternoon by Federal Reserve Board Chairman Ben Bernanke in which he commented on the slow growth in jobs.
U.S. employers added only 36,000 jobs last month, not the 140,000 positions that Wall Street economists expected. Severe weather may have impacted hiring more than expected. But the unemployment rate did fall to 9% from December's 9.4%, the lowest reading since April 2009. Wall Street thought the jobless rate would tick up to 9.5%.
In a speech Thursday, the Fed chairman said stronger payroll data and a drop in the unemployment rate could be expected soon. But he also said that the slow job market improvement so far is holding back the broader economic recovery.
In company news:
Cisco Systems ( CSCO ) announced plans to acquire Inlet technologies, a privately-held provider of Adaptive Bit Rate ( ABR ) digital media processing platforms. Under the agreement, CSCO will pay approximately $95 million in cash and retention-based incentives in exchange for all shares of Inlet. According to the company, the acquisition of Inlet will bolster the capabilities of CSCO's Videoscape TV platform, allowing service and content providers to deliver video experiences to any device over any Internet Protocol ( IP ) network.
Bank of America ( BAC ) shares are trending lower as Bloomberg reports the bank will get at least $700 million from QBE Insurance Group for BofA's Balboa insurance unit. The move is part of BofA's plan to focus on retail customers, commercial borrowers and investment banking while getting rid of unrelated assets in order to raise capital.
Google ( GOOG ) shares are lower after the company said it received more than 75,000 job applications last week as the Internet search giant begins a hiring spree, Bloomberg reports. This figure tops a previously-reached high set in May 2007 by 15%, the report said.
K-V Pharmaceutical (KV.A) said the US Food and Drug Administration approved its drug Makena, which reduces the risk of preterm births in women with singleton pregnancy. Per the terms of an asset purchase agreement between Hologic (HOLX) and KV Pharmaceutical, Hologic will transfer the company's Makena assets to KV upon the satisfaction of certain conditions, including receipt of a $12.5 million cash payment from KV. Transfer is expected to be completed by February 11.
Verizon (VZ) stopped online sales of the Apple (AAPL) iPhone 4 after one day, in what the company called the "most successful first day" of online sales its history, according to a statement. The general market launch of the iPhone 4 on the Verizon Wireless network will occur on Feb. 10. The company will open its more than 2,000 Verizon Wireless stores at 7 a.m. It will also be available at all Apple store locations, Best Buy, select Wal-Mart stores.
Silverleaf Resorts (SVLF) soared after it says it will be bought by SL Resort Holdings Inc., an affiliate of Cerberus Capital Management, L.P, for $2.50 in cash per share.
GameStop Corp.(GME) is up after the company announced that its Board of Director had authorized $500 million in additional funds for its share and debt repurchase program.
In earnings news:
--Shares of health insurer Aetna (AET) are higher after the firm reported Q4 earnings of $0.63, a penny better than the Street view. Revenue was $8.51 billion, vs. the analyst consensus of $8.4 billion on Thomson Reuters. Aetna projects full-year 2011 operating earnings per share of $3.70 to $3.80. The Street is at $3.27 per share.
--Yum! Brands (YUM) is fractionally lower after the company reported net income of $0.63 per share for the quarter, beating the Thomson Reuters consensus estimate of $0.60. Sales grew 6% to $3.56 billion, also topping the Street.
--MoneyGram International (MGI) reports Q4 revenue of $303.4 mln, ahead of Street expectations of $295 mln. EPS loss was $0.23, narrower than the analyst consensus of a loss of $0.35 per share on Thomson Reuters.
Tyson Foods (TSN) reports Q1 earnings of $0.78 per share, including a $0.03 per share gain, up from $0.42 per share a year ago. Sales were $7.61 bln, up from $6.63 bln last year. The Street view was a profit of $0.62 per share on sales of $7.15 bln.
Commodities are down. April gold contracts are down $5, or 0.37%, to $1,348 an ounce while March crude oil contracts are down 2.07%, or $1.88., at $88.66 a barrel.
In energy ETFs, the United States Oil Fund (USO) is down 1.97% to $37.34 and the United States Natural Gas fund (UNG) is down 0.52% to $5.86.
In precious metal ETFs, the SPDR Gold Trust (GLD) is down 0.57% to $131.44. Market Vectors Gold Miners (GDX) is down 0.58% to $56.19. iShares Silver Trust (SLV) is down 0.12% to $28.25.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news: Cisco Systems ( CSCO ) announced plans to acquire Inlet technologies, a privately-held provider of Adaptive Bit Rate ( ABR ) digital media processing platforms. According to the company, the acquisition of Inlet will bolster the capabilities of CSCO's Videoscape TV platform, allowing service and content providers to deliver video experiences to any device over any Internet Protocol ( IP ) network. Google ( GOOG ) shares are lower after the company said it received more than 75,000 job applications last week as the Internet search giant begins a hiring spree, Bloomberg reports. | In company news: Cisco Systems ( CSCO ) announced plans to acquire Inlet technologies, a privately-held provider of Adaptive Bit Rate ( ABR ) digital media processing platforms. Per the terms of an asset purchase agreement between Hologic (HOLX) and KV Pharmaceutical, Hologic will transfer the company's Makena assets to KV upon the satisfaction of certain conditions, including receipt of a $12.5 million cash payment from KV. Revenue was $8.51 billion, vs. the analyst consensus of $8.4 billion on Thomson Reuters. | In company news: Cisco Systems ( CSCO ) announced plans to acquire Inlet technologies, a privately-held provider of Adaptive Bit Rate ( ABR ) digital media processing platforms. In earnings news: --Shares of health insurer Aetna (AET) are higher after the firm reported Q4 earnings of $0.63, a penny better than the Street view. Brands (YUM) is fractionally lower after the company reported net income of $0.63 per share for the quarter, beating the Thomson Reuters consensus estimate of $0.60. | In company news: Cisco Systems ( CSCO ) announced plans to acquire Inlet technologies, a privately-held provider of Adaptive Bit Rate ( ABR ) digital media processing platforms. In earnings news: --Shares of health insurer Aetna (AET) are higher after the firm reported Q4 earnings of $0.63, a penny better than the Street view. The Street is at $3.27 per share. |
30513.0 | 2011-02-04 00:00:00 UTC | Mid-Day Update: Stocks Mixed as Investors Seek Direction Following Jobs Data; Earnings Provide Lift | ABR | https://www.nasdaq.com/articles/mid-day-update-stocks-mixed-investors-seek-direction-following-jobs-data-earnings-provide | nan | nan | Here's where markets stand at mid-day:
-NYSE down 35.36 (-0.43%) to 8,253.49
-DJIA down 14.27 (-0.12%) to 12,047.99
-S&P 500 down 1.98 (-0.16%) to 1,305.12
-Nasdaq up 1.38 (+0.05%) to 2,755.29
GLOBAL SENTIMENT
Hang Seng up 1.81%
Nikkei up 1.08%
FTSE up 0.23%
MID-DAY NYSE INDEX WATCH
NYSE Energy down 0.88% at 13,440.46
NYSE Financial down 0.35% at 5,206.46
NYSE Health Care down 0.2% at 6,587.91
NYSE Arca Tech 100 up 0.59% at 1,142.97
UPSIDE MOVERS
(+) JDSU (+22.6%) continues evening gain that followed earnings, guidance
beat.
(+) TSN (+5.8%) beats with Q1 results.
(+) PHM (+0.7%) revenue tops expectations.
(+) CEG (+0.8) Q4 results top year-ago quarte, guidance mostly above Street view.
(+) AVID (+5.8%) easily tops Q4 estimates.
(+) AET (+9.1%) beats with Q4 results, guides for 2011 EPS above Street view.
(+) CLX (+1.8%) beats with Q2 results.
(+) YRCW (+7.9%) beats sales estimates.
(+,-) WY (+3.4%) seeing mixed trade after earnings beat.
(+) CRBC (+9.9%) among morning actives.
(+) SVLF (+70%) sold to Cerberus Capital.
DOWNSIDE MOVERS
(-) LVS (-6.3%) continues downside reaction to mostly in line to better-than-expected earnings.
(-) FSLR (-2.5%) downgraded.
(-) LCC (-3.2%) downgraded.
(-) CSTR (-12.4%) continues evening drop that followed revenue miss.
(-) HOV (-2.2%) prices shares.
(-) MGI (-1.8%) beats with Q4 earnings.
(-) MGI (-1.8%) beats with Q4 results.
(-) CELL (-0.33%) upgraded.
MARKET DIRECTION
Stocks are mixed at mid-session as investors digest a relatively disappointing jobs report that added far fewer jobs than analysts had predicted. The data comes after a speech yesterday afternoon by Federal Reserve Board Chairman Ben Bernanke in which he commented on the slow growth in jobs.
U.S. employers added only 36,000 jobs last month, not the 140,000 positions that Wall Street economists expected. Severe weather may have impacted hiring more than expected. But the unemployment rate did fall to 9% from December's 9.4%, the lowest reading since April 2009. Wall Street thought the jobless rate would tick up to 9.5%.
In a speech Thursday, the Fed chairman said stronger payroll data and a drop in the unemployment rate could be expected soon. But he also said that the slow job market improvement so far is holding back the broader economic recovery.
In company news:
Cisco Systems ( CSCO ) announced plans to acquire Inlet technologies, a privately-held provider of Adaptive Bit Rate ( ABR ) digital media processing platforms. Under the agreement, CSCO will pay approximately $95 million in cash and retention-based incentives in exchange for all shares of Inlet. According to the company, the acquisition of Inlet will bolster the capabilities of CSCO's Videoscape TV platform, allowing service and content providers to deliver video experiences to any device over any Internet Protocol ( IP ) network.
Bank of America ( BAC ) shares are trending lower as Bloomberg reports the bank will get at least $700 million from QBE Insurance Group for BofA's Balboa insurance unit. The move is part of BofA's plan to focus on retail customers, commercial borrowers and investment banking while getting rid of unrelated assets in order to raise capital.
Google ( GOOG ) shares are lower after the company said it received more than 75,000 job applications last week as the Internet search giant begins a hiring spree, Bloomberg reports. This figure tops a previously-reached high set in May 2007 by 15%, the report said.
K-V Pharmaceutical (KV.A) said the US Food and Drug Administration approved its drug Makena, which reduces the risk of preterm births in women with singleton pregnancy. Per the terms of an asset purchase agreement between Hologic (HOLX) and KV Pharmaceutical, Hologic will transfer the company's Makena assets to KV upon the satisfaction of certain conditions, including receipt of a $12.5 million cash payment from KV. Transfer is expected to be completed by February 11.
Verizon (VZ) stopped online sales of the Apple (AAPL) iPhone 4 after one day, in what the company called the "most successful first day" of online sales its history, according to a statement. The general market launch of the iPhone 4 on the Verizon Wireless network will occur on Feb. 10. The company will open its more than 2,000 Verizon Wireless stores at 7 a.m. It will also be available at all Apple store locations, Best Buy, select Wal-Mart stores.
Silverleaf Resorts (SVLF) soared after it says it will be bought by SL Resort Holdings Inc., an affiliate of Cerberus Capital Management, L.P, for $2.50 in cash per share.
GameStop Corp.(GME) is up after the company announced that its Board of Director had authorized $500 million in additional funds for its share and debt repurchase program.
In earnings news:
--Shares of health insurer Aetna (AET) are higher after the firm reported Q4 earnings of $0.63, a penny better than the Street view. Revenue was $8.51 billion, vs. the analyst consensus of $8.4 billion on Thomson Reuters. Aetna projects full-year 2011 operating earnings per share of $3.70 to $3.80. The Street is at $3.27 per share.
--Yum! Brands (YUM) is fractionally lower after the company reported net income of $0.63 per share for the quarter, beating the Thomson Reuters consensus estimate of $0.60. Sales grew 6% to $3.56 billion, also topping the Street.
--MoneyGram International (MGI) reports Q4 revenue of $303.4 mln, ahead of Street expectations of $295 mln. EPS loss was $0.23, narrower than the analyst consensus of a loss of $0.35 per share on Thomson Reuters.
Tyson Foods (TSN) reports Q1 earnings of $0.78 per share, including a $0.03 per share gain, up from $0.42 per share a year ago. Sales were $7.61 bln, up from $6.63 bln last year. The Street view was a profit of $0.62 per share on sales of $7.15 bln.
Commodities are down. April gold contracts are down $5, or 0.37%, to $1,348 an ounce while March crude oil contracts are down 2.07%, or $1.88., at $88.66 a barrel.
In energy ETFs, the United States Oil Fund (USO) is down 1.97% to $37.34 and the United States Natural Gas fund (UNG) is down 0.52% to $5.86.
In precious metal ETFs, the SPDR Gold Trust (GLD) is down 0.57% to $131.44. Market Vectors Gold Miners (GDX) is down 0.58% to $56.19. iShares Silver Trust (SLV) is down 0.12% to $28.25.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news: Cisco Systems ( CSCO ) announced plans to acquire Inlet technologies, a privately-held provider of Adaptive Bit Rate ( ABR ) digital media processing platforms. According to the company, the acquisition of Inlet will bolster the capabilities of CSCO's Videoscape TV platform, allowing service and content providers to deliver video experiences to any device over any Internet Protocol ( IP ) network. The move is part of BofA's plan to focus on retail customers, commercial borrowers and investment banking while getting rid of unrelated assets in order to raise capital. | In company news: Cisco Systems ( CSCO ) announced plans to acquire Inlet technologies, a privately-held provider of Adaptive Bit Rate ( ABR ) digital media processing platforms. Per the terms of an asset purchase agreement between Hologic (HOLX) and KV Pharmaceutical, Hologic will transfer the company's Makena assets to KV upon the satisfaction of certain conditions, including receipt of a $12.5 million cash payment from KV. In earnings news: --Shares of health insurer Aetna (AET) are higher after the firm reported Q4 earnings of $0.63, a penny better than the Street view. | In company news: Cisco Systems ( CSCO ) announced plans to acquire Inlet technologies, a privately-held provider of Adaptive Bit Rate ( ABR ) digital media processing platforms. In earnings news: --Shares of health insurer Aetna (AET) are higher after the firm reported Q4 earnings of $0.63, a penny better than the Street view. Brands (YUM) is fractionally lower after the company reported net income of $0.63 per share for the quarter, beating the Thomson Reuters consensus estimate of $0.60. | In company news: Cisco Systems ( CSCO ) announced plans to acquire Inlet technologies, a privately-held provider of Adaptive Bit Rate ( ABR ) digital media processing platforms. (+) PHM (+0.7%) revenue tops expectations. (-) MGI (-1.8%) beats with Q4 earnings. |
30514.0 | 2023-12-16 05:00:00 UTC | Abbott (ABT) Rises Higher Than Market: Key Facts | ABT | https://www.nasdaq.com/articles/abbott-abt-rises-higher-than-market%3A-key-facts-0 | nan | nan | Abbott (ABT) closed the latest trading day at $108.06, indicating a +0.72% change from the previous session's end. This change outpaced the S&P 500's 0.45% gain on the day.
Market participants will be closely following the financial results of Abbott in its upcoming release. It is anticipated that the company will report an EPS of $1.19, marking a 15.53% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $10.14 billion, reflecting a 0.49% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $4.44 per share and revenue of $40.01 billion, which would represent changes of -16.85% and -8.35%, respectively, from the prior year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Abbott. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Abbott is currently a Zacks Rank #3 (Hold).
In terms of valuation, Abbott is currently trading at a Forward P/E ratio of 24.16. This signifies a premium in comparison to the average Forward P/E of 21.73 for its industry.
We can also see that ABT currently has a PEG ratio of 2.68. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. ABT's industry had an average PEG ratio of 2.72 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 144, putting it in the bottom 43% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABT in the coming trading sessions, be sure to utilize Zacks.com.
Zacks Naming Top 10 Stocks for 2024
Want to be tipped off early to our 10 top picks for the entirety of 2024?
History suggests their performance could be sensational.
From 2012 (when our Director of Research, Sheraz Mian assumed responsibility for the portfolio) through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2024. Don’t miss your chance to get in on these stocks when they’re released on January 2.
Be First to New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed the latest trading day at $108.06, indicating a +0.72% change from the previous session's end. We can also see that ABT currently has a PEG ratio of 2.68. ABT's industry had an average PEG ratio of 2.72 as of yesterday's close. | Abbott (ABT) closed the latest trading day at $108.06, indicating a +0.72% change from the previous session's end. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. We can also see that ABT currently has a PEG ratio of 2.68. | Abbott (ABT) closed the latest trading day at $108.06, indicating a +0.72% change from the previous session's end. We can also see that ABT currently has a PEG ratio of 2.68. ABT's industry had an average PEG ratio of 2.72 as of yesterday's close. | Abbott (ABT) closed the latest trading day at $108.06, indicating a +0.72% change from the previous session's end. We can also see that ABT currently has a PEG ratio of 2.68. ABT's industry had an average PEG ratio of 2.72 as of yesterday's close. |
30515.0 | 2023-12-16 00:00:00 UTC | Abbott (ABT) Gains From Global Expansion Amid Macro Woes | ABT | https://www.nasdaq.com/articles/abbott-abt-gains-from-global-expansion-amid-macro-woes | nan | nan | Abbott’s ABT branded generics within Established Pharmaceuticals Division (EPD) and diabetes businesses should drive growth in the coming quarters. New product launches should boost sales. However, the business environment continues to be challenging globally. The stock carries a Zack Rank #3 (Hold).
Abbott is expanding its Diagnostics business foothold (consisting of 24% of the company’s total revenues in the third quarter of 2023). Although, over the past few quarters, there has been a decline in demand for Abbott’s rapid diagnostic tests to detect COVID-19, it is largely being offset by higher growth across other businesses.
In the United States and internationally, Abbott is experiencing increased demand for routine diagnostics. Further, in the United States, Abbott is registering strong growth within the blood transfusion testing business, which is consistently recovering from the impact of lower plasma donations that occurred during the COVID-19 pandemic. Within Rapid Diagnostics, in the third quarter, the base business gained from increased demand for respiratory tests in anticipation of an earlier-than-normal start to the flu season in the Northern Hemisphere.
Abbott’s EPD business operates solely in emerging geographies, with leading positions in many of the largest and fastest-growing pharmaceutical markets for branded generics in the world. These markets include India, Russia, China and Latin America. The company recently noted that banking on the successful execution of its Branded Generic operating model, EPD is well positioned for sustained growth in many of these growing pharmaceutical markets.
Over the past two years, this business has managed to sustain low double-digit growth and has successfully positioned itself as one of the best-positioned large healthcare companies in emerging markets. In September, Abbott entered into an agreement with global biotech leader mAbxience to commercialize several biosimilars in emerging markets. This collaboration will help introduce cutting-edge medicines in the areas of oncology, women's health and respiratory diseases in countries that have historically lacked access to these treatment options.
Abbott Laboratories Price
Abbott Laboratories price | Abbott Laboratories Quote
On the flip side, during the COVID-19 public health emergency, Abbott’s diagnostic tests witnessed stupendous revenue growth backed by increased demand for testing as well as government-enacted favorable policies to expedite or promote access to healthcare in order to slow down or stop the spread of the virus. However, in the last few months of 2022 and following the official ending of the public health emergency in May, Abbott experienced a continuous decline in COVID testing-related demand.
In the third quarter of 2023, Abbott’s Rapid Diagnostics sales decreased 59.2% from the year-ago period due to lower demand for COVID-19 tests. The 27.3% decline in Molecular Diagnostics sales in the third quarter of 2023 was due to lower demand for laboratory-based molecular tests for COVID-19 as well as respiratory testing compared to significantly high demand in the year-ago period when the severity of the pandemic was quite prominent.
In the upcoming months too, this year-over-year decline in testing demand is expected to mar Abbott’s overall Diagnostics business sales.
Further, foreign exchange is a major headwind for Abbott due to a considerable percentage of its revenues coming from outside the United States. The strengthening of the euro and some other developed market currencies has constantly been hampering the company’s performance in the international markets.
In the third quarter, foreign exchange had an unfavorable year-over-year impact of 1.4% on sales.
Over the past year, shares of Abbott have declined 2.3% compared with the industry’s 3.6% decline.
Key Picks
Some better-ranked stocks in the broader medical space are Insulet PODD, Haemonetics HAE and DexCom DXCM. While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Insulet’s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 40.9% in the past year compared with the industry’s decline of 7%.
PODD’s earnings surpassed estimates in the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%.
Haemonetics’ stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 for 2023 and from $4.07 to $4.11 for 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%.
Estimates for DexCom’s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry’s decline of 7.1%.
DXCM’s earnings surpassed estimates in the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%.
Zacks Naming Top 10 Stocks for 2024
Want to be tipped off early to our 10 top picks for the entirety of 2024?
History suggests their performance could be sensational.
From 2012 (when our Director of Research, Sheraz Mian assumed responsibility for the portfolio) through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2024. Don’t miss your chance to get in on these stocks when they’re released on January 2.
Be First to New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Insulet Corporation (PODD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott’s ABT branded generics within Established Pharmaceuticals Division (EPD) and diabetes businesses should drive growth in the coming quarters. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Further, in the United States, Abbott is registering strong growth within the blood transfusion testing business, which is consistently recovering from the impact of lower plasma donations that occurred during the COVID-19 pandemic. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott’s ABT branded generics within Established Pharmaceuticals Division (EPD) and diabetes businesses should drive growth in the coming quarters. Abbott Laboratories Price Abbott Laboratories price | Abbott Laboratories Quote On the flip side, during the COVID-19 public health emergency, Abbott’s diagnostic tests witnessed stupendous revenue growth backed by increased demand for testing as well as government-enacted favorable policies to expedite or promote access to healthcare in order to slow down or stop the spread of the virus. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott’s ABT branded generics within Established Pharmaceuticals Division (EPD) and diabetes businesses should drive growth in the coming quarters. Although, over the past few quarters, there has been a decline in demand for Abbott’s rapid diagnostic tests to detect COVID-19, it is largely being offset by higher growth across other businesses. | Abbott’s ABT branded generics within Established Pharmaceuticals Division (EPD) and diabetes businesses should drive growth in the coming quarters. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Although, over the past few quarters, there has been a decline in demand for Abbott’s rapid diagnostic tests to detect COVID-19, it is largely being offset by higher growth across other businesses. |
30516.0 | 2023-12-16 00:00:00 UTC | Peter Lynch Detailed Fundamental Analysis - ABT | ABT | https://www.nasdaq.com/articles/peter-lynch-detailed-fundamental-analysis-abt-14 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Top Healthcare Stocks
Dividend Aristocrats2023
Wide Moat Stocks2023
High Insider Ownership Stocks
Factor-Based Stock Portfolios
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
30517.0 | 2023-12-16 00:00:00 UTC | Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now? | ABT | https://www.nasdaq.com/articles/is-proshares-sp-500-dividend-aristocrats-etf-nobl-a-strong-etf-right-now-9 | nan | nan | Launched on 10/09/2013, the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) is a smart beta exchange traded fund offering broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
Market cap weighted indexes were created to reflect the market, or a specific segment of the market, and the ETF industry has traditionally been dominated by products based on this strategy.
Market cap weighted indexes work great for investors who believe in market efficiency. They provide a low-cost, convenient and transparent way of replicating market returns.
If you're the kind of investor who would rather try and beat the market through good stock selection, then smart beta funds are your best choice; this fund class is known for tracking non-cap weighted strategies.
These indexes attempt to select stocks that have better chances of risk-return performance, based on certain fundamental characteristics or a combination of such characteristics.
Methodologies like equal-weighting, one of the simplest options out there, fundamental weighting, and volatility/momentum based weighting are all choices offered to investors in this space, but not all of them can deliver superior returns.
Fund Sponsor & Index
The fund is managed by Proshares. NOBL has been able to amass assets over $11.73 billion, making it one of the larger ETFs in the Style Box - Large Cap Value. This particular fund, before fees and expenses, seeks to match the performance of the S&P 500 DividendAristocrats Index.
The S&P 500 Dividend Aristocrats Index targets companies that are currently members of the S&P 500, have increased dividend payments each year for at least 25 years & meet certain market capitalization & liquidity requirements.
Cost & Other Expenses
Since cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF's expense ratio.
Operating expenses on an annual basis are 0.35% for this ETF, which makes it on par with most peer products in the space.
It's 12-month trailing dividend yield comes in at 2.05%.
Performance and Risk
The ETF has added about 6.47% and is up roughly 5.53% so far this year and in the past one year (as of 12/18/2023), respectively. NOBL has traded between $84.12 and $97.15 during this last 52-week period.
NOBL has a beta of 0.90 and standard deviation of 15.30% for the trailing three-year period, which makes the fund a medium risk choice in the space. With about 68 holdings, it effectively diversifies company-specific risk.
Alternatives
ProShares S&P 500 Dividend Aristocrats ETF is an excellent option for investors seeking to outperform the Style Box - Large Cap Value segment of the market. There are other ETFs in the space which investors could consider as well.
IShares Core Dividend Growth ETF (DGRO) tracks Morningstar US Dividend Growth Index and the Vanguard Dividend Appreciation ETF (VIG) tracks NASDAQ US Dividend Achievers Select Index. IShares Core Dividend Growth ETF has $25 billion in assets, Vanguard Dividend Appreciation ETF has $73.35 billion. DGRO has an expense ratio of 0.08% and VIG charges 0.06%.
Investors looking for cheaper and lower-risk options should consider traditional market cap weighted ETFs that aim to match the returns of the Style Box - Large Cap Value.
Bottom Line
To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week.
Get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports
Abbott Laboratories (ABT) : Free Stock Analysis Report
Aflac Incorporated (AFL) : Free Stock Analysis Report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
Vanguard Dividend Appreciation ETF (VIG): ETF Research Reports
iShares Core Dividend Growth ETF (DGRO): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Reports iShares Core Dividend Growth ETF (DGRO): ETF Research Reports To read this article on Zacks.com click here. Launched on 10/09/2013, the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) is a smart beta exchange traded fund offering broad exposure to the Style Box - Large Cap Value category of the market. NOBL has a beta of 0.90 and standard deviation of 15.30% for the trailing three-year period, which makes the fund a medium risk choice in the space. | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Reports iShares Core Dividend Growth ETF (DGRO): ETF Research Reports To read this article on Zacks.com click here. IShares Core Dividend Growth ETF (DGRO) tracks Morningstar US Dividend Growth Index and the Vanguard Dividend Appreciation ETF (VIG) tracks NASDAQ US Dividend Achievers Select Index. IShares Core Dividend Growth ETF has $25 billion in assets, Vanguard Dividend Appreciation ETF has $73.35 billion. | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Reports iShares Core Dividend Growth ETF (DGRO): ETF Research Reports To read this article on Zacks.com click here. Launched on 10/09/2013, the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) is a smart beta exchange traded fund offering broad exposure to the Style Box - Large Cap Value category of the market. IShares Core Dividend Growth ETF (DGRO) tracks Morningstar US Dividend Growth Index and the Vanguard Dividend Appreciation ETF (VIG) tracks NASDAQ US Dividend Achievers Select Index. | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Reports iShares Core Dividend Growth ETF (DGRO): ETF Research Reports To read this article on Zacks.com click here. Methodologies like equal-weighting, one of the simplest options out there, fundamental weighting, and volatility/momentum based weighting are all choices offered to investors in this space, but not all of them can deliver superior returns. NOBL has a beta of 0.90 and standard deviation of 15.30% for the trailing three-year period, which makes the fund a medium risk choice in the space. |
30518.0 | 2023-12-16 00:00:00 UTC | The Zacks Analyst Blog Highlights JPMorgan Chase, Abbott Laboratories, Qualcomm, Johnson & Johnson and BHP | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-jpmorgan-chase-abbott-laboratories-qualcomm-johnson | nan | nan | For Immediate Release
Chicago, IL – December 18, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: JPMorgan Chase & Co. JPM, Abbott Laboratories ABT, Qualcomm Inc. QCOM, Johnson & Johnson JNJ and BHP Group Ltd. BHP.
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for JPMorgan, Abbott Labs and Qualcomm
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co., Abbott Laboratories and Qualcomm Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of JPMorgan have outperformed the Zacks Banks - Major Regional industry over the past year (+29.8% vs. +17.7%). High interest rates, buyouts, global expansion efforts and decent loan demand will aid net interest income (NII), though rising funding costs will weigh on it.
According to the Zacks analyst estimates for NII (managed) and loans imply a CAGR of 9.8% and 7.2%, respectively, by 2025. Aided by solid earnings strength and balance sheet, it will be able to sustain capital distributions. Despite visibility of some greenshoots in the investment banking (IB) business, IB fees are less likely to improve soon.
This, along with the volatile nature of the capital markets business and high mortgage rates, will likely hamper fee income growth. Owing to these challenges, we expect total non-interest income (managed) to witness a CAGR of just 3.6% by 2025. Mounting costs are a woe and we expect it to rise 11% in 2023.
(You can read the full research report on JPMorgan here >>>)
Abbott shares have outperformed the Zacks Medical - Products industry over the past year (+2.1% vs. -0.1%). The company is strategically expanding its global presence to address the unmet demand for advanced medical technologies. Within the EPD business, which is solely based in emerging markets, the Zacks analyst expects Abbott to register a sales CAGR of nearly 6% through fiscal 2025.
Within Core Diagnostics, Abbott is gaining market share following the end of the public health emergency, particularly in the United States and Europe region. Within Diabetes Care, Abbott is scaling up the production of Libre and gaining reimbursement approval in several countries. Innovations and market expansion efforts are helping it offset the impact of inflation and supply disruptions.
However, a steep year-over-year decline in COVID testing-related sales hurt growth. Further, the decision to exit the pediatric nutrition business in China continues to impede overall growth in Nutrition.
(You can read the full research report on Abbott here >>>)
Shares of Qualcomm have outperformed the Zacks Wireless Equipment industry over the past year (+24.6% vs. +9.2%). The company is well poised to benefit from solid 5G traction, greater visibility and a diversified revenue stream. Strength in the snapdragon portfolio is an additional tailwind as exemplified by the multi-year.
Apple deals for 5G modems for iPhones. It is focusing on a seamless transition from a wireless communications firm for the mobile industry to a connected processor firm for the intelligent edge. Qualcomm is also witnessing solid momentum in IoT.
However, it reported relatively soft fourth-quarter fiscal 2023 results owing to a challenging macroeconomic environment, inflationary pressures and soft recovery in China, resulting in lower-than-expected demand and elevated inventory levels.
Weakness in the smartphone industry and cautious client approach are weighing on margins. Rising geopolitical conflicts and high debt burden remain headwinds.
(You can read the full research report on QUALCOMM here >>>)
Other noteworthy reports we are featuring today include Johnson & Johnson and BHP Group Ltd.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks Naming Top 10 Stocks for 2024
Want to be tipped off early to our 10 top picks for the entirety of 2024?
History suggests their performance could be sensational.
From 2012 (when our Director of Research, Sheraz Mian assumed responsibility for the portfolio) through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2024. Don’t miss your chance to get in on these stocks when they’re released on January 2.
Be First to New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report
Abbott Laboratories (ABT) : Free Stock Analysis Report
QUALCOMM Incorporated (QCOM) : Free Stock Analysis Report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
BHP Group Limited Sponsored ADR (BHP) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include: JPMorgan Chase & Co. JPM, Abbott Laboratories ABT, Qualcomm Inc. QCOM, Johnson & Johnson JNJ and BHP Group Ltd. BHP. Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report QUALCOMM Incorporated (QCOM) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report BHP Group Limited Sponsored ADR (BHP) : Free Stock Analysis Report To read this article on Zacks.com click here. Within the EPD business, which is solely based in emerging markets, the Zacks analyst expects Abbott to register a sales CAGR of nearly 6% through fiscal 2025. | Stocks recently featured in the blog include: JPMorgan Chase & Co. JPM, Abbott Laboratories ABT, Qualcomm Inc. QCOM, Johnson & Johnson JNJ and BHP Group Ltd. BHP. Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report QUALCOMM Incorporated (QCOM) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report BHP Group Limited Sponsored ADR (BHP) : Free Stock Analysis Report To read this article on Zacks.com click here. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co., Abbott Laboratories and Qualcomm Inc. | Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report QUALCOMM Incorporated (QCOM) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report BHP Group Limited Sponsored ADR (BHP) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: JPMorgan Chase & Co. JPM, Abbott Laboratories ABT, Qualcomm Inc. QCOM, Johnson & Johnson JNJ and BHP Group Ltd. BHP. Here are highlights from Friday’s Analyst Blog: Top Stock Reports for JPMorgan, Abbott Labs and Qualcomm The Zacks Research Daily presents the best research output of our analyst team. | Stocks recently featured in the blog include: JPMorgan Chase & Co. JPM, Abbott Laboratories ABT, Qualcomm Inc. QCOM, Johnson & Johnson JNJ and BHP Group Ltd. BHP. Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report QUALCOMM Incorporated (QCOM) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report BHP Group Limited Sponsored ADR (BHP) : Free Stock Analysis Report To read this article on Zacks.com click here. Here are highlights from Friday’s Analyst Blog: Top Stock Reports for JPMorgan, Abbott Labs and Qualcomm The Zacks Research Daily presents the best research output of our analyst team. |
30519.0 | 2023-12-14 00:00:00 UTC | ABT Quantitative Stock Analysis - Peter Lynch | ABT | https://www.nasdaq.com/articles/abt-quantitative-stock-analysis-peter-lynch-2 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Top Healthcare Stocks
Dividend Aristocrats2023
Wide Moat Stocks2023
High Insider Ownership Stocks
Factor-Based Stock Portfolios
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
30520.0 | 2023-12-14 00:00:00 UTC | Top Stock Reports for JPMorgan, Abbott, Qualcomm & Others | ABT | https://www.nasdaq.com/articles/top-stock-reports-for-jpmorgan-abbott-qualcomm-others | nan | nan | Friday, December 15, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT) and Qualcomm Inc. (QCOM). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of JPMorgan have outperformed the Zacks Banks - Major Regional industry over the past year (+29.8% vs. +17.7%). High interest rates, buyouts, global expansion efforts and decent loan demand will aid net interest income (NII), though rising funding costs will weigh on it.
According to the Zacks analyst estimates for NII (managed) and loans imply a CAGR of 9.8% and 7.2%, respectively, by 2025. Aided by solid earnings strength and balance sheet, it will be able to sustain capital distributions. Despite visibility of some greenshoots in the investment banking (IB) business, IB fees are less likely to improve soon.
This, along with the volatile nature of the capital markets business and high mortgage rates, will likely hamper fee income growth. Owing to these challenges, we expect total non-interest income (managed) to witness a CAGR of just 3.6% by 2025. Mounting costs are a woe and we expect it to rise 11% in 2023.
(You can read the full research report on JPMorgan here >>>)
Abbott shares have outperformed the Zacks Medical - Products industry over the past year (+2.1% vs. -0.1%). The company is strategically expanding its global presence to address the unmet demand for advanced medical technologies. Within the EPD business, which is solely based in emerging markets, the Zacks analyst expects Abbott to register a sales CAGR of nearly 6% through fiscal 2025.
Within Core Diagnostics, Abbott is gaining market share following the end of the public health emergency, particularly in the United States and Europe region. Within Diabetes Care, Abbott is scaling up the production of Libre and gaining reimbursement approval in several countries. Innovations and market expansion efforts are helping it offset the impact of inflation and supply disruptions.
However, a steep year-over-year decline in COVID testing-related sales hurt growth. Further, the decision to exit the pediatric nutrition business in China continue to impede overall growth in Nutrition.
(You can read the full research report on Abbott here >>>)
Shares of Qualcomm have outperformed the Zacks Wireless Equipment industry over the past year (+24.6% vs. +9.2%). The company is well poised to benefit from solid 5G traction, greater visibility and a diversified revenue stream. Strength in the snapdragon portfolio is an additional tailwind as exemplified by the multi-year.
Apple deal for 5G modems for iPhones. It is focusing on a seamless transition from a wireless communications firm for the mobile industry to a connected processor firm for the intelligent edge. Qualcomm is also witnessing solid momentum in IoT.
However, it reported relatively soft fourth-quarter fiscal 2023 results owing to a challenging macroeconomic environment, inflationary pressures and soft recovery in China, resulting in lower-than-expected demand and elevated inventory levels.
Weakness in the smartphone industry and cautious client approach are weighing on margins. Rising geopolitical conflicts and high debt burden remain headwinds.
(You can read the full research report on QUALCOMM here >>>)
Other noteworthy reports we are featuring today include Johnson & Johnson (JNJ), Fomento Económico Mexicano, S.A.B. de C.V. (FMX) and BHP Group Ltd. (BHP).
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Buyouts, Rates & Loans Aid JPMorgan (JPM), Fee Income Ails
Market Share Gain, EPD Business Growth Aid Abbott (ABT)
Qualcomm (QCOM) Rides on 5G Traction, Portfolio Strength
Featured Reports
J&J's (JNJ) Innovative Medicine & MedTech Units Drive Growth
J&J's Innovative Medicine sales are being driven by existing key drugs and new products. Per the Zacks analyst, the MedTech unit is showing improving trends due to recovery in surgical procedures.
Investments to Drive BHP Group (BHP) Amid Price Volatility
The Zacks analyst believes BHP's strong cash flow, focus on lowering debt, investment in growth projects and operational efficiency will aid growth despite decline in iron ore prices so far this year.
MetLife's (MET) Cost-Cut Efforts & Strategic Buyouts Aid
Per the Zacks analyst, MetLife's cost-control measures are driving margins, while acquisitions are expanding its portfolio. However, volatile variable investment income is concerning.
Hess (HES) Banks On Oil-Rich Offshore Guyana Resources
Hess achieves numerous world-class oil findings in the Stabroek Block, securing a strong production outlook. However, increasing operating costs concern the Zacks analyst.
IQVIA Benefits From Global IT Infrastructure, Liquidity Low
Per the Zacks Analyst, IQVIA's strong healthcare-specific global IT infrastructure places it firmly in the life sciences space. Low liquidity remains a concern.
Investments & Growing Regulated Base Aid FirstEnergy (FE)
Per the Zacks analyst, FirstEnergy's investment of $12 billion through 2025, will strengthen its existing operations. Energizing the Future program will boost its regulated transmission capabilities.
Robust Sports Betting & Expansion Efforts Aid MGM Resorts (MGM)
Per the Zacks analyst, MGM Resorts is likely to benefit from international expansion and sports betting. Also, its focus on asset light strategy and strategic partnerships bode well.
New Upgrades
Investments in Specialized Distribution to Aid FEMSA (FMX)
Per the Zacks analyst, FEMSA has been on track with its strategy of creating a national distribution platform in the United States, through the expansion in the specialized distribution industry.
Casey's (CASY) Gains From Grocery & Prepared Food Businesses
Per the Zacks analyst, solid performance of Casey's Grocery & Prepared Food businesses, fueled by strength in bakery, whole pizza pies and dispensed beverage categories, will lend momentum to it.
SkyWest (SKYW) Rides on Buybacks & Fleet Upgrade Efforts
SkyWest's fleet modernization program is praiseworthy. The Zacks analyst is also impressed by the company's shareholder-friendly approach.
New Downgrades
Sluggish Smartphone Market Hurts Skyworks' (SWKS) Prospects
Per Zacks analyst, Skyworks is struggling due a weak smartphone market and stiff competition from the likes of Qorvo.
Subdued IB Business, High Costs Hurt Raymond James (RJF)
Per the Zacks analyst, volatile nature of the investment banking business makes us apprehensive about Raymond James' prospects. Mounting expenses are expected to hurt the company's bottom line.
Rising costs and Stiff Rivalry Impede Envista' (NVST) Growth
The Zacks analyst is worried about Envista facing challenging macroeconomic conditions resulting in a significant escalation in its costs and expenses. Stiff rivalry remains a concern.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report
Abbott Laboratories (ABT) : Free Stock Analysis Report
QUALCOMM Incorporated (QCOM) : Free Stock Analysis Report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
BHP Group Limited Sponsored ADR (BHP) : Free Stock Analysis Report
Fomento Economico Mexicano S.A.B. de C.V. (FMX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Buyouts, Rates & Loans Aid JPMorgan (JPM), Fee Income Ails Market Share Gain, EPD Business Growth Aid Abbott (ABT) Qualcomm (QCOM) Rides on 5G Traction, Portfolio Strength Featured Reports J&J's (JNJ) Innovative Medicine & MedTech Units Drive Growth J&J's Innovative Medicine sales are being driven by existing key drugs and new products. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT) and Qualcomm Inc. (QCOM). Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report QUALCOMM Incorporated (QCOM) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report BHP Group Limited Sponsored ADR (BHP) : Free Stock Analysis Report Fomento Economico Mexicano S.A.B. | Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT) and Qualcomm Inc. (QCOM). If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Buyouts, Rates & Loans Aid JPMorgan (JPM), Fee Income Ails Market Share Gain, EPD Business Growth Aid Abbott (ABT) Qualcomm (QCOM) Rides on 5G Traction, Portfolio Strength Featured Reports J&J's (JNJ) Innovative Medicine & MedTech Units Drive Growth J&J's Innovative Medicine sales are being driven by existing key drugs and new products. Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report QUALCOMM Incorporated (QCOM) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report BHP Group Limited Sponsored ADR (BHP) : Free Stock Analysis Report Fomento Economico Mexicano S.A.B. | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Buyouts, Rates & Loans Aid JPMorgan (JPM), Fee Income Ails Market Share Gain, EPD Business Growth Aid Abbott (ABT) Qualcomm (QCOM) Rides on 5G Traction, Portfolio Strength Featured Reports J&J's (JNJ) Innovative Medicine & MedTech Units Drive Growth J&J's Innovative Medicine sales are being driven by existing key drugs and new products. Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report QUALCOMM Incorporated (QCOM) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report BHP Group Limited Sponsored ADR (BHP) : Free Stock Analysis Report Fomento Economico Mexicano S.A.B. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT) and Qualcomm Inc. (QCOM). | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Buyouts, Rates & Loans Aid JPMorgan (JPM), Fee Income Ails Market Share Gain, EPD Business Growth Aid Abbott (ABT) Qualcomm (QCOM) Rides on 5G Traction, Portfolio Strength Featured Reports J&J's (JNJ) Innovative Medicine & MedTech Units Drive Growth J&J's Innovative Medicine sales are being driven by existing key drugs and new products. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT) and Qualcomm Inc. (QCOM). Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report QUALCOMM Incorporated (QCOM) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report BHP Group Limited Sponsored ADR (BHP) : Free Stock Analysis Report Fomento Economico Mexicano S.A.B. |
30521.0 | 2023-12-13 00:00:00 UTC | 3 No-Brainer Healthcare Stocks to Buy Right Now | ABT | https://www.nasdaq.com/articles/3-no-brainer-healthcare-stocks-to-buy-right-now | nan | nan | Earlier in the pandemic, coronavirus products boosted the revenue and the stock prices of companies selling those products. But these days, those products actually have done just the opposite, dragging down performance.
It's important to keep in mind, though, that some of these players offer (or are set to offer) revenue growth well beyond the coronavirus portfolio. So right now, with their shares trading at bargain prices, they've become no-brainer buys.
Which companies am I talking about? Coronavirus testing giant Abbott Laboratories (NYSE: ABT) and vaccine leaders Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE). Let's take a closer look at each of these stocks as possible buys right now.
Image source: Getty Images.
1. Abbott Laboratories
Abbott Labs became a coronavirus testing giant during the pandemic. But this company has four strong units that continue to deliver growth, even as demand for coronavirus testing declines.
The healthcare giant's diagnostics, medical devices, established pharmaceuticals, and nutrition businesses each grew in the double digits in the most recent quarter if we exclude coronavirus tests from the calculations. And these businesses together, excluding COVID tests, generated sales growth of more than 13% to $10 billion.
The company also has grown profit into the billions of dollars over time, thanks to its strengths across these businesses, and remains a giant in the area of diabetes care. Abbott sells one the of the leading continuous glucose monitors, the FreeStyle Libre, which reported a sales increase of 30% in the recent quarter.
You'll like Abbott for its solid earnings track record, its four strong businesses -- and one other thing -- its dividend. Abbott is a Dividend King, meaning it's increased payments for more than 50 straight years, so you can count on this company for passive income growth.
Trading at 24x forward earnings estimates, this stock is a must-buy right now.
2. Moderna
Moderna took center stage as it brought its coronavirus vaccine from the drawing board to market in less than a year -- and the vaccine generated billions of dollars in earnings as the biotech's first and only product. Those earnings helped Moderna build up cash and fund other programs in the pipeline.
Today, even though vaccine demand is on the decline, Moderna's future looks bright. First, vaccine demand isn't what it was at the height of the pandemic but isn't disappearing. Seasonal vaccination should represent significant recurring revenue for Moderna. And the company is developing a combined COVID/flu candidate that may become a popular product as it could interest the population that generally goes for an annual flu shot.
Second, Moderna may not be a single-product company for long. The biotech says it aims to launch 15 new products within the coming five years. Even if it only wins approval for a few, it still could deliver impressive growth.
That's why, trading at 8.5x forward earnings estimates, Moderna looks like a bargain you don't want to miss.
3. Pfizer
Like Moderna, Pfizer sells one of the leading coronavirus vaccines -- and Pfizer sells a billion-dollar coronavirus treatment, Paxlovid. Also, like Moderna, Pfizer faces declines in sales of these products. On top of that, some of Pfizer's other blockbusters outside of the coronavirus program are facing patent expirations later this decade -- and this should lead to a drop in sales.
Why should you buy this stock? Because Pfizer is prepared to compensate for those losses -- and go on to grow over the long term, thanks to new products. The company aims to launch 19 new products or indications during an 18-month period, and has already released 13. So it's well on its way to meeting the goal.
Pfizer also pays a dividend, with a yield that beats that of the S&P 500, and has put the focus on dividend growth. So, you can count on this company for passive income while you wait for the return to earnings growth.
For all of this, 18x forward earnings estimates seems a reasonable price to pay, making this stock a no-brainer to add to your portfolio right now.
Should you invest $1,000 in Abbott Laboratories right now?
Before you buy stock in Abbott Laboratories, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Abbott Laboratories wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.
See the 10 stocks
*Stock Advisor returns as of December 11, 2023
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories and Pfizer. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Coronavirus testing giant Abbott Laboratories (NYSE: ABT) and vaccine leaders Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE). The healthcare giant's diagnostics, medical devices, established pharmaceuticals, and nutrition businesses each grew in the double digits in the most recent quarter if we exclude coronavirus tests from the calculations. The company also has grown profit into the billions of dollars over time, thanks to its strengths across these businesses, and remains a giant in the area of diabetes care. | Coronavirus testing giant Abbott Laboratories (NYSE: ABT) and vaccine leaders Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE). Pfizer Like Moderna, Pfizer sells one of the leading coronavirus vaccines -- and Pfizer sells a billion-dollar coronavirus treatment, Paxlovid. Before you buy stock in Abbott Laboratories, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Abbott Laboratories wasn't one of them. | Coronavirus testing giant Abbott Laboratories (NYSE: ABT) and vaccine leaders Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE). Moderna Moderna took center stage as it brought its coronavirus vaccine from the drawing board to market in less than a year -- and the vaccine generated billions of dollars in earnings as the biotech's first and only product. Pfizer Like Moderna, Pfizer sells one of the leading coronavirus vaccines -- and Pfizer sells a billion-dollar coronavirus treatment, Paxlovid. | Coronavirus testing giant Abbott Laboratories (NYSE: ABT) and vaccine leaders Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE). Earlier in the pandemic, coronavirus products boosted the revenue and the stock prices of companies selling those products. But this company has four strong units that continue to deliver growth, even as demand for coronavirus testing declines. |
30522.0 | 2023-12-12 00:00:00 UTC | Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know | ABT | https://www.nasdaq.com/articles/investors-heavily-search-abbott-laboratories-abt%3A-here-is-what-you-need-to-know-3 | nan | nan | Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this maker of infant formula, medical devices and drugs have returned +10.9%, compared to the Zacks S&P 500 composite's +4.9% change. During this period, the Zacks Medical - Products industry, which Abbott falls in, has gained 9.9%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Abbott is expected to post earnings of $1.19 per share for the current quarter, representing a year-over-year change of +15.5%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.
For the current fiscal year, the consensus earnings estimate of $4.44 points to a change of -16.9% from the prior year. Over the last 30 days, this estimate has remained unchanged.
For the next fiscal year, the consensus earnings estimate of $4.62 indicates a change of +3.9% from what Abbott is expected to report a year ago. Over the past month, the estimate has remained unchanged.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Abbott is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
In the case of Abbott, the consensus sales estimate of $10.14 billion for the current quarter points to a year-over-year change of +0.5%. The $40.01 billion and $41.49 billion estimates for the current and next fiscal years indicate changes of -8.4% and +3.7%, respectively.
Last Reported Results and Surprise History
Abbott reported revenues of $10.14 billion in the last reported quarter, representing a year-over-year change of -2.6%. EPS of $1.14 for the same period compares with $1.15 a year ago.
Compared to the Zacks Consensus Estimate of $9.79 billion, the reported revenues represent a surprise of +3.6%. The EPS surprise was +3.64%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
Valuation
Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Abbott is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Abbott. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Over the past month, shares of this maker of infant formula, medical devices and drugs have returned +10.9%, compared to the Zacks S&P 500 composite's +4.9% change. | Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. For the next fiscal year, the consensus earnings estimate of $4.62 indicates a change of +3.9% from what Abbott is expected to report a year ago. | Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. | Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. And if earnings estimates go up for a company, the fair value for its stock goes up. |
30523.0 | 2023-12-12 00:00:00 UTC | ABT Quantitative Stock Analysis - Peter Lynch | ABT | https://www.nasdaq.com/articles/abt-quantitative-stock-analysis-peter-lynch-1 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Top Healthcare Stocks
Dividend Aristocrats2023
Wide Moat Stocks2023
High Insider Ownership Stocks
Factor-Based Stock Portfolios
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
30524.0 | 2023-12-12 00:00:00 UTC | ABT August 2024 Options Begin Trading | ABT | https://www.nasdaq.com/articles/abt-august-2024-options-begin-trading | nan | nan | Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the August 2024 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 246 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new August 2024 contracts and identified one put and one call contract of particular interest.
The put contract at the $105.00 strike price has a current bid of $4.65. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $105.00, but will also collect the premium, putting the cost basis of the shares at $100.35 (before broker commissions). To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $108.12/share today.
Because the $105.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 4.43% return on the cash commitment, or 6.57% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Abbott Laboratories, and highlighting in green where the $105.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $110.00 strike price has a current bid of $6.85. If an investor was to purchase shares of ABT stock at the current price level of $108.12/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $110.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 8.07% if the stock gets called away at the August 2024 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red:
Considering the fact that the $110.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 6.34% boost of extra return to the investor, or 9.40% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $108.12) to be 20%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of Stocks Analysts Like »
Also see:
Dow Component Preferreds
EPB Insider Buying
Quanex Building Prods Next Earnings Date
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the August 2024 expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the August 2024 expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the August 2024 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new August 2024 contracts and identified one put and one call contract of particular interest. | At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new August 2024 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the August 2024 expiration. |
30525.0 | 2023-12-12 00:00:00 UTC | MDT, ABT: 2 Healthcare Dividend Aristocrat Stocks Hedge Funds are Bullish On | ABT | https://www.nasdaq.com/articles/mdt-abt%3A-2-healthcare-dividend-aristocrat-stocks-hedge-funds-are-bullish-on | nan | nan | The volatile stock market scenario makes it prudent to invest in defensive investment options, such as healthcare stocks. Among these stocks, Medtronic (NYSE:MDT) and Abbott Laboratories (NYSE:ABT) stand out due to their status as Dividend Aristocrats (companies that have increased their dividends for over 25 consecutive years). Interestingly, hedge fund managers have been increasing their holdings in these two stocks.
Let’s take a closer look.
Medtronic Plc.
MDT has increased its dividend for 45 consecutive years. The company’s strong financials and leadership position within the medical device industry support its impressive dividend growth history. In addition, the company is focusing on digital technology adoption and cost-saving measures, with a target of achieving $1 billion in savings by 2025.
Furthermore, MDT stock has a “Very Positive” signal from TipRanks’ Hedge Fund Trading Activity tool. Per the tool, hedge funds bought 4.4 million shares of this healthcare giant last quarter. According to the tool, popular hedge fund managers, including Fisher Asset Management’s Ken Fisher and Morningstar Investment Management’s Kunal Kapoor, increased their positions in Medtronic stock.
What is the Price Target for MDT?
Following the company’s announcement to terminate the acquisition of wearable insulin patch maker EOFlow last week, two analysts rated the stock a Buy, while two assigned a Hold.
Overall, MDT stock has received six Buys, 10 Holds, and one Sell recommendation for a Moderate Buy consensus rating. Meanwhile, the average MDT stock price target of $88.20 implies 7.7% upside potential from current levels.
Importantly, MDT has an Outperform Smart Score of “Perfect 10” on TipRanks, which suggests that it can beat the overall market from here.
Abbott Laboratories
ABT has raised its dividend payout for 51 consecutive years, making it a perfect choice for income investors. The company’s well-diversified range of products, including diagnostics, medical devices, and pharmaceuticals, supports its growth in earnings and dividends.
Furthermore, the stock has a “Very Positive” signal from TipRanks’ Hedge Fund Trading Activity tool. The tool shows that hedge funds bought 819,300 shares of this healthcare company in the last quarter. Our data shows that Echo Street Capital Management’s Greg Poole and Bridgewater Associates’ Ray Dalio were among the hedge fund managers who increased their exposure to ABT stock.
What is the Future of ABT Stock?
This week, two analysts have reaffirmed a Buy rating on the stock, including Citi analyst Joanne Wuensch. The analyst expressed cautious optimism for MedTech in 2024, citing a stable macro backdrop and historical election-year performance.
ABT stock has received 10 Buy and three Hold recommendations for a Strong Buy consensus rating. The average Abbott stock price target of $118.46 implies 10.5% upside potential from the current level.
Ending Thoughts
Both ABT and MDT stocks have a proven track record of dividend growth. This makes them attractive to investors seeking reliable income and long-term portfolio stability. Additionally, the bullish view of hedge fund managers helps instill further confidence in these stocks.
Disclosure
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT has raised its dividend payout for 51 consecutive years, making it a perfect choice for income investors. Among these stocks, Medtronic (NYSE:MDT) and Abbott Laboratories (NYSE:ABT) stand out due to their status as Dividend Aristocrats (companies that have increased their dividends for over 25 consecutive years). Our data shows that Echo Street Capital Management’s Greg Poole and Bridgewater Associates’ Ray Dalio were among the hedge fund managers who increased their exposure to ABT stock. | Among these stocks, Medtronic (NYSE:MDT) and Abbott Laboratories (NYSE:ABT) stand out due to their status as Dividend Aristocrats (companies that have increased their dividends for over 25 consecutive years). Abbott Laboratories ABT has raised its dividend payout for 51 consecutive years, making it a perfect choice for income investors. Our data shows that Echo Street Capital Management’s Greg Poole and Bridgewater Associates’ Ray Dalio were among the hedge fund managers who increased their exposure to ABT stock. | Among these stocks, Medtronic (NYSE:MDT) and Abbott Laboratories (NYSE:ABT) stand out due to their status as Dividend Aristocrats (companies that have increased their dividends for over 25 consecutive years). Abbott Laboratories ABT has raised its dividend payout for 51 consecutive years, making it a perfect choice for income investors. Our data shows that Echo Street Capital Management’s Greg Poole and Bridgewater Associates’ Ray Dalio were among the hedge fund managers who increased their exposure to ABT stock. | Ending Thoughts Both ABT and MDT stocks have a proven track record of dividend growth. Among these stocks, Medtronic (NYSE:MDT) and Abbott Laboratories (NYSE:ABT) stand out due to their status as Dividend Aristocrats (companies that have increased their dividends for over 25 consecutive years). Abbott Laboratories ABT has raised its dividend payout for 51 consecutive years, making it a perfect choice for income investors. |
30526.0 | 2023-12-12 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-28 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Top Healthcare Stocks
Dividend Aristocrats2023
Wide Moat Stocks2023
High Insider Ownership Stocks
Factor-Based Stock Portfolios
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
30527.0 | 2023-12-11 00:00:00 UTC | Abbott (ABT) Advances But Underperforms Market: Key Facts | ABT | https://www.nasdaq.com/articles/abbott-abt-advances-but-underperforms-market%3A-key-facts | nan | nan | The most recent trading session ended with Abbott (ABT) standing at $106.68, reflecting a +0.43% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.46%. Elsewhere, the Dow gained 0.48%, while the tech-heavy Nasdaq added 0.7%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had gained 10.89% over the past month. This has outpaced the Medical sector's gain of 4.8% and the S&P 500's gain of 4.85% in that time.
Investors will be eagerly watching for the performance of Abbott in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $1.19, marking a 15.53% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $10.14 billion, up 0.49% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $4.44 per share and a revenue of $40.01 billion, representing changes of -16.85% and -8.35%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Abbott. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Abbott is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, Abbott is holding a Forward P/E ratio of 23.92. This denotes a premium relative to the industry's average Forward P/E of 20.69.
Also, we should mention that ABT has a PEG ratio of 2.66. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Medical - Products industry stood at 2.59 at the close of the market yesterday.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 138, positioning it in the bottom 46% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABT in the coming trading sessions, be sure to utilize Zacks.com.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The most recent trading session ended with Abbott (ABT) standing at $106.68, reflecting a +0.43% shift from the previouse trading day's closing. Also, we should mention that ABT has a PEG ratio of 2.66. To follow ABT in the coming trading sessions, be sure to utilize Zacks.com. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. The most recent trading session ended with Abbott (ABT) standing at $106.68, reflecting a +0.43% shift from the previouse trading day's closing. Also, we should mention that ABT has a PEG ratio of 2.66. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. The most recent trading session ended with Abbott (ABT) standing at $106.68, reflecting a +0.43% shift from the previouse trading day's closing. Also, we should mention that ABT has a PEG ratio of 2.66. | The most recent trading session ended with Abbott (ABT) standing at $106.68, reflecting a +0.43% shift from the previouse trading day's closing. Also, we should mention that ABT has a PEG ratio of 2.66. To follow ABT in the coming trading sessions, be sure to utilize Zacks.com. |
30528.0 | 2023-12-10 00:00:00 UTC | Validea's Top Health Care Stocks Based On Peter Lynch - 12/10/2023 | ABT | https://www.nasdaq.com/articles/valideas-top-health-care-stocks-based-on-peter-lynch-12-10-2023 | nan | nan | The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
DANAHER CORPORATION (DHR) is a large-cap growth stock in the Scientific & Technical Instr. industry. The rating according to our strategy based on Peter Lynch is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Danaher Corporation designs, manufactures and markets professional, medical, industrial, and commercial products and services. The Company's Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables and services that are used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. Its Life Sciences segment offers a range of instruments and consumables that are used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, and vaccines. Its Diagnostics segment offers clinical instruments, reagents, consumables, software that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of DANAHER CORPORATION
DHR Guru Analysis
DHR Fundamental Analysis
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is a global healthcare company. The Company's portfolio of technologies spans the spectrum of healthcare, with businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
ASTRAZENECA PLC (ADR) (AZN) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch is 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. Its geographical segments include United Kingdom, Rest of Europe, the Americas and Asia, Africa and Australasia. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: FAIL
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ASTRAZENECA PLC (ADR)
AZN Guru Analysis
AZN Fundamental Analysis
HCA HEALTHCARE INC (HCA) is a large-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on Peter Lynch is 72% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: HCA Healthcare, Inc. is a holding company. The Company is primarily engaged in providing healthcare services. Its general, acute care hospitals typically provide a full range of services to accommodate such medical specialties as internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, as well as diagnostic and emergency services. Outpatient and ancillary healthcare services are provided by its general, acute care hospitals, freestanding surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic centers and rehabilitation facilities. Its psychiatric hospitals provide a full range of mental healthcare services through inpatient, partial hospitalization and outpatient settings. The Company operates in two geographically organized groups: the National and American Groups. It operates over 182 hospitals, approximately 126 freestanding surgery centers, and over 21 freestanding endoscopy centers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of HCA HEALTHCARE INC
HCA Guru Analysis
HCA Fundamental Analysis
STAAR SURGICAL CO (STAA) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch is 69% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. Its manufacturing facility in Monrovia, California, makes the Visian implantable Collamer lens product family, including the EVO Visian ICL, preloaded silicone cataract intraocular lenses and injector systems. Its manufacturing facility in Brugg, Switzerland, operates an administrative, distribution and operational through its subsidiary, STAAR Surgical AG. It operates administrative and distribution facilities in Japan through its subsidiary, STAAR Japan Inc.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
INVENTORY TO SALES: PASS
EPS GROWTH RATE: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of STAAR SURGICAL CO
STAA Guru Analysis
STAA Fundamental Analysis
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of DANAHER CORPORATION DHR Guru Analysis DHR Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis ASTRAZENECA PLC (ADR) (AZN) is a large-cap growth stock in the Biotechnology & Drugs industry. The Company's Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables and services that are used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. | Detailed Analysis of DANAHER CORPORATION DHR Guru Analysis DHR Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis ASTRAZENECA PLC (ADR) (AZN) is a large-cap growth stock in the Biotechnology & Drugs industry. Detailed Analysis of STAAR SURGICAL CO STAA Guru Analysis STAA Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Detailed Analysis of DANAHER CORPORATION DHR Guru Analysis DHR Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis ASTRAZENECA PLC (ADR) (AZN) is a large-cap growth stock in the Biotechnology & Drugs industry. Detailed Analysis of ASTRAZENECA PLC (ADR) AZN Guru Analysis AZN Fundamental Analysis HCA HEALTHCARE INC (HCA) is a large-cap value stock in the Healthcare Facilities industry. | Detailed Analysis of DANAHER CORPORATION DHR Guru Analysis DHR Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis ASTRAZENECA PLC (ADR) (AZN) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: Danaher Corporation designs, manufactures and markets professional, medical, industrial, and commercial products and services. |
30529.0 | 2023-12-08 00:00:00 UTC | 2 Healthcare Stocks to Buy Hand Over Fist in December | ABT | https://www.nasdaq.com/articles/2-healthcare-stocks-to-buy-hand-over-fist-in-december | nan | nan | As the year draws to a close, it's as good a time as any to review one's investments and consider adding more money into the stock market. The goal shouldn't be to take advantage of the January effect -- the tendency equities have to rise early in the year. These market trends are short-lived, so as usual, it's better to focus on those companies that can perform well in the long run.
Two great examples in the healthcare sector are Abbott Laboratories (NYSE: ABT) and Intuitive Surgical (NASDAQ: ISRG). Let's investigate why you can safely put your hard-earned money into both stocks this month.
1. Abbott Laboratories
Shares of medical device specialist Abbott Laboratories have failed to keep pace with the market this year. There are several reasons, one of which is that its coronavirus diagnostic revenue continues to fluctuate. Abbott's total sales haven't been consistently pointing up as a result. In the third quarter, the healthcare giant's revenue of $10.1 billion decreased by 2.6% year over year.
Still, this is hardly a serious problem long-term investors need to worry about right now. For one thing, Abbott's coronavirus-related sales allowed it to keep its financial results afloat in the earlier days of the pandemic, when the rest of its business experienced severe disruptions. And now that this unit is no longer a reliable and consistent moneymaker, the rest of its operations are doing just fine.
In the third quarter, Abbott Labs' total sales, excluding its COVID-19 products, recorded an organic year-over-year increase of 13.8%. Medical devices performed particularly well, with the segment's revenue up by 16.6% compared to the year-ago period. Abbott boasts several key growth opportunities here, none more important than its continuous glucose monitoring (CGM) franchise, the FreeStyle Libre.
CGM systems have gained considerable traction -- and continue to do so -- because they allow diabetes patients to better keep track of their blood glucose levels. Abbott is also looking to continue innovating in this field. It recently acquired Bigfoot Biomedical, a company that develops insulin management systems. Abbott hopes to combine its expertise with that of its new subsidiary. Of course, this merely represents one of the company's growth areas.
Abbott's stock is also attractive due to its excellent reputation in the healthcare industry. A brand name that inspires confidence and trust, especially in matters of potential life and death, is an excellent economic moat. Abbott is also an outstanding dividend stock. The company is now on its 51st consecutive year of payout increases, which makes it a Dividend King.
All this makes Abbott Laboratories a top stock for income-seekers and long-term investors looking for steady and reliable returns.
2. Intuitive Surgical
Intuitive Surgical has performed more or less in line with the broader market this year despite lingering issues related to the pandemic, which also slowed down its business. However, Intuitive continues to make headway in the robotic-assisted surgery (RAS) market, where it is the undisputed leader. In the third quarter, the company's revenue increased by 12% year over year $1.74 billion.
Importantly, the number of procedures performed with its crown jewel, the da Vinci surgical system, grew by 19% year over year. This metric also registered a compound annual growth rate of 17% between the third quarters of 2019 and 2023. While Intuitive's procedure volume dropped early in the pandemic, this merely created a backlog of surgeries waiting to be performed. The company more or less caught up once things started getting back to normal.
Over the long run, we should see similarly strong procedure growth because the RAS market is deeply underpenetrated; fewer than 5% of procedures that could be performed robotically currently are. Much of Intuitive Surgical's revenue comes from the instruments and accessories it sells along with its da Vinci system. This number rises along with procedures, which means the company's revenue will continue increasing.
That's especially the case since Intuitive Surgical benefits from high switching costs. The price of a da Vinci system (between $0.5 million and $2.5 million), added to the time and cost of training medical personnel, makes it hard for hospital systems to switch to another RAS machine easily. That's why Intuitive Surgical continues to grow its installed base. It ended the third quarter with 7,364 installed da Vinci systems, an increase of 13% compared to the year-ago period.
Thanks to its leadership in this high-growth niche of the healthcare sector, Intuitive Surgical should continue delivering competitive returns for a long time.
10 stocks we like better than Abbott Laboratories
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 4, 2023
Prosper Junior Bakiny has positions in Intuitive Surgical. The Motley Fool has positions in and recommends Abbott Laboratories and Intuitive Surgical. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Two great examples in the healthcare sector are Abbott Laboratories (NYSE: ABT) and Intuitive Surgical (NASDAQ: ISRG). For one thing, Abbott's coronavirus-related sales allowed it to keep its financial results afloat in the earlier days of the pandemic, when the rest of its business experienced severe disruptions. Abbott boasts several key growth opportunities here, none more important than its continuous glucose monitoring (CGM) franchise, the FreeStyle Libre. | Two great examples in the healthcare sector are Abbott Laboratories (NYSE: ABT) and Intuitive Surgical (NASDAQ: ISRG). The price of a da Vinci system (between $0.5 million and $2.5 million), added to the time and cost of training medical personnel, makes it hard for hospital systems to switch to another RAS machine easily. It ended the third quarter with 7,364 installed da Vinci systems, an increase of 13% compared to the year-ago period. | Two great examples in the healthcare sector are Abbott Laboratories (NYSE: ABT) and Intuitive Surgical (NASDAQ: ISRG). Abbott Laboratories Shares of medical device specialist Abbott Laboratories have failed to keep pace with the market this year. Intuitive Surgical Intuitive Surgical has performed more or less in line with the broader market this year despite lingering issues related to the pandemic, which also slowed down its business. | Two great examples in the healthcare sector are Abbott Laboratories (NYSE: ABT) and Intuitive Surgical (NASDAQ: ISRG). Intuitive Surgical Intuitive Surgical has performed more or less in line with the broader market this year despite lingering issues related to the pandemic, which also slowed down its business. In the third quarter, the company's revenue increased by 12% year over year $1.74 billion. |
30530.0 | 2023-12-08 00:00:00 UTC | Peter Lynch Detailed Fundamental Analysis - ABT | ABT | https://www.nasdaq.com/articles/peter-lynch-detailed-fundamental-analysis-abt-13 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Top Healthcare Stocks
Dividend Aristocrats2023
Wide Moat Stocks2023
High Insider Ownership Stocks
Factor-Based Stock Portfolios
Excess Returns Investing Podcast
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. |
30531.0 | 2023-12-07 00:00:00 UTC | VIG, UNH, JPM, ABT: ETF Inflow Alert | ABT | https://www.nasdaq.com/articles/vig-unh-jpm-abt%3A-etf-inflow-alert | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $619.0 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 428,308,525 to 432,067,546). Among the largest underlying components of VIG, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 0.5%, JPMorgan Chase & Co (Symbol: JPM) is up about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average:
Looking at the chart above, VIG's low point in its 52 week range is $146.17 per share, with $167.33 as the 52 week high point — that compares with a last trade of $165.12. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
Also see:
CEW shares outstanding history
La-Z-Boy Historical PE Ratio
GRMN shares outstanding history
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VIG, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 0.5%, JPMorgan Chase & Co (Symbol: JPM) is up about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. | Among the largest underlying components of VIG, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 0.5%, JPMorgan Chase & Co (Symbol: JPM) is up about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $146.17 per share, with $167.33 as the 52 week high point — that compares with a last trade of $165.12. Click here to find out which 9 other ETFs had notable inflows » Also see: CEW shares outstanding history La-Z-Boy Historical PE Ratio GRMN shares outstanding history The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VIG, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 0.5%, JPMorgan Chase & Co (Symbol: JPM) is up about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $619.0 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 428,308,525 to 432,067,546). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $146.17 per share, with $167.33 as the 52 week high point — that compares with a last trade of $165.12. | Among the largest underlying components of VIG, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 0.5%, JPMorgan Chase & Co (Symbol: JPM) is up about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $619.0 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 428,308,525 to 432,067,546). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $146.17 per share, with $167.33 as the 52 week high point — that compares with a last trade of $165.12. |
30532.0 | 2023-12-07 00:00:00 UTC | Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now. | ABT | https://www.nasdaq.com/articles/looking-for-dividend-growth-in-the-new-year-3-magnificent-stocks-to-buy-now. | nan | nan | It's too early to predict what the market will do next year, but there's one way to guarantee some stock market gains. And that's by investing in dividend stocks.
These players offer you passive income -- even when their share prices are falling or the general market is declining. They represent returns you can count on.
For that reason, as you prepare your portfolio for the next investing year, it's a great idea to add a few dividend stocks to the mix. Which dividend stocks should you select?
Right now, three in particular are trading at bargain prices, offering you a great opportunity to scoop them up. I'm talking about healthcare giants AbbVie (NYSE: ABBV), Medtronic (NYSE: MDT), and Pfizer (NYSE: PFE). Plus, the sooner you get in on these players, the sooner you can start collecting dividends. Let's take a closer look at each one.
Image source: Getty Images.
1. AbbVie
AbbVie has made dividends its priority since its start, back in 2013 when it was spun off from Abbott Laboratories. Since then, it's grown its dividend a mind-boggling 285%. The company now pays a dividend of $6.20 per share, which represents a dividend yield of 4.29%, surpassing the 1.62% yield of the S&P 500.
The pharma company has continued to lift payments even now, as it's reached a difficult transition point: The company's top blockbuster lost exclusivity, opening it up to competition. At its peak last year, immunology drug Humira generated $21 billion in revenue, but these days, its revenue is on the decline as rivals offer cheaper alternatives.
AbbVie says that once earnings pick up, the company will further boost its dividend payments, and there's reason to believe this will happen. Here's why. AbbVie has prepared two newer immunology drugs -- Rinvoq and Skyrizi -- for potential approval in all of Humira's approved indications.
The company predicts they will actually surpass Humira's peak revenue in 2027. On top of that, AbbVie has a portfolio of top-selling drugs in other areas, from oncology to neuroscience.
Trading at about 12x forward earnings estimates, down from more than 14x earlier in the year, AbbVie looks like a buy right now.
2. Medtronic
Medtronic, with 46 years of dividend increases, is just a few years away from becoming a Dividend King -- a company that's lifted its dividend for at least 50 consecutive years. After so many years of Medtronic prioritizing dividend growth, it would be surprising if the company stopped now. So there's reason to be optimistic about collecting more and more passive income from Medtronic each year.
Plus, the company said in its recent earnings report that it aims to return at least 50% of free cash flow annually to shareholders. Right now, the medical-device giant pays a dividend of $2.76 per share with a yield of 3.50%, and that beats the yield of the S&P 500.
You'll like Medtronic for reasons beyond dividend growth, too. The company is a significant player in the medical-devices industry, with a presence in cardiovascular, neuroscience, diabetes, and medical surgical. Medtronic's growth slowed in recent years, but the company took action to transform the business by focusing on efficiency, divesting slower-growth businesses, and investing in high-growth technologies like artificial intelligence (AI).
Meanwhile, the stock trades for about 15x forward earnings estimates, down from 24 a couple of years ago -- even as growth is accelerating. Now is a great time to get in on this dividend story.
3. Pfizer
Investors have fled Pfizer stock because some of its top products are heading for declines. The coronavirus vaccine and treatment are posting decreasing sales due to lower demand at this later pandemic stage, and other blockbusters are losing exclusivity.
But here's why you shouldn't worry: As these declines and losses unfold, Pfizer is launching other new drugs that should compensate and even deliver further growth down the road. The company aims to launch 19 new drugs or indications over an 18-month period and already has completed 13. Pfizer says all of these new products could help the company deliver $84 billion in revenue by 2030.
On top of this, Pfizer is a great dividend stock to own. Growing the dividend is one of the three pillars of the company's capital-allocation strategy (the others are reinvesting in the business and making share repurchases). Today, Pfizer pays a dividend of $1.64 per share, representing a yield of 5.64%.
Pfizer shares have dropped 40% this year, and valuation metrics don't reflect the level of revenue the company may deliver several years down the road. But it's still fair to say, considering the huge wave of new products, that Pfizer looks like a top dirt cheap dividend stock to buy now.
10 stocks we like better than AbbVie
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 4, 2023
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories and Pfizer. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The coronavirus vaccine and treatment are posting decreasing sales due to lower demand at this later pandemic stage, and other blockbusters are losing exclusivity. But here's why you shouldn't worry: As these declines and losses unfold, Pfizer is launching other new drugs that should compensate and even deliver further growth down the road. But it's still fair to say, considering the huge wave of new products, that Pfizer looks like a top dirt cheap dividend stock to buy now. | I'm talking about healthcare giants AbbVie (NYSE: ABBV), Medtronic (NYSE: MDT), and Pfizer (NYSE: PFE). The company now pays a dividend of $6.20 per share, which represents a dividend yield of 4.29%, surpassing the 1.62% yield of the S&P 500. At its peak last year, immunology drug Humira generated $21 billion in revenue, but these days, its revenue is on the decline as rivals offer cheaper alternatives. | The company now pays a dividend of $6.20 per share, which represents a dividend yield of 4.29%, surpassing the 1.62% yield of the S&P 500. Medtronic Medtronic, with 46 years of dividend increases, is just a few years away from becoming a Dividend King -- a company that's lifted its dividend for at least 50 consecutive years. Pfizer shares have dropped 40% this year, and valuation metrics don't reflect the level of revenue the company may deliver several years down the road. | The company now pays a dividend of $6.20 per share, which represents a dividend yield of 4.29%, surpassing the 1.62% yield of the S&P 500. Medtronic Medtronic, with 46 years of dividend increases, is just a few years away from becoming a Dividend King -- a company that's lifted its dividend for at least 50 consecutive years. On top of this, Pfizer is a great dividend stock to own. |
30533.0 | 2023-12-06 00:00:00 UTC | PETQ vs. ABT: Which Stock Is the Better Value Option? | ABT | https://www.nasdaq.com/articles/petq-vs.-abt%3A-which-stock-is-the-better-value-option | nan | nan | Investors interested in Medical - Products stocks are likely familiar with PetIQ (PETQ) and Abbott (ABT). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.
PetIQ and Abbott are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that PETQ is likely seeing its earnings outlook improve to a greater extent. But this is just one factor that value investors are interested in.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
PETQ currently has a forward P/E ratio of 15.37, while ABT has a forward P/E of 23.50. We also note that PETQ has a PEG ratio of 1.92. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. ABT currently has a PEG ratio of 2.61.
Another notable valuation metric for PETQ is its P/B ratio of 2.17. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, ABT has a P/B of 4.81.
Based on these metrics and many more, PETQ holds a Value grade of A, while ABT has a Value grade of C.
PETQ is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that PETQ is likely the superior value option right now.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetIQ, Inc. (PETQ) : Free Stock Analysis Report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors interested in Medical - Products stocks are likely familiar with PetIQ (PETQ) and Abbott (ABT). PETQ currently has a forward P/E ratio of 15.37, while ABT has a forward P/E of 23.50. ABT currently has a PEG ratio of 2.61. | Click to get this free report PetIQ, Inc. (PETQ) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in Medical - Products stocks are likely familiar with PetIQ (PETQ) and Abbott (ABT). PETQ currently has a forward P/E ratio of 15.37, while ABT has a forward P/E of 23.50. | Based on these metrics and many more, PETQ holds a Value grade of A, while ABT has a Value grade of C. PETQ is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. Click to get this free report PetIQ, Inc. (PETQ) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in Medical - Products stocks are likely familiar with PetIQ (PETQ) and Abbott (ABT). | Investors interested in Medical - Products stocks are likely familiar with PetIQ (PETQ) and Abbott (ABT). ABT currently has a PEG ratio of 2.61. PETQ currently has a forward P/E ratio of 15.37, while ABT has a forward P/E of 23.50. |
30534.0 | 2023-12-06 00:00:00 UTC | Abbott (ABT) Advances While Market Declines: Some Information for Investors | ABT | https://www.nasdaq.com/articles/abbott-abt-advances-while-market-declines%3A-some-information-for-investors | nan | nan | Abbott (ABT) closed the latest trading day at $104.94, indicating a +0.57% change from the previous session's end. The stock's change was more than the S&P 500's daily loss of 0.39%. On the other hand, the Dow registered a loss of 0.19%, and the technology-centric Nasdaq decreased by 0.59%.
Coming into today, shares of the maker of infant formula, medical devices and drugs had gained 10.07% in the past month. In that same time, the Medical sector gained 3.38%, while the S&P 500 gained 5.08%.
Market participants will be closely following the financial results of Abbott in its upcoming release. The company's upcoming EPS is projected at $1.19, signifying a 15.53% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $10.14 billion, up 0.49% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $4.44 per share and revenue of $40.01 billion, indicating changes of -16.85% and -8.35%, respectively, compared to the previous year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Abbott. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Currently, Abbott is carrying a Zacks Rank of #3 (Hold).
From a valuation perspective, Abbott is currently exchanging hands at a Forward P/E ratio of 23.5. This represents a premium compared to its industry's average Forward P/E of 19.55.
Also, we should mention that ABT has a PEG ratio of 2.61. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Medical - Products industry stood at 2.59 at the close of the market yesterday.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 143, placing it within the bottom 44% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed the latest trading day at $104.94, indicating a +0.57% change from the previous session's end. Also, we should mention that ABT has a PEG ratio of 2.61. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Abbott (ABT) closed the latest trading day at $104.94, indicating a +0.57% change from the previous session's end. Also, we should mention that ABT has a PEG ratio of 2.61. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Abbott (ABT) closed the latest trading day at $104.94, indicating a +0.57% change from the previous session's end. Also, we should mention that ABT has a PEG ratio of 2.61. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Abbott (ABT) closed the latest trading day at $104.94, indicating a +0.57% change from the previous session's end. Also, we should mention that ABT has a PEG ratio of 2.61. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30535.0 | 2023-12-04 00:00:00 UTC | Peter Lynch Detailed Fundamental Analysis - ABT | ABT | https://www.nasdaq.com/articles/peter-lynch-detailed-fundamental-analysis-abt-12 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Top Healthcare Stocks
Dividend Aristocrats2023
Wide Moat Stocks2023
High Insider Ownership Stocks
Factor-Based Stock Portfolios
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
30536.0 | 2023-12-01 00:00:00 UTC | Peter Lynch Detailed Fundamental Analysis - ABT | ABT | https://www.nasdaq.com/articles/peter-lynch-detailed-fundamental-analysis-abt-11 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Top Healthcare Stocks
Dividend Aristocrats2023
Wide Moat Stocks2023
High Insider Ownership Stocks
Factor-Based Stock Portfolios
Excess Returns Investing Podcast
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. |
30537.0 | 2023-11-30 00:00:00 UTC | Abbott (ABT) Rises Higher Than Market: Key Facts | ABT | https://www.nasdaq.com/articles/abbott-abt-rises-higher-than-market%3A-key-facts | nan | nan | Abbott (ABT) closed the most recent trading day at $104.29, moving +0.64% from the previous trading session. The stock's change was more than the S&P 500's daily gain of 0.38%. Meanwhile, the Dow experienced a rise of 1.47%, and the technology-dominated Nasdaq saw a decrease of 0.23%.
Shares of the maker of infant formula, medical devices and drugs have appreciated by 9.07% over the course of the past month, outperforming the Medical sector's gain of 5.96% and lagging the S&P 500's gain of 10.72%.
The investment community will be closely monitoring the performance of Abbott in its forthcoming earnings report. In that report, analysts expect Abbott to post earnings of $1.19 per share. This would mark year-over-year growth of 15.53%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $10.14 billion, up 0.49% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $4.44 per share and a revenue of $40.01 billion, signifying shifts of -16.85% and -8.35%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for Abbott. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Abbott is currently a Zacks Rank #3 (Hold).
Looking at its valuation, Abbott is holding a Forward P/E ratio of 23.34. This signifies a premium in comparison to the average Forward P/E of 18.14 for its industry.
One should further note that ABT currently holds a PEG ratio of 2.59. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Products was holding an average PEG ratio of 2.5 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 141, this industry ranks in the bottom 45% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed the most recent trading day at $104.29, moving +0.64% from the previous trading session. One should further note that ABT currently holds a PEG ratio of 2.59. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Abbott (ABT) closed the most recent trading day at $104.29, moving +0.64% from the previous trading session. One should further note that ABT currently holds a PEG ratio of 2.59. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Abbott (ABT) closed the most recent trading day at $104.29, moving +0.64% from the previous trading session. One should further note that ABT currently holds a PEG ratio of 2.59. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Abbott (ABT) closed the most recent trading day at $104.29, moving +0.64% from the previous trading session. One should further note that ABT currently holds a PEG ratio of 2.59. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30538.0 | 2023-11-29 00:00:00 UTC | Wall Street Bulls Look Optimistic About Abbott (ABT): Should You Buy? | ABT | https://www.nasdaq.com/articles/wall-street-bulls-look-optimistic-about-abbott-abt%3A-should-you-buy | nan | nan | The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?
Let's take a look at what these Wall Street heavyweights have to say about Abbott (ABT) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Abbott currently has an average brokerage recommendation (ABR) of 1.56, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 18 brokerage firms. An ABR of 1.56 approximates between Strong Buy and Buy.
Of the 18 recommendations that derive the current ABR, 12 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 66.7% and 11.1% of all recommendations.
Brokerage Recommendation Trends for ABT
Check price target & stock forecast for Abbott here>>>
The ABR suggests buying Abbott, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
ABR Should Not Be Confused With Zacks Rank
In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Is ABT Worth Investing In?
Looking at the earnings estimate revisions for Abbott, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $4.44.
Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Abbott. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Abbott.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.
It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Let's take a look at what these Wall Street heavyweights have to say about Abbott (ABT) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Brokerage Recommendation Trends for ABT Is ABT Worth Investing In? | Let's take a look at what these Wall Street heavyweights have to say about Abbott (ABT) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Brokerage Recommendation Trends for ABT Is ABT Worth Investing In? | Let's take a look at what these Wall Street heavyweights have to say about Abbott (ABT) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Brokerage Recommendation Trends for ABT Is ABT Worth Investing In? | Brokerage Recommendation Trends for ABT Let's take a look at what these Wall Street heavyweights have to say about Abbott (ABT) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Is ABT Worth Investing In? |
30539.0 | 2023-11-29 00:00:00 UTC | Should You Invest in the iShares U.S. Medical Devices ETF (IHI)? | ABT | https://www.nasdaq.com/articles/should-you-invest-in-the-ishares-u.s.-medical-devices-etf-ihi-9 | nan | nan | The iShares U.S. Medical Devices ETF (IHI) was launched on 05/01/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Medical Devices segment of the equity market.
Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors.
Sector ETFs are also funds of convenience, offering many ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Medical Devices is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 1, placing it in top 6%.
Index Details
The fund is sponsored by Blackrock. It has amassed assets over $5.01 billion, making it one of the largest ETFs attempting to match the performance of the Healthcare - Medical Devices segment of the equity market. IHI seeks to match the performance of the Dow Jones U.S. Select Medical Equipment Index before fees and expenses.
The Dow Jones U.S. Select Medical Equipment Index measures the performance of the medical equipment sector of the U.S. equity market.
Costs
Since cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF's expense ratio.
Annual operating expenses for this ETF are 0.40%, making it one of the cheaper products in the space.
It has a 12-month trailing dividend yield of 0.53%.
Sector Exposure and Top Holdings
While ETFs offer diversified exposure, which minimizes single stock risk, a deep look into a fund's holdings is a valuable exercise. And, most ETFs are very transparent products that disclose their holdings on a daily basis.
This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio.
Looking at individual holdings, Abbott Laboratories (ABT) accounts for about 17.58% of total assets, followed by Intuitive Surgical Inc (ISRG) and Medtronic Plc (MDT).
The top 10 holdings account for about 71.67% of total assets under management.
Performance and Risk
So far this year, IHI has lost about -5.37%, and is down about -3.11% in the last one year (as of 11/29/2023). During this past 52-week period, the fund has traded between $44.46 and $57.76.
The ETF has a beta of 0.86 and standard deviation of 20% for the trailing three-year period, making it a medium risk choice in the space. With about 59 holdings, it effectively diversifies company-specific risk.
Alternatives
IShares U.S. Medical Devices ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, IHI is a sufficient option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.
First Trust Indxx Medical Devices ETF (MDEV) tracks INDXX GLOBAL MEDICAL EQUIPMENT INDEX and the SPDR S&P Health Care Equipment ETF (XHE) tracks S&P Health Care Equipment Select Industry Index. First Trust Indxx Medical Devices ETF has $2.77 million in assets, SPDR S&P Health Care Equipment ETF has $304.88 million. MDEV has an expense ratio of 0.70% and XHE charges 0.35%.
Bottom Line
To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week.
Get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
iShares U.S. Medical Devices ETF (IHI): ETF Research Reports
Abbott Laboratories (ABT) : Free Stock Analysis Report
Medtronic PLC (MDT) : Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report
SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports
First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at individual holdings, Abbott Laboratories (ABT) accounts for about 17.58% of total assets, followed by Intuitive Surgical Inc (ISRG) and Medtronic Plc (MDT). Click to get this free report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. | Click to get this free report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. Looking at individual holdings, Abbott Laboratories (ABT) accounts for about 17.58% of total assets, followed by Intuitive Surgical Inc (ISRG) and Medtronic Plc (MDT). First Trust Indxx Medical Devices ETF (MDEV) tracks INDXX GLOBAL MEDICAL EQUIPMENT INDEX and the SPDR S&P Health Care Equipment ETF (XHE) tracks S&P Health Care Equipment Select Industry Index. | Click to get this free report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. Looking at individual holdings, Abbott Laboratories (ABT) accounts for about 17.58% of total assets, followed by Intuitive Surgical Inc (ISRG) and Medtronic Plc (MDT). First Trust Indxx Medical Devices ETF (MDEV) tracks INDXX GLOBAL MEDICAL EQUIPMENT INDEX and the SPDR S&P Health Care Equipment ETF (XHE) tracks S&P Health Care Equipment Select Industry Index. | Looking at individual holdings, Abbott Laboratories (ABT) accounts for about 17.58% of total assets, followed by Intuitive Surgical Inc (ISRG) and Medtronic Plc (MDT). Click to get this free report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. The iShares U.S. Medical Devices ETF (IHI) was launched on 05/01/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Medical Devices segment of the equity market. |
30540.0 | 2023-11-29 00:00:00 UTC | Notable ETF Inflow Detected - OEF, UNH, ABT, NEE | ABT | https://www.nasdaq.com/articles/notable-etf-inflow-detected-oef-unh-abt-nee | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $107.8 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 54,950,000 to 55,450,000). Among the largest underlying components of OEF, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 0.8%, Abbott Laboratories (Symbol: ABT) is up about 1.1%, and NextEra Energy Inc (Symbol: NEE) is higher by about 1.3%. For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average:
Looking at the chart above, OEF's low point in its 52 week range is $167.20 per share, with $217 as the 52 week high point — that compares with a last trade of $216.01. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
Also see:
ETF Fund Flows
Top Ten Hedge Funds Holding IFSH
AGTI Average Annual Return
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of OEF, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 0.8%, Abbott Laboratories (Symbol: ABT) is up about 1.1%, and NextEra Energy Inc (Symbol: NEE) is higher by about 1.3%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. | Among the largest underlying components of OEF, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 0.8%, Abbott Laboratories (Symbol: ABT) is up about 1.1%, and NextEra Energy Inc (Symbol: NEE) is higher by about 1.3%. For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $167.20 per share, with $217 as the 52 week high point — that compares with a last trade of $216.01. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of OEF, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 0.8%, Abbott Laboratories (Symbol: ABT) is up about 1.1%, and NextEra Energy Inc (Symbol: NEE) is higher by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $107.8 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 54,950,000 to 55,450,000). For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $167.20 per share, with $217 as the 52 week high point — that compares with a last trade of $216.01. | Among the largest underlying components of OEF, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 0.8%, Abbott Laboratories (Symbol: ABT) is up about 1.1%, and NextEra Energy Inc (Symbol: NEE) is higher by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $107.8 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 54,950,000 to 55,450,000). For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $167.20 per share, with $217 as the 52 week high point — that compares with a last trade of $216.01. |
30541.0 | 2023-11-28 00:00:00 UTC | ABT Quantitative Stock Analysis - Peter Lynch | ABT | https://www.nasdaq.com/articles/abt-quantitative-stock-analysis-peter-lynch-0 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Top Healthcare Stocks
Dividend Aristocrats2023
Wide Moat Stocks2023
High Insider Ownership Stocks
Factor-Based Stock Portfolios
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
30542.0 | 2023-11-28 00:00:00 UTC | 3 Defensive Dividend Stocks to Protect Your Portfolio | ABT | https://www.nasdaq.com/articles/3-defensive-dividend-stocks-to-protect-your-portfolio | nan | nan | After a historically bad performance during the first half of the year, dividend stocks have come under quite a bit of scrutiny lately. A new Bloomberg analysis of the dividend stock underperformance in 2023 observed, “Investors wanted exposure to companies with a history of paying out profits as a precaution amid the Federal Reserve’s most aggressive tightening cycle in 40 years. Instead they were saddled with underperforming companies that proved especially vulnerable when yields shot higher.”
Clearly, dividend stocks are facing a tough time in this market. However, it's worth pointing out that there are still some names in the group that combine consistent dividend income with steady growth. Here, we've highlighted three of those names - all top-rated by analysts, with room for upside in the year ahead.
Domino's Pizza
Domino's Pizza (DPZ) is a name synonymous with success in the pizza industry, boasting more than 20,000 locations worldwide. Founded in 1960, Domino's has evolved into a global powerhouse in the fast-food sector, with a market capitalization of approximately $12.91 billion.
Particularly noteworthy is the company's quarterly dividend of $1.21 per share, for a forward yield of 1.31%. Domino's has raised its dividend consistently for a decade, with a very sustainable payout ratio of 32% - indicating a strategic balance between rewarding shareholders and reinvesting in the business. With $80.9 million in cash and equivalents and a robust free cash flow of $362.9 million, Domino's financial resilience is evident.
Innovation is also at the forefront of Domino's strategy. Its partnership with Microsoft (MSFT) for AI-driven solutions, in-store logistics, and personalized ordering indicates a commitment to technological growth alongside income generation.
In 2023, Domino's Pizza stock has gained just about 13%. That's not quite on pace with the broader S&P 500 Index ($SPX), but it's considerably better than some of the broader dividend stock benchmarks.
www.barchart.com
In the most recent quarter, Domino's reported adjusted earnings of $4.18 per share, which topped expectations - even as revenue of $1.03 billion fell slightly short. Looking ahead, analysts are targeting 15% EPS growth for this fiscal year, followed by roughly 9% for FY 2024.
www.barchart.com
Domino's Pizza has an average "Moderate Buy" rating from 25 analysts, with 14 of those calling it a “Strong Buy." The average 12-month price target of $406.30 implies expected upside of 5% from current levels.
www.barchart.com
Home Depot
Founded in 1978, Home Depot (HD) is a major player in the home improvement retail sector, and operates over 2,300 stores across North America. The retailer caters to a diverse clientele, including DIY enthusiasts and professional contractors.
In 2023, Home Depot's stock is slightly negative on the year - lagging both the S&P 500 and the Dow Jones Industrial Average ($DOWI) - due to unfavorable macroeconomic trends and sector-specific issues that pressured both housing and retail.
www.barchart.com
Home Depot has increased its dividend annually for 14 years, and the quarterly payout now stands at $2.09 per share, offering a forward yield of 2.69%. The payout ratio stands at just 13%, indicating plenty of room for future dividend growth.
In fact, income investors will note that HD's cash from operations rose by 49% to $4.23 billion in the latest quarter, highlighting the company's effective cash management.
Meanwhile, quarterly EPS of $3.81 and revenue of $37.71 billion both topped analysts' expectations. On average, Wall Street expects HD to return to EPS growth in fiscal 2025.
www.barchart.com
The stock is a "Moderate Buy" among the 27 analysts in coverage, with 15 “Strong Buys,” 1 “Moderate Buy,” and 11 “Holds.” The average 12-month price target of $336.32 represents a premium of 8% to current levels.
www.barchart.com
AbbVie
Chicago-based AbbVie Inc. (ABBV) started out as a spin-off from Abbott Laboratories (ABT) in 2013. Specializing in pharmaceutical research and development, AbbVie focuses on immunology, oncology, neuroscience, and virology. The company's portfolio includes top drugs such as Humira, Skyrizi, and Rinvoq. Its growth strategy encompasses in-house innovation and strategic acquisitions, including the 2020 purchase of Allergan, which expanded its range to medical aesthetics.
In 2023, AbbVie's stock is down about 10% on the year, due in large part to declining sales of its key drug, Humira - which faces stiff competition from biosimilars after losing patent protection. The broader market volatility and rising interest rates have also impacted AbbVie's stock.
www.barchart.com
Despite these challenges, including a decline in Botox sales, AbbVie remains fundamentally robust, with a diverse product portfolio and significant investment in research and development. In the third quarter of 2023, ABBV reported adjusted earnings of $2.95 per share, while revenues declined by 6.0% to $13.93 billion. The results topped Wall Street's expectations, continuing a trend of bottom-line beats for ABBV.
www.barchart.com
AbbVie stands out with a strong dividend record, offering a quarterly dividend of $1.55 per share, backed by over a decade of growth. The forward yield is 4.47%, with a balanced payout ratio of 49%.
The average analyst rating for AbbVie is a "Moderate Buy," with 8 “Strong Buys” and 2 “Moderate Buys" outweighing 8 “Hold” ratings. The average 12-month price target of $171.81 implies expected upside of 23.5% from current levels.
www.barchart.com
On the date of publication, Faizan Farooque did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | www.barchart.com AbbVie Chicago-based AbbVie Inc. (ABBV) started out as a spin-off from Abbott Laboratories (ABT) in 2013. A new Bloomberg analysis of the dividend stock underperformance in 2023 observed, “Investors wanted exposure to companies with a history of paying out profits as a precaution amid the Federal Reserve’s most aggressive tightening cycle in 40 years. In 2023, Home Depot's stock is slightly negative on the year - lagging both the S&P 500 and the Dow Jones Industrial Average ($DOWI) - due to unfavorable macroeconomic trends and sector-specific issues that pressured both housing and retail. | www.barchart.com AbbVie Chicago-based AbbVie Inc. (ABBV) started out as a spin-off from Abbott Laboratories (ABT) in 2013. www.barchart.com In the most recent quarter, Domino's reported adjusted earnings of $4.18 per share, which topped expectations - even as revenue of $1.03 billion fell slightly short. On average, Wall Street expects HD to return to EPS growth in fiscal 2025. www.barchart.com The stock is a "Moderate Buy" among the 27 analysts in coverage, with 15 “Strong Buys,” 1 “Moderate Buy,” and 11 “Holds.” The average 12-month price target of $336.32 represents a premium of 8% to current levels. | www.barchart.com AbbVie Chicago-based AbbVie Inc. (ABBV) started out as a spin-off from Abbott Laboratories (ABT) in 2013. Looking ahead, analysts are targeting 15% EPS growth for this fiscal year, followed by roughly 9% for FY 2024. www.barchart.com Domino's Pizza has an average "Moderate Buy" rating from 25 analysts, with 14 of those calling it a “Strong Buy." On average, Wall Street expects HD to return to EPS growth in fiscal 2025. www.barchart.com The stock is a "Moderate Buy" among the 27 analysts in coverage, with 15 “Strong Buys,” 1 “Moderate Buy,” and 11 “Holds.” The average 12-month price target of $336.32 represents a premium of 8% to current levels. | www.barchart.com AbbVie Chicago-based AbbVie Inc. (ABBV) started out as a spin-off from Abbott Laboratories (ABT) in 2013. Looking ahead, analysts are targeting 15% EPS growth for this fiscal year, followed by roughly 9% for FY 2024. www.barchart.com Domino's Pizza has an average "Moderate Buy" rating from 25 analysts, with 14 of those calling it a “Strong Buy." Meanwhile, quarterly EPS of $3.81 and revenue of $37.71 billion both topped analysts' expectations. |
30543.0 | 2023-11-28 00:00:00 UTC | ABT Dividend Yield Pushes Past 2% | ABT | https://www.nasdaq.com/articles/abt-dividend-yield-pushes-past-2-0 | nan | nan | Looking at the universe of stocks we cover at Dividend Channel, in trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $2.04), with the stock changing hands as low as $101.35 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return. To illustrate, suppose for example you purchased shares of the S&P 500 ETF (SPY) back on 12/31/1999 — you would have paid $146.88 per share. Fast forward to 12/31/2012 and each share was worth $142.41 on that date, a decrease of $4.67/share over all those years. But now consider that you collected a whopping $25.98 per share in dividends over the same period, for a positive total return of 23.36%. Even with dividends reinvested, that only amounts to an average annual total return of about 1.6%; so by comparison collecting a yield above 2% would appear considerably attractive if that yield is sustainable. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index.
In general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield.
ABT has been growing its dividend for more than 20 years consecutively. For more dividend growth stocks view our Dividend Aristocrats List on Dividend Channel.
Click here to find out which 9 other dividend stocks just recently went on sale »
Also see:
Funds Holding SIGA
BHAC Options Chain
Funds Holding HUBC
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the universe of stocks we cover at Dividend Channel, in trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $2.04), with the stock changing hands as low as $101.35 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. | Looking at the universe of stocks we cover at Dividend Channel, in trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $2.04), with the stock changing hands as low as $101.35 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. | Looking at the universe of stocks we cover at Dividend Channel, in trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $2.04), with the stock changing hands as low as $101.35 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. | Looking at the universe of stocks we cover at Dividend Channel, in trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $2.04), with the stock changing hands as low as $101.35 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. |
30544.0 | 2023-11-27 00:00:00 UTC | Here's Why Investors Should Retain Abbott (ABT) Stock Now | ABT | https://www.nasdaq.com/articles/heres-why-investors-should-retain-abbott-abt-stock-now-3 | nan | nan | Abbott Laboratories ABT is well-poised for growth in the coming quarters, driven by the expansion of its global presence to address the unmet demand for advanced medical technologies. The raised 2023 outlook buoys optimism. However, forex woes and lower COVID sales impede growth.
In the past year, this Zacks Rank #3 (Hold) stock has declined 2.4% compared with 3.1% decline of the industry and a 15.5% rise of the S&P 500 composite.
This renowned provider of a diversified line of healthcare products has a market capitalization of $178.59 billion. The company projects 9% growth for the next five years and expects to maintain its strong performance. Abbott’s earnings surpassed estimates in all of the trailing four quarters, the average surprise being 6.76%.
Let’s delve deeper.
Factors at Play
Strong Prospects Within Core Diagnostics: Abbott is expanding the Diagnostics business foothold (comprising 24% of the company’s total revenues in the third quarter of 2023). Although there has been a decline in demand for Abbott’s rapid diagnostic tests to detect COVID-19 in the past few quarters, it is largely being offset by higher growth across other businesses. Particularly in the United States and internationally, Abbott is experiencing increased demand for routine diagnostics.
Abbott is successfully continuing the rollout of Alinity, the company’s fully integrated and automated molecular diagnostics analyzer. It is expanding test menus across its platforms for immunoassay, clinical chemistry and molecular testing.
Libre Drives Diabetes Care: Abbott’s Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. In a relatively short span, FreeStyle Libre has achieved global leadership among constant glucose monitoring (CGM) systems for Type 1 and Type 2 users. In 2022, Abbott received FDA clearance for the Freestyle Libre 3 system, which automatically delivers up-to-the-minute glucose readings and 14-day accuracy in a wearable sensor. In 2023, as a major milestone for the company, Libre became the first and only CGM system to be nationally reimbursed in France. In 2023, Libre also received FDA clearance for connectivity with automated insulin delivery systems. Abbott is currently working with leading insulin pump manufacturers to integrate their systems with Libre 2 and Libre 3.
Upbeat Guidance: Full-year adjusted earnings (excluding specified items of $1.28 per share) are expected in the range of $4.42-$4.46 (previously $4.30-$4.40).
Image Source: Zacks Investment Research
Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, in the low double digits (unchanged from the previous outlook) and COVID-19 testing-related sales of around $1.5 billion (earlier $1.3 billion).
Downsides
Foreign Exchange Translation Impacts Sales: Foreign exchange is a major headwind for Abbott due to a considerable percentage of its revenues coming from outside the United States. The strengthening of the euro and some other developed market currencies has constantly been hampering the company’s performance in the international markets.
In the third quarter, foreign exchange had an unfavorable year-over-year impact of 1.4% on sales.
Declining COVID Testing Dents Growth: During the COVID-19 public health emergency, Abbott’s diagnostic tests witnessed stupendous revenue growth backed by increasing demand for testing and government-enacted favorable policies to expedite or promote access to healthcare to slow down or stop the spread of the virus. However, through the last few months of 2022 and following the official ending of the public health emergency in May, Abbott is experiencing a persistent decline in COVID testing-related demand. In the third quarter of 2023, Abbott’s Rapid Diagnostics sales decreased 59.2% from the year-ago period due to lower demand for COVID-19 tests.
Estimate Trends
In the past 90 days, the Zacks Consensus Estimate for earnings has moved up 4.40% to $4.44.
The Zacks Consensus Estimate for the company’s 2023 revenues is pegged at $40.01 billion, suggesting an 8.4% decline from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, Biodesix BDSX and Integer Holdings Corporation ITGR.
DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 18.3%. DVA’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 36.55%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have risen 30.6% year to date compared with the industry’s 1.6% growth.
Biodesix, carrying a Zacks Rank of 2 at present, has an estimated growth rate of 32.3% for 2024. BDSX’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 9.76%.
Biodesix’s shares have declined 36.5% year to date against the industry’s 12.6% decline.
Integer Holdings, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 15.8%. ITGR’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.9%.
Integer Holdings’ shares have rallied 30.6% year to date against the industry’s 7.3% decline.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
DaVita Inc. (DVA) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
Biodesix, Inc. (BDSX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT is well-poised for growth in the coming quarters, driven by the expansion of its global presence to address the unmet demand for advanced medical technologies. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Biodesix, Inc. (BDSX) : Free Stock Analysis Report To read this article on Zacks.com click here. In 2022, Abbott received FDA clearance for the Freestyle Libre 3 system, which automatically delivers up-to-the-minute glucose readings and 14-day accuracy in a wearable sensor. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Biodesix, Inc. (BDSX) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is well-poised for growth in the coming quarters, driven by the expansion of its global presence to address the unmet demand for advanced medical technologies. Image Source: Zacks Investment Research Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, in the low double digits (unchanged from the previous outlook) and COVID-19 testing-related sales of around $1.5 billion (earlier $1.3 billion). | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Biodesix, Inc. (BDSX) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is well-poised for growth in the coming quarters, driven by the expansion of its global presence to address the unmet demand for advanced medical technologies. Image Source: Zacks Investment Research Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, in the low double digits (unchanged from the previous outlook) and COVID-19 testing-related sales of around $1.5 billion (earlier $1.3 billion). | Abbott Laboratories ABT is well-poised for growth in the coming quarters, driven by the expansion of its global presence to address the unmet demand for advanced medical technologies. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Biodesix, Inc. (BDSX) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott is currently working with leading insulin pump manufacturers to integrate their systems with Libre 2 and Libre 3. |
30545.0 | 2023-11-26 00:00:00 UTC | Should You Pick Medtronic Stock At $80 After An Upbeat Q2? | ABT | https://www.nasdaq.com/articles/should-you-pick-medtronic-stock-at-%2480-after-an-upbeat-q2 | nan | nan | Medtronic (NYSE: MDT) recently reported its Q2 fiscal 2024 results (fiscal ends in April), with revenues and earnings beating our estimates, and we believe that MDT stock is undervalued, as discussed below. The company reported revenue of $8.0 billion and adjusted earnings of $1.25 per share compared to our estimates of $7.8 billion in sales and $1.17 profit per share. In this note, we discuss Medtronic’s stock performance, key takeaways from its recent results, and valuation.
MDT stock has suffered a sharp decline of 30% from levels of $115 in early January 2021 to around $80 now, vs. an increase of about 20% for the S&P 500 over this roughly 3-year period. Notably, MDT stock has underperformed the broader market in each of the last three years. Returns for the stock were -12% in 2021, -25% in 2022, and 1% in 2023 (YTD). In comparison, returns for the S&P 500 have been 27% in 2021, -19% in 2022, and 19% in 2023 (YTD) – indicating that MDT underperformed the S&P in 2021, 2022, and 2023.
In fact, consistently beating the S&P 500 – in good times and bad – has been difficult over recent years for individual stocks; for heavyweights in the Health Care sector, including LLY, UNH, and JNJ, and even for the megacap stars GOOG, TSLA, and MSFT. In contrast, the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has outperformed the S&P 500 each year over the same period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index, less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.
Given the current uncertain macroeconomic environment with high oil prices and elevated interest rates, could MDT face a similar situation as it did in 2021, 2022, and 2023 and underperform the S&P over the next 12 months – or will it see a recovery? From a valuation perspective, MDT stock looks undervalued. We estimate Medtronic’s valuation to be $96 per share, reflecting an upside of over 20% from its current level of $79. Our forecast is based on an 18x P/E multiple for MDT and expected earnings of $5.19 on a per-share and adjusted basis for fiscal 2024. The 18x P/E ratio compares with the stock’s last three-year average of 20x. The company raised its earnings outlook to be in the range of $5.13 and $5.19 (versus the $5.08 and $5.16 range earlier).
Medtronic’s revenue of $8.0 billion in Q2 was up 5% y-o-y, primarily due to higher sales of its diabetes products. The diabetes segment sales were up 10% due to the increased adoption of its MiniMed 780G system, which anticipates and automatically adjusts insulin delivery. The company’s other segments also performed well, with cardiovascular sales rising 6%, neuroscience up 5%, and medical-surgical sales up 7%. Medtronic raised its organic sales outlook to 4.75% growth in fiscal 2024 versus its prior guidance of 4.5% growth.
Medtronic’s adjusted earnings of $1.67 billion in Q2 reflected a 3% fall from its $1.73 billion profit figure in the prior-year quarter. This can partly be attributed to $793 million in certain tax adjustments in the prior year quarter compared to $176 million in Q2’24. Adjusted EPS of $1.25 was slightly lower than $1.30 in the prior-year quarter.
MDT stock is trading at 15x its 2024 expected earnings of $5.19 per share, compared to its last three-year average of 20x. We believe MDT stock will likely see this gap in the valuation multiple narrow toward its historical average as the company benefits from market share gains for its new products, including the Micra AV pacemaker and Onyx Frontier drug-eluting stent. It should also see continued strength in cardiac products. The increased adoption of its MiniMed 780G insulin system in the U.S. and international markets will further bolster its overall performance.
While MDT stock looks undervalued, it is helpful to see how Medtronic’s Peers fare on metrics that matter. You will find other valuable comparisons for companies across industries at Peer Comparisons.
Returns Nov 2023
MTD [1] 2023
YTD [1] 2017-23
Total [2]
MDT Return 11% 1% 10%
S&P 500 Return 8% 18% 103%
Trefis Reinforced Value Portfolio 7% 26% 548%
[1] Month-to-date and year-to-date as of 11/22/2023
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In fact, consistently beating the S&P 500 – in good times and bad – has been difficult over recent years for individual stocks; for heavyweights in the Health Care sector, including LLY, UNH, and JNJ, and even for the megacap stars GOOG, TSLA, and MSFT. Given the current uncertain macroeconomic environment with high oil prices and elevated interest rates, could MDT face a similar situation as it did in 2021, 2022, and 2023 and underperform the S&P over the next 12 months – or will it see a recovery? We believe MDT stock will likely see this gap in the valuation multiple narrow toward its historical average as the company benefits from market share gains for its new products, including the Micra AV pacemaker and Onyx Frontier drug-eluting stent. | Medtronic (NYSE: MDT) recently reported its Q2 fiscal 2024 results (fiscal ends in April), with revenues and earnings beating our estimates, and we believe that MDT stock is undervalued, as discussed below. The company reported revenue of $8.0 billion and adjusted earnings of $1.25 per share compared to our estimates of $7.8 billion in sales and $1.17 profit per share. Medtronic raised its organic sales outlook to 4.75% growth in fiscal 2024 versus its prior guidance of 4.5% growth. | Medtronic (NYSE: MDT) recently reported its Q2 fiscal 2024 results (fiscal ends in April), with revenues and earnings beating our estimates, and we believe that MDT stock is undervalued, as discussed below. The company reported revenue of $8.0 billion and adjusted earnings of $1.25 per share compared to our estimates of $7.8 billion in sales and $1.17 profit per share. Total [2] MDT Return 11% 1% 10% S&P 500 Return 8% 18% 103% Trefis Reinforced Value Portfolio 7% 26% 548% [1] Month-to-date and year-to-date as of 11/22/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Medtronic (NYSE: MDT) recently reported its Q2 fiscal 2024 results (fiscal ends in April), with revenues and earnings beating our estimates, and we believe that MDT stock is undervalued, as discussed below. In comparison, returns for the S&P 500 have been 27% in 2021, -19% in 2022, and 19% in 2023 (YTD) – indicating that MDT underperformed the S&P in 2021, 2022, and 2023. Medtronic’s revenue of $8.0 billion in Q2 was up 5% y-o-y, primarily due to higher sales of its diabetes products. |
30546.0 | 2023-11-24 00:00:00 UTC | Peter Lynch Detailed Fundamental Analysis - ABT | ABT | https://www.nasdaq.com/articles/peter-lynch-detailed-fundamental-analysis-abt-10 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Top Healthcare Stocks
Dividend Aristocrats2023
Wide Moat Stocks2023
High Insider Ownership Stocks
Factor-Based Stock Portfolios
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
30547.0 | 2023-11-22 00:00:00 UTC | Abbott (ABT) Benefits From Innovation Amid FX Headwinds | ABT | https://www.nasdaq.com/articles/abbott-abt-benefits-from-innovation-amid-fx-headwinds | nan | nan | Abbott’s ABT new product launches and geographic expansion should boost sales. Low diagnostic testing demand continues to dent sales. The stock carries a Zacks Rank #3 (Hold).
Abbott is expanding its Diagnostics business (consisting of 24% of the company’s total revenues in the third quarter of 2023). Although, over the past few quarters, there has been a significant decline in demand for Abbott’s rapid diagnostic tests to detect COVID-19 as compared to the year-ago period, it is largely being offset by higher growth across other businesses.
Within Established Pharmaceuticals Division (EPD), in September, Abbott entered into an agreement with global biotech leader mAbxience to commercialize several biosimilars in emerging markets. This collaboration will help introduce cutting-edge medicines in the areas of oncology, women's health and respiratory diseases to people in countries that have historically lacked access to these treatment options.
Abbott’s EPD sales in the third quarter increased 11.1% year over organically. In key emerging markets, organic sales improved 8.8% year over year, led by growth in several geographies and therapeutic areas, including gastroenterology, women's health and central nervous system/pain management.
Abbott Laboratories Price
Abbott Laboratories price | Abbott Laboratories Quote
Further, following a slew of developments, the Diabetes Care business achieved organic sales growth of 24.5% in the third quarter of 2023. This was led by FreeStyle Libre, which contributed $1.4 billion in revenues in the reported quarter. At the end of the third quarter, the global Libre user base exceeded 5 million people, with nearly 2 million in the United States, where the Libre user base has nearly doubled in the last two years.
Over the past year, shares of Abbott have lost 2.8% compared with the industry’s 5.4% fall.
On the flip side, Abbott has been experiencing a continuous decline in COVID testing-related demand. In the third quarter of 2023, Abbott’s Rapid Diagnostics sales decreased 59.2% from the year-ago period due to lower demand for COVID-19 tests.
Further, foreign exchange is a major headwind for Abbott as a considerable percentage of its revenues comes from outside the United States. The strengthening of the euro and some other developed market currencies has constantly been hampering the company’s performance in the international markets. In the third quarter, foreign exchange had an unfavorable year-over-year impact of 1.4% on sales.
Key Picks
Some better-ranked stocks in the broader medical space are Insulet PODD, Haemonetics HAE and DexCom DXCM. While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Insulet’s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 40.1% in the past year compared with the industry’s decline of 6.3%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%.
Haemonetics’ stock has risen 2.8% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and from $4.07 to $4.11 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%.
Estimates for DexCom’s 2023 earnings per share have increased from $1.23 to $1.43 in the past 30 days. Shares of the company have fallen 6.8% in the past year compared with the industry’s decline of 6.6%.
DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Insulet Corporation (PODD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott’s ABT new product launches and geographic expansion should boost sales. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Although, over the past few quarters, there has been a significant decline in demand for Abbott’s rapid diagnostic tests to detect COVID-19 as compared to the year-ago period, it is largely being offset by higher growth across other businesses. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott’s ABT new product launches and geographic expansion should boost sales. Abbott Laboratories Price Abbott Laboratories price | Abbott Laboratories Quote Further, following a slew of developments, the Diabetes Care business achieved organic sales growth of 24.5% in the third quarter of 2023. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott’s ABT new product launches and geographic expansion should boost sales. Although, over the past few quarters, there has been a significant decline in demand for Abbott’s rapid diagnostic tests to detect COVID-19 as compared to the year-ago period, it is largely being offset by higher growth across other businesses. | Abbott’s ABT new product launches and geographic expansion should boost sales. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Although, over the past few quarters, there has been a significant decline in demand for Abbott’s rapid diagnostic tests to detect COVID-19 as compared to the year-ago period, it is largely being offset by higher growth across other businesses. |
30548.0 | 2023-11-22 00:00:00 UTC | Bullish Two Hundred Day Moving Average Cross - ABT | ABT | https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-abt | nan | nan | In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $103.10, changing hands as high as $103.22 per share. Abbott Laboratories shares are currently trading up about 0.9% on the day. The chart below shows the one year performance of ABT shares, versus its 200 day moving average:
Looking at the chart above, ABT's low point in its 52 week range is $89.674 per share, with $115.83 as the 52 week high point — that compares with a last trade of $102.85. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com
Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average »
Also see:
Top Ranked Dividend Stocks With Insider Buying
DTLK Options Chain
SRK Historical Stock Prices
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $103.10, changing hands as high as $103.22 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $89.674 per share, with $115.83 as the 52 week high point — that compares with a last trade of $102.85. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Also see: Top Ranked Dividend Stocks With Insider Buying DTLK Options Chain SRK Historical Stock Prices The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $103.10, changing hands as high as $103.22 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $89.674 per share, with $115.83 as the 52 week high point — that compares with a last trade of $102.85. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Also see: Top Ranked Dividend Stocks With Insider Buying DTLK Options Chain SRK Historical Stock Prices The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $103.10, changing hands as high as $103.22 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $89.674 per share, with $115.83 as the 52 week high point — that compares with a last trade of $102.85. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Also see: Top Ranked Dividend Stocks With Insider Buying DTLK Options Chain SRK Historical Stock Prices The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $103.10, changing hands as high as $103.22 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $89.674 per share, with $115.83 as the 52 week high point — that compares with a last trade of $102.85. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Also see: Top Ranked Dividend Stocks With Insider Buying DTLK Options Chain SRK Historical Stock Prices The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
30549.0 | 2023-11-21 00:00:00 UTC | Top Analyst Reports for Novo Nordisk, Bank of America & Netflix | ABT | https://www.nasdaq.com/articles/top-analyst-reports-for-novo-nordisk-bank-of-america-netflix | nan | nan | Tuesday, November 21, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Bank of America Corporation (BAC) and Netflix, Inc. (NFLX). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Novo Nordisk have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+81.2% vs. +11.7%). The company beat earnings and revenue estimates in Q3 due to higher GLP-1 product sales. It has one of the broadest diabetes portfolios in the industry. Ozempic and Rybelsus have been performing well in the diabetes market.
Obesity drug Wegovy has been enjoying increasing demand. Label expansions of diabetes and obesity care drugs in cardiovascular and other indications will likely boost sales. Novo Nordisk raised its 2023 view due to higher demand for Ozempic and Wegovy. Its diversifying efforts to develop new treatments are encouraging.
However, stiffer competition from pharma bigwigs like Pfizer, who are likely to eat away from Novo Nordisk’s Diabetes care market share due to serious supply constraints in international markets. Patent expiry and pricing pressure across the diabetes market also remain a woe.
(You can read the full research report on Novo Nordisk here >>>)
Shares of Bank of America have gained +7.6% over the past six months against the Zacks Banks - Major Regional industry’s gain of +9.9%. The company’s third-quarter 2023 results reflect higher revenues and costs. Because of inflationary pressure, overall costs are expected to remain elevated.
The current tough macroeconomic outlook might weigh on the company’s investment banking (IB) business. This, along with the volatile nature of the capital markets, might hurt non-interest income growth.
Despite these headwinds, we believe that higher rates and decent loan demand will keep aiding the company’s net interest income (NII) growth, which the Zacks analyst expects to grow 8.5% this year. The opening of financial centers and improving digital capabilities is expected to further aid the top line.
(You can read the full research report on Bank of America here >>>)
Shares of Netflix have outperformed the Zacks Broadcast Radio and Television industry over the past year (+65.5% vs. +29.3%). The company is benefiting from growing subscriber base thanks to a robust portfolio. Crackdown on password-sharing and the introduction of paid sharing in more than 100 countries, which represents more than 80% of Netflix’s revenue base, is also expected to aid growth.
Netflix’s diversified content portfolio, which is attributable to heavy investments in the production and distribution of localized, foreign-language content, has been driving its growth prospects.
However, stiff competition in the streaming space from the likes of Apple, Amazon Prime Video, Disney+, Peacock and Paramount+ is a headwind. Netflix’s leveraged balance sheet and a higher streaming obligation are concerns. Additionally, unfavorable forex is expected to hurt operating income in the fourth quarter of 2023.
(You can read the full research report on Netflix here >>>)
Other noteworthy reports we are featuring today include Johnson & Johnson (JNJ), Abbott Laboratories (ABT) and TotalEnergies SE (TTE).
Director of Research
Sheraz Mian
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Wegovy & Ozempic Drive Novo Nordisk (NVO), Competition Stiff
Higher Rates Aid Bank of America (BAC) Amid Fee Income Woes
Netflix (NFLX) Benefits from Paid Sharing & Robust Portfolio
Featured Reports
J&J (JNJ) Pharma and MedTech Unit to Drive Growth
J&J's Pharma sales are being driven by existing key drugs and new products. The Zacks analyst believes J&J's MedTech unit is showing improving trends driven by recovery in surgical procedures.
Market Share Gain, EPD Business Growth Aid Abbott (ABT)
The Zacks analyst is impressed with Abbott's strong market share gains in core businesses. Within Established Pharmaceuticals, robust performance in key emerging markets is encouraging.
Expanding LNG & Clean Energy Assets Aid TotalEnergies (TTE)
Per the Zacks analyst TotalEnergies's presence in entire LNG value chain and expansion of clean energy generation through joint venture and acquisition will boost its performance.
Transformation Initiatives Aid ADP, Escalating Expenses Hurt
The Zacks analyst is positive about ADP's transformation initiatives that are helping the company to innovate, improve operations and expand margins. Rising expenses remain a concern.
EOG Resources (EOG) Banks on Oil-Rich Permian Basin
With highly productive acreages in the oil-rich Permian basin, EOG Resources' production outlook seems bright. However, rising lease and well expenses concerns the Zacks analyst.
Colgate's (CL) Higher Pricing & Productivity Aid Margins
Per the Zacks analyst, Colgate's strong pricing, benefits of funding growth and other productivity plans, are aiding gross margin. It expects continued adjusted gross margin growth in FY23.
Improvement in Mass Capacity Demand to Drive Seagate (STX)
Per the Zacks analyst, Seagate's performance is likely to gain from improving demand for mass capacity storage solutions among domestic cloud customers amid persisting global macroeconomic weakness.
New Upgrades
CNA Financial (CNA) Poised to Grow on Improving Premiums
Per the Zacks analyst, CNA Financial is poised to row on rising premiums driven by compelling product portfolio, better retention, improving pricing, and new business growth.
EMCOR (EME) Benefits From Solid Demand in the US Businesses
Per the Zacks analyst, EMCOR's U.S. businesses remain solid during the third quarter, backed by solid end-market demand and top-tier execution initiatives.
Cost-Cutting Actions, Solid Order Trends Aid Apogee (APOG)
Per the Zacks analyst, Apogee's efforts to cut costs, and improve productivity and efficiency will drive its growth. Strong project pipeline and order trends will continue to boost results.
New Downgrades
Lower Production & High Costs to Hurt Southern Copper (SCCO)
The Zacks analyst is worried that lower production due to lower ore grades at Cuajone and high labor and operating costs will hurt the company's results.
High Costs, Macroeconomic Concern Hurt Moelis & Company (MC)
Per the Zacks analyst, elevated costs might hurt Moelis & Company's bottom line. Amid the economic uncertainity, geopolitical and macroeconomic headwinds are likely to affect the company's growth.n
Weaker Seasonality, Lower COVID Sales Drag Walgreens (WBA)
The Zacks Analyst is worried about Walgreens facing further slowdown in respiratory events and macroeconomic driven consumer pressure. Impact from lower COVID-19 related contributions adds to worry.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bank of America Corporation (BAC) : Free Stock Analysis Report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
Netflix, Inc. (NFLX) : Free Stock Analysis Report
TotalEnergies SE Sponsored ADR (TTE) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other noteworthy reports we are featuring today include Johnson & Johnson (JNJ), Abbott Laboratories (ABT) and TotalEnergies SE (TTE). Market Share Gain, EPD Business Growth Aid Abbott (ABT) The Zacks analyst is impressed with Abbott's strong market share gains in core businesses. Click to get this free report Bank of America Corporation (BAC) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Netflix, Inc. (NFLX) : Free Stock Analysis Report TotalEnergies SE Sponsored ADR (TTE) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Bank of America Corporation (BAC) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Netflix, Inc. (NFLX) : Free Stock Analysis Report TotalEnergies SE Sponsored ADR (TTE) : Free Stock Analysis Report To read this article on Zacks.com click here. Other noteworthy reports we are featuring today include Johnson & Johnson (JNJ), Abbott Laboratories (ABT) and TotalEnergies SE (TTE). Market Share Gain, EPD Business Growth Aid Abbott (ABT) The Zacks analyst is impressed with Abbott's strong market share gains in core businesses. | Click to get this free report Bank of America Corporation (BAC) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Netflix, Inc. (NFLX) : Free Stock Analysis Report TotalEnergies SE Sponsored ADR (TTE) : Free Stock Analysis Report To read this article on Zacks.com click here. Other noteworthy reports we are featuring today include Johnson & Johnson (JNJ), Abbott Laboratories (ABT) and TotalEnergies SE (TTE). Market Share Gain, EPD Business Growth Aid Abbott (ABT) The Zacks analyst is impressed with Abbott's strong market share gains in core businesses. | Other noteworthy reports we are featuring today include Johnson & Johnson (JNJ), Abbott Laboratories (ABT) and TotalEnergies SE (TTE). Market Share Gain, EPD Business Growth Aid Abbott (ABT) The Zacks analyst is impressed with Abbott's strong market share gains in core businesses. Click to get this free report Bank of America Corporation (BAC) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Netflix, Inc. (NFLX) : Free Stock Analysis Report TotalEnergies SE Sponsored ADR (TTE) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30550.0 | 2023-11-21 00:00:00 UTC | Medical device maker Medtronic raises fiscal 2024 profit view | ABT | https://www.nasdaq.com/articles/medical-device-maker-medtronic-raises-fiscal-2024-profit-view-0 | nan | nan | Adds background in paragraphs 2 and 3, profit in paragraph 5
Nov 21 (Reuters) - Medtronic MDT.N raised its annual profit forecast for the second time this year on Tuesdayafter beating second-quarter earnings estimates, as a post-pandemic pickup in surgical volumes boosted demand for its medical devices.
Medical device makers are seeing higher demand for their products due to a steady recovery in surgical procedures that were deferred during the pandemic, especially by older adults, as well as easing staff shortages at hospitals.
Medtronic joins medical device makers including Abbott Laboratories ABT.N and Boston ScientificBSX.N that have benefited from soaring demand for non-urgent surgeries.
On an adjusted basis, the Dublin-based company reported a profit of $1.25 per share for the second quarter, above analysts' average estimate of $1.18 per share, according to LSEG data.
(Reporting by Khushi Mandowara and Christy Santhosh in Bengaluru; Editing by Pooja Desai)
((Christy.santhosh@thomsonreuters.com))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Medtronic joins medical device makers including Abbott Laboratories ABT.N and Boston ScientificBSX.N that have benefited from soaring demand for non-urgent surgeries. Adds background in paragraphs 2 and 3, profit in paragraph 5 Nov 21 (Reuters) - Medtronic MDT.N raised its annual profit forecast for the second time this year on Tuesdayafter beating second-quarter earnings estimates, as a post-pandemic pickup in surgical volumes boosted demand for its medical devices. Medical device makers are seeing higher demand for their products due to a steady recovery in surgical procedures that were deferred during the pandemic, especially by older adults, as well as easing staff shortages at hospitals. | Medtronic joins medical device makers including Abbott Laboratories ABT.N and Boston ScientificBSX.N that have benefited from soaring demand for non-urgent surgeries. Adds background in paragraphs 2 and 3, profit in paragraph 5 Nov 21 (Reuters) - Medtronic MDT.N raised its annual profit forecast for the second time this year on Tuesdayafter beating second-quarter earnings estimates, as a post-pandemic pickup in surgical volumes boosted demand for its medical devices. Medical device makers are seeing higher demand for their products due to a steady recovery in surgical procedures that were deferred during the pandemic, especially by older adults, as well as easing staff shortages at hospitals. | Medtronic joins medical device makers including Abbott Laboratories ABT.N and Boston ScientificBSX.N that have benefited from soaring demand for non-urgent surgeries. Adds background in paragraphs 2 and 3, profit in paragraph 5 Nov 21 (Reuters) - Medtronic MDT.N raised its annual profit forecast for the second time this year on Tuesdayafter beating second-quarter earnings estimates, as a post-pandemic pickup in surgical volumes boosted demand for its medical devices. Medical device makers are seeing higher demand for their products due to a steady recovery in surgical procedures that were deferred during the pandemic, especially by older adults, as well as easing staff shortages at hospitals. | Medtronic joins medical device makers including Abbott Laboratories ABT.N and Boston ScientificBSX.N that have benefited from soaring demand for non-urgent surgeries. Adds background in paragraphs 2 and 3, profit in paragraph 5 Nov 21 (Reuters) - Medtronic MDT.N raised its annual profit forecast for the second time this year on Tuesdayafter beating second-quarter earnings estimates, as a post-pandemic pickup in surgical volumes boosted demand for its medical devices. Medical device makers are seeing higher demand for their products due to a steady recovery in surgical procedures that were deferred during the pandemic, especially by older adults, as well as easing staff shortages at hospitals. |
30551.0 | 2023-11-20 00:00:00 UTC | Validea's Top Health Care Stocks Based On Martin Zweig - 11/20/2023 | ABT | https://www.nasdaq.com/articles/valideas-top-health-care-stocks-based-on-martin-zweig-11-20-2023 | nan | nan | The following are the top rated Health Care stocks according to Validea's Growth Investor model based on the published strategy of Martin Zweig. This strategy looks for growth stocks with persistent accelerating earnings and sales growth, reasonable valuations and low debt.
NOVO NORDISK A/S (ADR) (NVO) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Martin Zweig is 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of NOVO NORDISK A/S (ADR)
NVO Guru Analysis
NVO Fundamental Analysis
UNITEDHEALTH GROUP INC (UNH) is a large-cap growth stock in the Insurance (Accident & Health) industry. The rating according to our strategy based on Martin Zweig is 69% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: UnitedHealth Group Incorporated is a diversified health care company that operates Optum and UnitedHealthcare platforms. Its segments include Optum Health, Optum Insight, Optum Rx and UnitedHealthcare. Optum Health segment is focused on care delivery, care management, wellness and consumer engagement, and health financial services. Optum Insight segment serves the needs of hospital systems, physicians, health plans, governments and life sciences companies. Optum Rx segment offers pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, purchasing and clinical capabilities, and develops programs in areas such as step therapy, formulary management, drug adherence and disease/drug therapy management. UnitedHealthcare includes the combined results of operations of UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement, UnitedHealthcare Community & State and UnitedHealthcare Global.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: FAIL
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of UNITEDHEALTH GROUP INC
UNH Guru Analysis
UNH Fundamental Analysis
BOSTON SCIENTIFIC CORPORATION (BSX) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Martin Zweig is 69% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Boston Scientific Corporation is a developer, manufacturer, and marketer of medical devices. The Company's segments include MedSurg and Cardiovascular. The MedSurg segment includes Endoscopy and Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal and pulmonary conditions. Its Urology and Neuromodulation business develops and manufactures devices to treat various urological, neurological movement disorders and pelvic conditions. Its Cardiac Rhythm Management develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment include Interventional Cardiology and Peripheral Interventions. Its Interventional Cardiology develops and manufactures technologies for diagnosing and treating coronary artery disease and structural heart conditions. Its product offerings include 360 Clips and RESONATE, among others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of BOSTON SCIENTIFIC CORPORATION
BSX Guru Analysis
BSX Fundamental Analysis
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Martin Zweig is 62% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is a global healthcare company. The Company's portfolio of technologies spans the spectrum of healthcare, with businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: FAIL
SALES GROWTH RATE: PASS
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: FAIL
EARNINGS PERSISTENCE: FAIL
LONG-TERM EPS GROWTH: PASS
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
Martin Zweig Portfolio
About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. Zweig has managed both mutual and hedge funds during his career, and he's put the fortune he's compiled to some interesting uses. He has owned what Forbes reported was the most expensive apartment in New York, a $70 million penthouse that sits atop Manhattan's Pierre Hotel, and he is a collector of all sorts of pop culture and historical memorabilia -- among his purchases are the gun used by Clint Eastwood in "Dirty Harry", a stock certificate signed by Commodore Vanderbilt, and even two old-fashioned gas pumps similar to those he'd seen at a nearby gas station while growing up in Cleveland, according to published reports.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of BOSTON SCIENTIFIC CORPORATION BSX Guru Analysis BSX Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Martin Zweig Portfolio About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. The Company's portfolio of technologies spans the spectrum of healthcare, with businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. | Detailed Analysis of BOSTON SCIENTIFIC CORPORATION BSX Guru Analysis BSX Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Martin Zweig Portfolio About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. Detailed Analysis of UNITEDHEALTH GROUP INC UNH Guru Analysis UNH Fundamental Analysis BOSTON SCIENTIFIC CORPORATION (BSX) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Martin Zweig Portfolio About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. Detailed Analysis of BOSTON SCIENTIFIC CORPORATION BSX Guru Analysis BSX Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. | Detailed Analysis of BOSTON SCIENTIFIC CORPORATION BSX Guru Analysis BSX Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Martin Zweig Portfolio About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. |
30552.0 | 2023-11-20 00:00:00 UTC | Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How. | ABT | https://www.nasdaq.com/articles/ozempic-might-be-helping-abbott-laboratories-and-dexcom-stock.-heres-how. | nan | nan | Novo Nordisk's (NYSE: NVO) Ozempic is indicated to treat diabetes, and its wild success and household name is making a few cardiometabolic device companies rather nervous. With a powerful tool to manage blood glucose levels in hand, patients may not have as much of a need for the glucose monitors and insulin pumps they formerly relied on, so the fearful argument goes. And newer drugs like Eli Lilly's Mounjaro are likely to exacerbate the same trend.
But at least two device companies, Abbott Laboratories (NYSE: ABT) and DexCom, (NASDAQ: DXCM) are actually anticipating that Ozempic and its peer medicines will give their businesses a boost. Here's how that might work, and how much it could help their share prices over the next few years.
Effective type 2 diabetes and weight loss medicines: Friend or foe for device makers?
Therapies made by Novo Nordisk and Eli Lilly like Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound treat diabetes and also obesity by prompting the patient's body to produce more insulin after they eat food, thereby lowering their blood glucose level after meals to within healthy ranges. Persistently high blood glucose levels, as occurs in untreated type 2 diabetes, are a major risk factor for developing cardiovascular illness. Separately, even in people who do not have diabetes, obesity is also a major risk factor for cardiovascular disease. So it isn't all that surprising to learn that those same medicines have been proven in a handful of different scientific investigations to reduce people's cardiovascular disease risks as a consequence of lowering their blood glucose levels and helping them to shed their excess weight.
But if your company makes devices that might get used by patients a lot less when Ozempic is easily available, there's clearly a potential problem. Medical device businesses like Abbott Labs and DexCom, both of which make continuous glucose monitors (CGMs) and heavily rely on the segment to drive growth, are particularly exposed to this risk. In the third quarter alone, Abbott brought in $1.4 billion from sales of its FreeStyle Libre CGM, 30% more than a year prior. In the same period, DexCom's revenue of $975 million from its lineup of CGMs and accessories was up 27% compared to last year. So much for Ozempic usage being a headwind at the moment.
In fact, per an analysis of insurance claims data by DexCom, patients on intensive insulin regimens increased their use of the company's monitors by double when they started on medicines in the same class as Ozempic. For those on non-insulin treatments, usage quadrupled. Simply checking the data from the monitor more won't necessarily drive more revenue, but it suggests that patients will not be in any hurry to stop buying the disposable sensors they need to make their monitor work.
A similar analysis by Abbott also reached favorable conclusions, finding that patients on the medications wore their monitor's sensors more days of the week than they did before. Furthermore, patients experienced significant improvements in their blood glucose levels beyond what they'd achieved with Ozempic, too. Wearing the sensor more frequently means needing to replace it more frequently. And that points to more spending, not less.
This issue is far from being settled
The rationale for why patients seem to increase their glucose monitor use when taking these drugs doesn't have to be complicated. Just as patients need to know when their blood glucose levels are too high so that they can moderate them by taking insulin, they need to know when their levels are too low so that they can avoid hypoglycemia. Taking these medicines is what opens the door to that possibility where it was improbable before. And that's why they aren't actually a threat to Abbott or DexCom.
Based on the available data, it looks like both businesses are picking up a brand new tailwind for sales of their CGMs. As DexCom's entire game is to sell CGMs and accessories, the additional revenue growth from this trend will probably be more significant for shareholders than it will be for Abbott Labs, as diabetes care devices are only a small portion of its colossal catalog of healthcare products.
At the moment, it's hard to say exactly how much additional revenue Mounjaro and Ozempic could generate over the coming years, as they're still early on in their history of use. Nonetheless, if you were thinking about buying either DexCom or Abbott Labs, be aware that there's now another point in their favor.
10 stocks we like better than Novo Nordisk
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Novo Nordisk wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of November 15, 2023
Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends DexCom and Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But at least two device companies, Abbott Laboratories (NYSE: ABT) and DexCom, (NASDAQ: DXCM) are actually anticipating that Ozempic and its peer medicines will give their businesses a boost. Therapies made by Novo Nordisk and Eli Lilly like Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound treat diabetes and also obesity by prompting the patient's body to produce more insulin after they eat food, thereby lowering their blood glucose level after meals to within healthy ranges. So it isn't all that surprising to learn that those same medicines have been proven in a handful of different scientific investigations to reduce people's cardiovascular disease risks as a consequence of lowering their blood glucose levels and helping them to shed their excess weight. | But at least two device companies, Abbott Laboratories (NYSE: ABT) and DexCom, (NASDAQ: DXCM) are actually anticipating that Ozempic and its peer medicines will give their businesses a boost. Medical device businesses like Abbott Labs and DexCom, both of which make continuous glucose monitors (CGMs) and heavily rely on the segment to drive growth, are particularly exposed to this risk. The Motley Fool recommends DexCom and Novo Nordisk. | But at least two device companies, Abbott Laboratories (NYSE: ABT) and DexCom, (NASDAQ: DXCM) are actually anticipating that Ozempic and its peer medicines will give their businesses a boost. Therapies made by Novo Nordisk and Eli Lilly like Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound treat diabetes and also obesity by prompting the patient's body to produce more insulin after they eat food, thereby lowering their blood glucose level after meals to within healthy ranges. Medical device businesses like Abbott Labs and DexCom, both of which make continuous glucose monitors (CGMs) and heavily rely on the segment to drive growth, are particularly exposed to this risk. | But at least two device companies, Abbott Laboratories (NYSE: ABT) and DexCom, (NASDAQ: DXCM) are actually anticipating that Ozempic and its peer medicines will give their businesses a boost. Persistently high blood glucose levels, as occurs in untreated type 2 diabetes, are a major risk factor for developing cardiovascular illness. Medical device businesses like Abbott Labs and DexCom, both of which make continuous glucose monitors (CGMs) and heavily rely on the segment to drive growth, are particularly exposed to this risk. |
30553.0 | 2023-11-20 00:00:00 UTC | PETQ vs. ABT: Which Stock Should Value Investors Buy Now? | ABT | https://www.nasdaq.com/articles/petq-vs.-abt%3A-which-stock-should-value-investors-buy-now | nan | nan | Investors with an interest in Medical - Products stocks have likely encountered both PetIQ (PETQ) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
PetIQ and Abbott are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. This means that PETQ's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one factor that value investors are interested in.
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
PETQ currently has a forward P/E ratio of 15.98, while ABT has a forward P/E of 22.42. We also note that PETQ has a PEG ratio of 2. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ABT currently has a PEG ratio of 2.49.
Another notable valuation metric for PETQ is its P/B ratio of 2.25. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, ABT has a P/B of 4.58.
These are just a few of the metrics contributing to PETQ's Value grade of A and ABT's Value grade of C.
PETQ sticks out from ABT in both our Zacks Rank and Style Scores models, so value investors will likely feel that PETQ is the better option right now.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.
It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetIQ, Inc. (PETQ) : Free Stock Analysis Report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors with an interest in Medical - Products stocks have likely encountered both PetIQ (PETQ) and Abbott (ABT). PETQ currently has a forward P/E ratio of 15.98, while ABT has a forward P/E of 22.42. ABT currently has a PEG ratio of 2.49. | These are just a few of the metrics contributing to PETQ's Value grade of A and ABT's Value grade of C. PETQ sticks out from ABT in both our Zacks Rank and Style Scores models, so value investors will likely feel that PETQ is the better option right now. Click to get this free report PetIQ, Inc. (PETQ) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors with an interest in Medical - Products stocks have likely encountered both PetIQ (PETQ) and Abbott (ABT). | Investors with an interest in Medical - Products stocks have likely encountered both PetIQ (PETQ) and Abbott (ABT). These are just a few of the metrics contributing to PETQ's Value grade of A and ABT's Value grade of C. PETQ sticks out from ABT in both our Zacks Rank and Style Scores models, so value investors will likely feel that PETQ is the better option right now. Click to get this free report PetIQ, Inc. (PETQ) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Investors with an interest in Medical - Products stocks have likely encountered both PetIQ (PETQ) and Abbott (ABT). ABT currently has a PEG ratio of 2.49. These are just a few of the metrics contributing to PETQ's Value grade of A and ABT's Value grade of C. PETQ sticks out from ABT in both our Zacks Rank and Style Scores models, so value investors will likely feel that PETQ is the better option right now. |
30554.0 | 2023-11-20 00:00:00 UTC | After A 6% Rise This Month Should You Pick Medtronic Stock Ahead of Its Q2? | ABT | https://www.nasdaq.com/articles/after-a-6-rise-this-month-should-you-pick-medtronic-stock-ahead-of-its-q2 | nan | nan | Medtronic (NYSE: MDT) is scheduled to report its fiscal 2024 second-quarter results on Tuesday, November 21. We expect Medtronic stock to trade sideways post-Q2 results announcement, with its revenues and earnings expected to miss the street estimates marginally. The company should continue to benefit from its new products and a better pricing environment. So, what are some trends likely to drive Medtronic’s results, and how has the company’s stock performed?
MDT stock has suffered a sharp decline of 35% from levels of $115 in early January 2021 to around $75 now, vs. an increase of about 20% for the S&P 500 over this roughly 3-year period. Notably, MDT stock has underperformed the broader market in each of the last 3 years. Returns for the stock were -12% in 2021, -25% in 2022, and -4% in 2023 (YTD). In comparison, returns for the S&P 500 have been 27% in 2021, -19% in 2022, and 18% in 2023 (YTD) – indicating that MDT underperformed the S&P in 2021, 2022, and 2023.
In fact, consistently beating the S&P 500 – in good times and bad – has been difficult over recent years for individual stocks; for heavyweights in the Health Care sector, including LLY, UNH, and JNJ, and even for the megacap stars GOOG, TSLA, and MSFT.
In contrast, the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has outperformed the S&P 500 each year over the same period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index, less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.
Given the current uncertain macroeconomic environment with high oil prices and elevated interest rates, could MDT face a similar situation as it did in 2021, 2022, and 2023 and underperform the S&P over the next 12 months – or will it see a recovery? Our forecast indicates that MDT stock is undervalued, as discussed below.
(1) Diabetes Segment To Drive Sales
Trefis estimates Medtronic’s Q2 fiscal 2024 total revenues to be around $7.8 billion, reflecting a low single-digit y-o-y rise but marginally below the $7.9 billion consensus estimate.
The company should benefit from its new products, including the Micra AV pacemaker and Onyx Frontier drug-eluting stent. It should also see continued strength in cardiac products.
Top-line growth will likely be driven by the increased adoption of its MiniMed 680G insulin system in the international markets. Earlier this year, 780G was launched in the U.S. along with Micra AV2 and Micra VR2 leadless pacemakers.
Looking at the last quarter, Medtronic’s revenue was up 4.5% to $7.7 billion. The Cardiovascular and Medical Surgical revenue grew 5.5%, Neuroscience was up 4.9%, and Diabetes sales were up 6.8%.
Our dashboard on Medtronic Revenues provides more details on the company’s segments.
(2) EPS expected to be slightly below the consensus estimates
Medtronic’s Q2 fiscal 2024 earnings per share (EPS) is expected to be $1.17 per Trefis analysis, marginally below the consensus estimate of $1.18.
Medtronic’s net income of $1.6 billion in Q1 reflected a 6% rise y-o-y, as the company’s adjusted operating margin expanded 90 bps to 24.8%.
Looking at the full fiscal year 2024, we expect EPS to be lower at $5.09, compared to the $5.29 seen in fiscal year 2023.
(3) MDT stock is undervalued
We estimate Medtronic’s Valuation to be $97 per share, reflecting a solid 30% upside from its current market price of around $75.
At its current level of $75, MDT stock is trading at just 15x its forward expected earnings compared to its last four-year average of 21x.
If the company reports upbeat Q2 results and the 2024 guidance is better than the street estimates, the P/E multiple will likely be revised upward, resulting in higher levels for MDT stock.
While MDT stock looks undervalued, it is helpful to see how Medtronic’s Peers fare on metrics that matter. You will find other valuable comparisons for companies across industries at Peer Comparisons.
Returns Nov 2023
MTD [1] 2023
YTD [1] 2017-23
Total [2]
MDT Return 6% -4% 5%
S&P 500 Return 7% 17% 101%
Trefis Reinforced Value Portfolio 6% 25% 541%
[1] Month-to-date and year-to-date as of 11/17/2023
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In fact, consistently beating the S&P 500 – in good times and bad – has been difficult over recent years for individual stocks; for heavyweights in the Health Care sector, including LLY, UNH, and JNJ, and even for the megacap stars GOOG, TSLA, and MSFT. Given the current uncertain macroeconomic environment with high oil prices and elevated interest rates, could MDT face a similar situation as it did in 2021, 2022, and 2023 and underperform the S&P over the next 12 months – or will it see a recovery? Medtronic’s net income of $1.6 billion in Q1 reflected a 6% rise y-o-y, as the company’s adjusted operating margin expanded 90 bps to 24.8%. | We expect Medtronic stock to trade sideways post-Q2 results announcement, with its revenues and earnings expected to miss the street estimates marginally. (1) Diabetes Segment To Drive Sales Trefis estimates Medtronic’s Q2 fiscal 2024 total revenues to be around $7.8 billion, reflecting a low single-digit y-o-y rise but marginally below the $7.9 billion consensus estimate. (2) EPS expected to be slightly below the consensus estimates Medtronic’s Q2 fiscal 2024 earnings per share (EPS) is expected to be $1.17 per Trefis analysis, marginally below the consensus estimate of $1.18. | (1) Diabetes Segment To Drive Sales Trefis estimates Medtronic’s Q2 fiscal 2024 total revenues to be around $7.8 billion, reflecting a low single-digit y-o-y rise but marginally below the $7.9 billion consensus estimate. (3) MDT stock is undervalued We estimate Medtronic’s Valuation to be $97 per share, reflecting a solid 30% upside from its current market price of around $75. Total [2] MDT Return 6% -4% 5% S&P 500 Return 7% 17% 101% Trefis Reinforced Value Portfolio 6% 25% 541% [1] Month-to-date and year-to-date as of 11/17/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (1) Diabetes Segment To Drive Sales Trefis estimates Medtronic’s Q2 fiscal 2024 total revenues to be around $7.8 billion, reflecting a low single-digit y-o-y rise but marginally below the $7.9 billion consensus estimate. Looking at the full fiscal year 2024, we expect EPS to be lower at $5.09, compared to the $5.29 seen in fiscal year 2023. (3) MDT stock is undervalued We estimate Medtronic’s Valuation to be $97 per share, reflecting a solid 30% upside from its current market price of around $75. |
30555.0 | 2023-11-17 00:00:00 UTC | Peter Lynch Detailed Fundamental Analysis - ABT | ABT | https://www.nasdaq.com/articles/peter-lynch-detailed-fundamental-analysis-abt-9 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Top Healthcare Stocks
Dividend Aristocrats2023
Wide Moat Stocks2023
High Insider Ownership Stocks
Factor-Based Stock Portfolios
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
30556.0 | 2023-11-17 00:00:00 UTC | Abbott (ABT) Up 5.1% Since Last Earnings Report: Can It Continue? | ABT | https://www.nasdaq.com/articles/abbott-abt-up-5.1-since-last-earnings-report%3A-can-it-continue | nan | nan | It has been about a month since the last earnings report for Abbott (ABT). Shares have added about 5.1% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Abbott due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Abbott's Q3 Earnings and Revenues Beat Estimates
Abbott reported third-quarter 2023 adjusted earnings of $1.14 per share, which topped the Zacks Consensus Estimate by 3.6%. However, the adjusted figure declined from the prior-year quarter’s levels by 0.9%. The quarter’s adjustments include 32 cents of certain non-recurring items.
GAAP earnings per share came in at 82 cents, which increased 1.2% year over year.
Third-quarter worldwide sales of $10.14 billion were down 2.6% year over year on a reported basis. The top line exceeded the Zacks Consensus Estimate by 3.6%.
On an organic basis (excluding the impact of foreign exchange, the Cardiovascular Systems acquisition, the impact of the business exit and the impact of COVID-19 testing sales), sales rose 13.8% year over year in the reported quarter.
Q3 Results in Detail
Abbott operates through four segments — Established Pharmaceuticals, Medical Devices, Nutrition and Diagnostics.
In the third quarter, Established Pharmaceuticals’ product sales increased 3.2% on a reported basis (up 11.1% on an organic basis) to $1.37 billion.
Organic sales in key emerging markets improved 8.8% year over year. This was led by growth in several geographies and therapeutic areas, including cardiometabolic, women's health and central nervous system/pain management.
The Medical Devices segment’s sales rose 16.6% year over year on a reported basis (up 14.7% on an organic basis) to $4.25 billion.
Sales growth was led by double-digit organic growth in Diabetes Care, Electrophysiology, Structural Heart and Neuromodulation. Several recently launched products and new indications contributed to the strong performance, including Amplatzer Amulet, Navitor, TriClip and AVEIR.
The Diabetes Care division reported organic sales growth of 24.5% year over year, led by FreeStyle Libre, which contributed $1.4 billion to revenues in the reported quarter. Structural Heart sales rose 15.3%, and Heart Failure sales improved 10.9% year over year organically.
The Vascular division recorded organic sales growth of 3.9% in the quarter under review. The Electrophysiology, Rhythm Management and Neuromodulation divisions recorded organic growth of 14.1%, 6% and 15.5%, respectively, in the quarter under review.
Nutrition sales rose 15.5% year over year on a reported basis (up 18.1% on an organic basis) to $2.07 billion.
Pediatric Nutrition sales registered 24.9% growth on an organic basis. Adult Nutrition sales improved 12.4% organically. Per the company, Adult Nutrition sales benefited from the strong global sales performance of Abbott's market-leading complete and balanced nutrition brand, Ensure.
Diagnostics sales were down 32.7% year over year on a reported basis (down 31.9% on an organic basis) to $2.45 billion.
Core Laboratory Diagnostics sales were up 9.7% organically. Molecular Diagnostics declined 27.8% on an organic basis. Rapid Diagnostics sales dropped 58.9% on an organic basis, whereas Point of Care Diagnostics sales rose 9.8% organically.
Margins
In the reported quarter, the gross profit fell 4.2% year over year to $5.54 billion. The gross margin contracted 93 basis points (bps) to 54.6%.
SG&A expenses were down 0.3% year over year to $2.72 billion. R&D expenses decreased 14.1% year over year to $672 million. The company reported an adjusted operating profit of $2.14 billion in the quarter under review, down 5.5% year over year. Also, the adjusted operating margin contracted 66 bps to 21.1%.
2023 Guidance
Abbott provided updated guidance for the full year 2023.
Full-year adjusted earnings (excluding specified items of $1.28 per share) are expected in the range of $4.42-$4.46 (previously $4.30-$4.40). The Zacks Consensus Estimate is pegged at $4.40.
Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, in the low double digits (unchanged from the previous outlook) and COVID-19 testing-related sales of around $1.5 billion (earlier $1.3 billion).
How Have Estimates Been Moving Since Then?
It turns out, estimates review flatlined during the past month.
VGM Scores
Currently, Abbott has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Abbott has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
Performance of an Industry Player
Abbott belongs to the Zacks Medical - Products industry. Another stock from the same industry, Neogen (NEOG), has gained 6.4% over the past month. More than a month has passed since the company reported results for the quarter ended August 2023.
Neogen reported revenues of $228.99 million in the last reported quarter, representing a year-over-year change of +73%. EPS of $0.11 for the same period compares with $0.15 a year ago.
For the current quarter, Neogen is expected to post earnings of $0.15 per share, indicating no change from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Neogen. Also, the stock has a VGM Score of D.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Neogen Corporation (NEOG) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It has been about a month since the last earnings report for Abbott (ABT). Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Neogen Corporation (NEOG) : Free Stock Analysis Report To read this article on Zacks.com click here. Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Neogen Corporation (NEOG) : Free Stock Analysis Report To read this article on Zacks.com click here. It has been about a month since the last earnings report for Abbott (ABT). Abbott's Q3 Earnings and Revenues Beat Estimates Abbott reported third-quarter 2023 adjusted earnings of $1.14 per share, which topped the Zacks Consensus Estimate by 3.6%. | It has been about a month since the last earnings report for Abbott (ABT). Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Neogen Corporation (NEOG) : Free Stock Analysis Report To read this article on Zacks.com click here. The Diabetes Care division reported organic sales growth of 24.5% year over year, led by FreeStyle Libre, which contributed $1.4 billion to revenues in the reported quarter. | It has been about a month since the last earnings report for Abbott (ABT). Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Neogen Corporation (NEOG) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott's Q3 Earnings and Revenues Beat Estimates Abbott reported third-quarter 2023 adjusted earnings of $1.14 per share, which topped the Zacks Consensus Estimate by 3.6%. |
30557.0 | 2023-11-17 00:00:00 UTC | UPRO, LIN, CMCSA, ABT: Large Outflows Detected at ETF | ABT | https://www.nasdaq.com/articles/upro-lin-cmcsa-abt%3A-large-outflows-detected-at-etf | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $131.2 million dollar outflow -- that's a 4.7% decrease week over week (from 59,650,000 to 56,850,000). Among the largest underlying components of UPRO, in trading today Linde PLC (Symbol: LIN) is off about 0.3%, Comcast Corp (Symbol: CMCSA) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average:
Looking at the chart above, UPRO's low point in its 52 week range is $30.89 per share, with $52.2214 as the 52 week high point — that compares with a last trade of $46.86. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
Also see:
Cheap Consumer Stocks
BSFT Insider Buying
STOK Stock Predictions
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of UPRO, in trading today Linde PLC (Symbol: LIN) is off about 0.3%, Comcast Corp (Symbol: CMCSA) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $131.2 million dollar outflow -- that's a 4.7% decrease week over week (from 59,650,000 to 56,850,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of UPRO, in trading today Linde PLC (Symbol: LIN) is off about 0.3%, Comcast Corp (Symbol: CMCSA) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $30.89 per share, with $52.2214 as the 52 week high point — that compares with a last trade of $46.86. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of UPRO, in trading today Linde PLC (Symbol: LIN) is off about 0.3%, Comcast Corp (Symbol: CMCSA) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $131.2 million dollar outflow -- that's a 4.7% decrease week over week (from 59,650,000 to 56,850,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $30.89 per share, with $52.2214 as the 52 week high point — that compares with a last trade of $46.86. | Among the largest underlying components of UPRO, in trading today Linde PLC (Symbol: LIN) is off about 0.3%, Comcast Corp (Symbol: CMCSA) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $131.2 million dollar outflow -- that's a 4.7% decrease week over week (from 59,650,000 to 56,850,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $30.89 per share, with $52.2214 as the 52 week high point — that compares with a last trade of $46.86. |
30558.0 | 2023-11-16 00:00:00 UTC | QIAGEN (QGEN) Expands Sample Technologies Line With New Launch | ABT | https://www.nasdaq.com/articles/qiagen-qgen-expands-sample-technologies-line-with-new-launch | nan | nan | QIAGEN N.V. QGEN recently launched TissueLyser III and the RNeasy PowerMax Soil Pro Kit to support researchers in managing diverse materials such as bone, tissue and soil samples.
The recent launch will expand its sample technologies portfolio.
More on the News
The TissueLyser III is a high-throughput instrument for enhanced and versatile disruption of a range of biological samples containing nucleic acids (DNA and RNA). Even with challenging-to-lyse materials like bones or tissues, the TissueLyser III is an excellent option for labs looking for effective sample disruption and high-quality DNA and RNA purification.
Building on the trusted technology of its prior-generation instrument, which has been cited in over 14,000 scientific publications, the TissueLyser III offers enhanced capabilities for efficient sample disruption — a critical aspect of nucleic acid purification procedures.
The TissueLyser III is compatible with many QIAGEN kits — including the new RNeasy PowerMax Soil Pro Kit. The kit is specifically designed for challenging soil samples, particularly those rich in PCR inhibitors such as compost, sediment and manure.
Significance of the Launch
The release of the TissueLyser III and the RNeasy PowerMax Soil Pro Kit are two more milestones in QIAGEN's commitment to expand its line of best-in-class sample technologies. These two items are intended to better address the special needs of researchers working with challenging samples, allowing them to work more efficiently and accurately.
TissueLyser III illustrates QIAGEN's unwavering commitment to continuously improve its automated sample preparation and analysis solutions. It adds to QIAGEN's high-throughput instrument portfolio, which includes the QIAcube HT, QIAxcel Connect and QIAsymphony.
Image Source: Zacks Investment Research
The kit produces high-yield, high-purity RNA suited for downstream applications such as real-time quantitative RT-PCR, digital PCR and next-generation sequencing by utilizing QIAGEN's innovative patent-pending Inhibitor Removal Technology (IRT) and efficient bead beating and lysis chemistry. The new kit's streamlined workflow saves processing time by 60% compared with its predecessor, the RNeasy PowerSoil Total RNA Kit, allowing for speedier discoveries and advances in the knowledge of microbial ecosystems.
Industry Prospects
According to a report, the global DNA/RNA extraction kit market is expected to register a CAGR of 7.26% from 2021 to 2026. Increased demand for the automation of DNA/RNA extraction technology, new user-friendly and easy extraction kits and use of DNA/RNA in profiling new diseases causing microorganisms are expected to boost the market.
Recent Developments
In September 2023, QIAGEN added two new nucleic acid extraction kits, extending its eco-friendly QIAwave product line. The two new kits are the QIAwave RNeasy Plus Mini Kit and the QIAwave DNA/RNA Mini Kit, eco-friendlier versions of the RNeasy Plus Mini Kit and the All DNA/RNA Mini Kit.
In July 2023, QIAGEN launched the QIAseq Normalizer Kits, giving researchers a fast, convenient and cost-effective method to pool different DNA libraries for best-quality results from next-generation sequencing (NGS) runs. Researchers can use QIAseq Normalizer with QIAGEN's existing QIAseq library prep solutions to streamline NGS workflows or with various DNA- and RNA-library prep methods from other vendors for Illumina sequencing platforms.
Price Performance
In the past year, QIAGEN’s shares have increased 7.3% against the industry’s fall of 5.7%.
Zacks Rank and Key Picks
QIAGEN carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2 (Buy), reported adjusted earnings per share (EPS) of $1.14 in third-quarter 2023, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2.
DexCom has a long-term estimated growth rate of 33.6%. DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%.
Integer Holdings reported adjusted EPS of $1.27 in third-quarter 2023, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
QIAGEN N.V. (QGEN) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30559.0 | 2023-11-16 00:00:00 UTC | Notable Thursday Option Activity: DVN, ABT, KMX | ABT | https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-dvn-abt-kmx | nan | nan | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Devon Energy Corp. (Symbol: DVN), where a total volume of 47,751 contracts has been traded thus far today, a contract volume which is representative of approximately 4.8 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 58.1% of DVN's average daily trading volume over the past month, of 8.2 million shares. Especially high volume was seen for the $44 strike call option expiring November 17, 2023, with 2,387 contracts trading so far today, representing approximately 238,700 underlying shares of DVN. Below is a chart showing DVN's trailing twelve month trading history, with the $44 strike highlighted in orange:
Abbott Laboratories (Symbol: ABT) options are showing a volume of 33,950 contracts thus far today. That number of contracts represents approximately 3.4 million underlying shares, working out to a sizeable 52.6% of ABT's average daily trading volume over the past month, of 6.5 million shares. Particularly high volume was seen for the $110 strike put option expiring November 17, 2023, with 12,196 contracts trading so far today, representing approximately 1.2 million underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $110 strike highlighted in orange:
And Carmax Inc. (Symbol: KMX) options are showing a volume of 9,221 contracts thus far today. That number of contracts represents approximately 922,100 underlying shares, working out to a sizeable 51% of KMX's average daily trading volume over the past month, of 1.8 million shares. Particularly high volume was seen for the $90 strike call option expiring April 19, 2024, with 6,017 contracts trading so far today, representing approximately 601,700 underlying shares of KMX. Below is a chart showing KMX's trailing twelve month trading history, with the $90 strike highlighted in orange:
For the various different available expirations for DVN options, ABT options, or KMX options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
Also see:
MOS DMA
CJT Historical Stock Prices
WHR Options Chain
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $110 strike put option expiring November 17, 2023, with 12,196 contracts trading so far today, representing approximately 1.2 million underlying shares of ABT. Below is a chart showing DVN's trailing twelve month trading history, with the $44 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) options are showing a volume of 33,950 contracts thus far today. That number of contracts represents approximately 3.4 million underlying shares, working out to a sizeable 52.6% of ABT's average daily trading volume over the past month, of 6.5 million shares. | Below is a chart showing DVN's trailing twelve month trading history, with the $44 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) options are showing a volume of 33,950 contracts thus far today. That number of contracts represents approximately 3.4 million underlying shares, working out to a sizeable 52.6% of ABT's average daily trading volume over the past month, of 6.5 million shares. Below is a chart showing ABT's trailing twelve month trading history, with the $110 strike highlighted in orange: And Carmax Inc. (Symbol: KMX) options are showing a volume of 9,221 contracts thus far today. | That number of contracts represents approximately 3.4 million underlying shares, working out to a sizeable 52.6% of ABT's average daily trading volume over the past month, of 6.5 million shares. Particularly high volume was seen for the $110 strike put option expiring November 17, 2023, with 12,196 contracts trading so far today, representing approximately 1.2 million underlying shares of ABT. Below is a chart showing DVN's trailing twelve month trading history, with the $44 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) options are showing a volume of 33,950 contracts thus far today. | Below is a chart showing KMX's trailing twelve month trading history, with the $90 strike highlighted in orange: For the various different available expirations for DVN options, ABT options, or KMX options, visit StockOptionsChannel.com. Below is a chart showing DVN's trailing twelve month trading history, with the $44 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) options are showing a volume of 33,950 contracts thus far today. That number of contracts represents approximately 3.4 million underlying shares, working out to a sizeable 52.6% of ABT's average daily trading volume over the past month, of 6.5 million shares. |
30560.0 | 2023-11-15 00:00:00 UTC | Alcon (ALC) Q3 Earnings Miss Estimates, Margins Increase | ABT | https://www.nasdaq.com/articles/alcon-alc-q3-earnings-miss-estimates-margins-increase | nan | nan | Alcon, Inc. ALC delivered core earnings per share (EPS) of 66 cents in the third quarter of 2023, up 32% from the year-ago quarter’s figure (up 41% at the constant exchange rate or CER). The figure missed the Zacks Consensus Estimate by 1.5%. Alcon’s “core” results are based on non-IFRS (International Financial Reporting Standards) measures.
In the third quarter, the company’s diluted EPS were 41 cents, up 78% from the prior-year quarter’s figures.
Revenues in Detail
Alcon’s net sales to third parties in the third quarter were $2.30 billion, missing the Zacks Consensus Estimate by 1.6%. The top line increased 8.4% from the year-ago quarter’s levels (up 9% at CER).
Quarter in Detail
Alcon reports operations through two reportable segments — Surgical (comprising Implantables, Consumables and Equipment/Other) and Vision Care (comprising Contact Lenses and Ocular Health).
Surgical
In the third quarter, Surgical sales amounted to $1.28 billion, up 5% year over year and 6% at CER. Our estimate projected a year-over-year improvement of 12.8%.
Net sales in Implantables increased 2%, led by demand for advanced technology intraocular lenses in the international market. Our estimate projected a year-over-year increase of 17.2% for the third quarter.
Consumables increased 7.7%, while Equipment/Other was up 4% from the prior-year quarter’s levels. Our estimate projected an improvement of 10.8% and 9.5% for consumables and equipment/other, respectively.
Vision Care
The segment reported total sales of $1.00 billion, up 13% year over year on a reported and CER basis. Our model projected a year-over-year rise of 8.6%.
Net sales of Contact Lenses increased 10% year over year, driven by product innovation, including toric modalities of Precision1, Total30 and Dailies Total1, outpacing declines in legacy lenses. Our model projected an improvement of 9.1% in this segment.
Ocular Health sales increased 19% year over year, primarily driven by the portfolio of eye drops, including acquired ophthalmic pharmaceutical products and price increases.
Margins
The cost of net sales in the third quarter was $1.02 billion, up 6.7% year over year. The core gross profit rose 10.6% to $1.31 billion in the reported quarter.
The core gross margin expanded 88 basis points (bps) to 56.1% in the third quarter of 2023.
The core operating margin expanded 103 bps in the third quarter to 13.2%. The upside was primarily driven by a higher gross margin and improved underlying operating leverage from higher sales.
Financial Position
Alcon exited the third quarter of 2023 with cash and cash equivalents of $1.05 billion compared with $661 million at the end of the second quarter.
The cumulative net cash flow from operating activities at the end of the third quarter was $937 million compared with $872 million a year ago. Free cash flow totaled $592 million at the end of the third quarter of 2023, compared with a cash inflow of $475 million a year ago.
2023 Outlook
Alcon provided an updated outlook for the full year.
The company anticipates 2023 net sales in the range of $9.3-$9.4 billion (previously $9.3-$9.5 billion). The revised range suggests growth of 10-11% at CER from 2022, up from the earlier projected growth of 9-11%. The Zacks Consensus Estimate for ALC’s revenues is pegged at $9.48 billion.
Alcon Price, Consensus and EPS Surprise
Alcon price-consensus-eps-surprise-chart | Alcon Quote
Core EPS for the full year is expected in the range of $2.70-$2.75 (previously $2.70-$2.75). This indicates growth of 31-33% at CER from 2022 levels, up from the earlier projected growth of 28-32%. The Zacks Consensus Estimate for Alcon’s 2023 earnings is currently pegged at $2.75 per share.
Our Take
Alcon delivered lower-than-expected earnings and revenues in the third quarter of 2023. However, the registered year-over-year increase in both revenues and EPS front. A competitive product portfolio, favorable market conditions, strong commercial execution and selective price increases drove the robust performance. During the reported quarter, the company witnessed strong demand for advanced technology intraocular lenses in international markets. The double-digit Vision Care growth reflects strength in contact lenses and eye drops, including acquired products and pricing. The expansion of both margins bodes well.
Within Implantables, international growth was partially offset by unfavorable currency impacts. Escalating costs are discouraging, too.
Zacks Rank and Other Key Picks
Alcon currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2, reported adjusted EPS of $1.14 in third-quarter 2023, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
DexCom reported a third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2.
DexCom has a long-term estimated growth rate of 33.6%. DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%.
Integer Holdings reported adjusted EPS of $1.27 in third-quarter 2023, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Alcon (ALC) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30561.0 | 2023-11-15 00:00:00 UTC | Abbott (ABT) Just Overtook the 50-Day Moving Average | ABT | https://www.nasdaq.com/articles/abbott-abt-just-overtook-the-50-day-moving-average-0 | nan | nan | After reaching an important support level, Abbott (ABT) could be a good stock pick from a technical perspective. ABT surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.
The 50-day simple moving average is a widely used technical indicator that helps determine support or resistance levels for different types of securities. It's one of three major moving averages, but takes precedent because it's the first sign of an up or down trend.
Over the past four weeks, ABT has gained 5.4%. The company is currently ranked a Zacks Rank #3 (Hold), another strong indication the stock could move even higher.
Once investors consider ABT's positive earnings estimate revisions, the bullish case only solidifies. No estimate has gone lower in the past two months for the current fiscal year, compared to 10 higher, and the consensus estimate has increased as well.
Investors should think about putting ABT on their watchlist given the ultra-important technical indicator and positive move in earnings estimate revisions.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | After reaching an important support level, Abbott (ABT) could be a good stock pick from a technical perspective. Investors should think about putting ABT on their watchlist given the ultra-important technical indicator and positive move in earnings estimate revisions. ABT surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend. | Once investors consider ABT's positive earnings estimate revisions, the bullish case only solidifies. Investors should think about putting ABT on their watchlist given the ultra-important technical indicator and positive move in earnings estimate revisions. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Investors should think about putting ABT on their watchlist given the ultra-important technical indicator and positive move in earnings estimate revisions. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. After reaching an important support level, Abbott (ABT) could be a good stock pick from a technical perspective. | ABT surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend. After reaching an important support level, Abbott (ABT) could be a good stock pick from a technical perspective. Over the past four weeks, ABT has gained 5.4%. |
30562.0 | 2023-11-15 00:00:00 UTC | Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-is-a-trending-stock%3A-facts-to-know-before-betting-on-it-3 | nan | nan | Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this maker of infant formula, medical devices and drugs have returned +5.4% over the past month versus the Zacks S&P 500 composite's +2% change. The Zacks Medical - Products industry, to which Abbott belongs, has gained 5.7% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Abbott is expected to post earnings of $1.19 per share, indicating a change of +15.5% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.2% over the last 30 days.
For the current fiscal year, the consensus earnings estimate of $4.44 points to a change of -16.9% from the prior year. Over the last 30 days, this estimate has changed +0.9%.
For the next fiscal year, the consensus earnings estimate of $4.62 indicates a change of +3.9% from what Abbott is expected to report a year ago. Over the past month, the estimate has changed +0.4%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Abbott is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For Abbott, the consensus sales estimate for the current quarter of $10.14 billion indicates a year-over-year change of +0.5%. For the current and next fiscal years, $40.01 billion and $41.55 billion estimates indicate -8.4% and +3.9% changes, respectively.
Last Reported Results and Surprise History
Abbott reported revenues of $10.14 billion in the last reported quarter, representing a year-over-year change of -2.6%. EPS of $1.14 for the same period compares with $1.15 a year ago.
Compared to the Zacks Consensus Estimate of $9.79 billion, the reported revenues represent a surprise of +3.6%. The EPS surprise was +3.64%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Abbott is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Abbott. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Shares of this maker of infant formula, medical devices and drugs have returned +5.4% over the past month versus the Zacks S&P 500 composite's +2% change. | Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. For the next fiscal year, the consensus earnings estimate of $4.62 indicates a change of +3.9% from what Abbott is expected to report a year ago. | Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. | Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. And if earnings estimates go up for a company, the fair value for its stock goes up. |
30563.0 | 2023-11-14 00:00:00 UTC | Charles River (CRL) to Advance AI Drug Discovery With New Pact | ABT | https://www.nasdaq.com/articles/charles-river-crl-to-advance-ai-drug-discovery-with-new-pact | nan | nan | Charles River Laboraties International, Inc. CRL recently inked a strategic deal that gives Aitia access to Logica — Charles River's Artificial Intelligence (AI)-powered drug solution platform. The partnership will enable the optimization of the discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.
Logica, an Integrated AI Program
Launched in 2022, Logica is an AI-powered drug solution that directly translates clients’ biological insights into optimized preclinical assets. The platform leverages Valo’s AI-powered Opal Computational Platform and Charles River’s leading preclinical expertise, providing clients with transformed drug discovery with a single integrated offering seamlessly translating targets into candidate nominations.
Logica reduces whitespace and produces findings quickly by integrating large-scale computing power, skilled drug searchers and laboratory equipment.
More on Collaboration
Per the terms of the agreement, Aitia will use Logica across their portfolio of novel drug targets in an effort to develop and advance drug candidates for cancers, such as multiple myeloma and prostate cancer as well as neurological indications, such as Alzheimer's, Parkinson's and Huntington's diseases.
Charles River and Aitia have also agreed to collaborate on the creation of a patient-derived xenograft (PDX) Digital Twin to predict the best tumor models for in vivo oncology research. To build PDX Digital Twins in many cancer types, the cooperation will combine Charles River's comprehensive, fully characterized, disease-relevant PDX data and expertise with Aitia's industry-leading Digital Twin technology. CRL has made an equity investment in Aitia as part of the cooperation.
Strategic Implications
Unraveling the complex genetic and molecular circuitry of neurodegenerative disorders is critical to the discovery of treatments that significantly slow or reverse these devastating diseases. Combined with the advantages of Logica, Charles River collaboration positions Aitia to translate its discoveries into novel drug candidates rapidly.
Image Source: Zacks Investment Research
The integration of Aitia's Digital Twins with Logica's cutting-edge solution has the potential to revolutionize the exploration and creation of innovative treatments for neurological disorders and cancer. The field of research on Huntington's, Parkinson's and Alzheimer's disease has advanced slowly in recent years, Charles River is enthusiastic about the potential benefits that patients may receive from this combined AI approach.
Industry Prospects
Per a report by Grand View Research, the global artificial intelligence in drug discovery market size was valued at $1.1 billion in 2022 and is expected to see a CAGR of 29.6% from 2023 to 2030. The growing demand for the discovery and development of novel drug therapies and increasing manufacturing capacities of the life science industry are driving the demand for artificial intelligence (AI)-empowered solutions in the drug discovery processes.
Recent Developments
In September 2023, Charles River entered into a multi-program collaboration agreement with Related Sciences, a data science-driven drug discovery firm. Through this partnership, Logica — the combined offering of Charles River and Valo Health — will be applied across several previously undrugged targets in Related Sciences’ portfolio.
Earlier in 2023, the company entered into a multi-program agreement with Pioneering Medicines — a strategic initiative of Flagship Pioneering — via which Pioneering Medicines will deploy Logica’s uniquely integrated AI platform across a portfolio of targets to create optimized small molecules that lead to novel therapies for unmet medical needs.
Price Performance
In the past six months, Charles River’s shares have declined 11.6% compared with the industry’s fall of 9.6%.
Zacks Rank and Key Picks
Charles River carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2 (Buy), reported adjusted EPS of $1.14 in third-quarter 2023, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
DexCom reported adjusted EPS of 50 cents in third-quarter 2023, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2.
DexCom has a long-term estimated growth rate of 33.6%. DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%.
Integer Holdings reported adjusted EPS of $1.27 in third-quarter 2023, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Charles River Laboratories International, Inc. (CRL) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Charles River Laboratories International, Inc. (CRL) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Charles River Laboratories International, Inc. (CRL) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Charles River Laboratories International, Inc. (CRL) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Charles River Laboratories International, Inc. (CRL) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30564.0 | 2023-11-14 00:00:00 UTC | 3 Dividend Giants to Grow Wealth no Matter What the Market Is Doing | ABT | https://www.nasdaq.com/articles/3-dividend-giants-to-grow-wealth-no-matter-what-the-market-is-doing | nan | nan | Growth stocks are known to stand out in bull markets, while stocks that are considered safer -- like a pharma company promising steady earnings -- generally excel in more difficult markets. It's a great idea to include a bit of both in your portfolio to support performance through any market environment. And there's one other extremely important element that could help your investments grow no matter what the market is doing: dividend stocks.
These players offer you payments every year regardless of their own market performance or the stock market environment. You can either keep these payments and enjoy the passive income or reinvest the dividends to further grow your position in a particular stock.
Now, the big question is: How should you choose a winning dividend player for your portfolio? It's important to consider a company's dividend track record, financial ability to continue payments, and general earnings prospects. Let's check out three dividend giants that could grow your wealth no matter what the market is doing.
Image source: Getty Images.
1. Coca-Cola
Coca-Cola (NYSE: KO) is a Dividend King, meaning it's increased its dividend for more than 50 consecutive years. This shows rewarding shareholders is a priority for the beverage powerhouse -- so it's likely to continue on that path. And Coca-Cola has the financial strength to do so, with more than $10 billion in free cash flow.
Today, you can count on an annual dividend of $1.84 per share from the company, representing a dividend yield of 3.24%. That's much higher than the 1.62% dividend yield of the S&P 500.
Meanwhile, you'll also like the fact that Coca-Cola's brand strength allows it to raise prices and continue to grow even through a difficult economic environment. In the most recent quarter, the company reported gains in revenue, earnings, and market share.
This moat, or competitive advantage, should keep the world's biggest non-alcoholic beverage maker growing over the long term. And that's great news for its dividend and shareholders.
2. Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) also is a Dividend King, offering evidence of its commitment to dividend growth. The pharma giant, like Coca-Cola, has plenty of free cash flow -- more than $15 billion -- to support these promises.
J&J pays an annual dividend of $4.76 at a yield of 3.23%, surpassing the yield of the S&P 500.
So, with J&J, you could collect a significant amount of passive income -- of course, the exact amount depends on how many shares you buy -- and you're likely to see that sum grow year after year.
Now is a particularly good time to get in on the J&J story as the company may be heading for a new era of growth. J&J recently spun off its consumer health unit, a slower-growth business, to favor its higher-growth businesses of pharma and medtech. The spinoff brought in proceeds of more than $13 billion -- and those and other funds focused on pharma and medtech could result in significant growth over time.
3. AbbVie
AbbVie (NYSE: ABBV) saw the light of day in 2013 when it spun off from Abbott Laboratories. And since then, the company has lifted its quarterly dividend more than 285%. The pharma player has more than $24 billion in free cash flow thanks to a solid portfolio of products including one of the world's top-selling drugs, Humira.
Right now, AbbVie pays an annual dividend of $6.20 at a yield of 4.47%, making it another dividend stock that tops the yield of the S&P 500.
Today, AbbVie is proving it has what it takes to lift its dividend even through difficult times. Humira recently lost exclusivity, which is weighing on earnings, and even though AbbVie is grooming two other immunology candidates to, together, top Humira's peak sales, this won't happen overnight. Yet the company recently emphasized its commitment to dividend growth and announced double-digit growth for those younger immunology candidates.
So, there's reason to be excited about AbbVie's ability to grow both its dividend and earnings over time.
10 stocks we like better than Coca-Cola
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Coca-Cola wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of November 6, 2023
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2024 $47.50 calls on Coca-Cola. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It's important to consider a company's dividend track record, financial ability to continue payments, and general earnings prospects. The spinoff brought in proceeds of more than $13 billion -- and those and other funds focused on pharma and medtech could result in significant growth over time. The pharma player has more than $24 billion in free cash flow thanks to a solid portfolio of products including one of the world's top-selling drugs, Humira. | It's important to consider a company's dividend track record, financial ability to continue payments, and general earnings prospects. Johnson & Johnson Johnson & Johnson (NYSE: JNJ) also is a Dividend King, offering evidence of its commitment to dividend growth. The pharma giant, like Coca-Cola, has plenty of free cash flow -- more than $15 billion -- to support these promises. | Growth stocks are known to stand out in bull markets, while stocks that are considered safer -- like a pharma company promising steady earnings -- generally excel in more difficult markets. Johnson & Johnson Johnson & Johnson (NYSE: JNJ) also is a Dividend King, offering evidence of its commitment to dividend growth. Right now, AbbVie pays an annual dividend of $6.20 at a yield of 4.47%, making it another dividend stock that tops the yield of the S&P 500. | Growth stocks are known to stand out in bull markets, while stocks that are considered safer -- like a pharma company promising steady earnings -- generally excel in more difficult markets. These players offer you payments every year regardless of their own market performance or the stock market environment. Right now, AbbVie pays an annual dividend of $6.20 at a yield of 4.47%, making it another dividend stock that tops the yield of the S&P 500. |
30565.0 | 2023-11-14 00:00:00 UTC | Here's Why You Should Retain Penumbra (PEN) Stock for Now | ABT | https://www.nasdaq.com/articles/heres-why-you-should-retain-penumbra-pen-stock-for-now | nan | nan | Penumbra, Inc. PEN is well poised for growth in the coming quarters driven by the company’s vascular and neuro businesses. Penumbra’s Immersive Healthcare business, too, is making significant progress. Its robust estimate for 2023 revenues reflects continued demand for its products. Yet, currency movements and a challenging competitive landscape affect the top line.
In the past year, the Zacks Rank #3 (Hold) stock has gained 11.2% compared with the industry’s 13.3% fall and the S&P 500’s 6.5% rise.
The global healthcare provider company has a market capitalization of $8.72 billion. It surpassed estimates in the trailing four quarters, the average surprise being 56.7%.
Key Growth Catalysts
Robust Vascular Business Growth: Penumbra is demonstrating strong growth within the company’s Vascular business, banking on the rapid increase in sales of the company’s vascular thrombectomy products in the United States. In this region, the company is benefiting from sales of new products and further market penetration of existing products. Despite supply-related issues, the Lightning Flash launch earlier in 2023 exceeded Penumbra’s expectations, becoming the biggest product launch in its history. Lightning Flash and Lightning Bolt are also accelerating in Penumbra’s U.S. vascular thrombectomy franchise, which increased 42% year over year in the third quarter. The company expects to see a robust growth trajectory in the Vascular arm in the next five years and beyond.
Improving Neuro Trend: Within the Neuro franchise, Penumbra is witnessing growth in the stroke business. It is experiencing strong customer uptake of RED 72 (with the proprietary SENDit technology), RED 43 and BMX81. According to Penumbra, coupled with the recently launched BMX81, these products will continue to increase the company’s growth and market share in Neuro, particularly as physicians continue to realize the trade-off with oversized aspiration catheters in the market in the past several years.
Image Source: Zacks Investment Research
In the third quarter, a strong increase in the company’s Neuro product sales was driven by an increase in sales of neuro thrombectomy products and neuro access products.
Upbeat 2023 Guidance: For the fourth quarter of 2023, the company projects total company revenue growth to accelerate to 28%-31% year over year. This correlates to the midpoint of the 2023 annual guidance of $1.05-$1.07 billion, suggesting a 24%-26% improvement from 2022 levels. The Zacks Consensus Estimate for fourth-quarter and full-year 2023 revenues is pegged at $290.2 million and $1.06 billion, respectively.
Downsides
Foreign Exchange Impacts Sales: A significant portion of Penumbra’s sales and costs are exposed to changes in foreign exchange rates. In 2022, approximately 30.2% of the company's consolidated revenues came from the non-U.S. markets. Its operations use multiple foreign currencies, including the euro and Japanese yen. Changes in those currencies relative to the U.S. dollar will impact sales, cost of sales and expenses, and consequently, net income.
Tough Competitive Landscape: The medical device industry is intensely competitive, subject to rapid change and significantly affected by new product introductions and other market activities of industry participants. Penumbra competes with a number of manufacturers and distributors of neuro and vascular medical devices. The company’s most notable competitors are Boston Scientific, Inari, Medtronic, Stryker, Terumo, AngioDynamics and several private companies.
Estimate Trends
In the past 90 days, the Zacks Consensus Estimate for its fiscal 2023 earnings has moved up 13.7% to $1.99.
The Zacks Consensus Estimate for fiscal 2023 revenues is pegged at $1.06 billion, indicating a 25.2% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2 (Buy), reported adjusted earnings per share (EPS) of $1.14 in third-quarter 2023, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2.
DexCom has a long-term estimated growth rate of 33.6%. DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%.
Integer Holdings reported adjusted EPS of $1.27 in third-quarter 2023, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Penumbra, Inc. (PEN) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Key Picks Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Key Picks Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30566.0 | 2023-11-14 00:00:00 UTC | Bio-Rad (BIO) Hurt by Macroeconomic Woes, Margin Pressure | ABT | https://www.nasdaq.com/articles/bio-rad-bio-hurt-by-macroeconomic-woes-margin-pressure | nan | nan | Bio-Rad BIO is currently grappling with industry-wide softness, global macroeconomic headwinds, competitive pressure and adverse currency impacts. The stock carries a Zacks Rank #5 (Strong Sell), at present.
Since the beginning of 2023, Bio-Rad has been witnessing softness in smaller biopharma companies, where historically, demand for life science products has been strong. This directly correlates with the funding constraints the broader pharmaceutical industry has been experiencing. Management stated that biopharma softness resulted in the Life Science Segment’s decelerated growth.
In the third quarter of 2023, negative BioPharma macro trends persisted. Bio-Rad experienced reduced demand from biopharma customers for its process chromatography resins and from both biopharma and smaller biotech customers for the Life Science research projects products. Bio-Rad experienced weaker demand from government accounts in China due to softening macroeconomic conditions.
On the third-quarterearnings call management stated that the situation might have a potentially larger impact on the company’s BioPharma business than initially communicated. This takes into account a core revenue guidance cut of 200 basis points related to the third-quarter revenue shortfall due to weakness in BioPharma and softer demand in China.
In recent times, Bio-Rad’s margin performance has been affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses. In the third quarter, the company’s gross margin was additionally impacted by an unfavorable product mix, with a higher-than-anticipated percentage of instrument sales versus reagents, as well as lower-than-projected revenues in the Life Science Group.
Bio-Rad Laboratories, Inc. Price
Bio-Rad Laboratories, Inc. price | Bio-Rad Laboratories, Inc. Quote
These macroeconomic factors, particularly the ongoing labor unrest, rising wage and raw material costs, along with ongoing geopolitical unrest, are leading to a significant escalation in the company’s operating expenses. Bio-Rad posted a 3.9% year-over-year decline in operating profit in the third quarter.
Added to this, Bio-Rad operates in a highly competitive environment dominated by firms varying from large multinational corporations with significant resources to start-ups. Also, the competitive and regulatory conditions in the markets where the company operates limit Bio-Rad’s ability to switch to strategies like price increases and other drivers of cost increases. Further, the extension of the public tender commitments to multiple years by the government, resulting in a reduced number of annual tenders, has led to aggressive tender pricing by Bio-Rad’s competitors. Thus, Bio-Rad faces pricing pressure resulting from increased competition, which makes it difficult for the company to manage operational, financial and business conditions efficiently.
Over the past year, shares of BIO have plummeted 28.1% compared with the industry’s 10.5% drop.
On a positive note, following the acquisition of Dropworks in 2021, Bio-Rad has been consistently developing its foothold in the rapidly growing digital PCR space to address additional opportunities in the PCR market. The pipeline of Bio-Rad’s QX600 Droplet Digital PCR platform is currently robust and growing. Backed by the tremendous customer response, the company continues to ramp up production capacity to accommodate the ongoing demand.
In the third quarter, within Life Science Group, academic and government sales of Life Sciences were strong in the Americas, encouraged by several noteworthy announcements involving ddPCR. On the clinical testing front, the Bio-Rad QX ONE platform has been selected for SMA testing for all newborns in Hong Kong and in the United States. Geneoscopy announced it had published the results of the pivotal CRC-PREVENT clinical trial, reporting the highest sensitivity for detecting colorectal cancer among similar tests powered by BIO’s QXDx ddPCR platform. In the United States, Verily won a major multi-year national wastewater testing contract from the CDC based on Bio-Rad’s QX600 platform. Management views these as contributors to future growth and a strong reinforcement of the versatility and the impact of the technology.
Key Picks
Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2 (Buy), reported adjusted EPS of $1.14 for third-quarter 2023, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2.
DexCom has a long-term estimated growth rate of 33.6%. DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%.
Integer Holdings reported adjusted EPS of $1.27 for third-quarter 2023, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Key Picks Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Key Picks Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30567.0 | 2023-11-13 00:00:00 UTC | Here's Why You Should Retain CVS Health (CVS) Stock for Now | ABT | https://www.nasdaq.com/articles/heres-why-you-should-retain-cvs-health-cvs-stock-for-now-9 | nan | nan | CVS Health Corporation CVS is well-poised for growth, backed by the entire range of insured and self-insured medical, pharmacy, dental and behavioral health products and services that instill optimism. The acquisition of Oak Street Health advances its care delivery strategy for consumers, which is likely to boost future growth.
However, stiff competition and poor macroeconomic conditions are a concern.
In the past year, this Zacks Rank #3 (Hold) stock has declined 30.3% compared with the industry’s 35.1% fall and the S&P 500’s 12.2% rise.
The pharmacy innovation company, with integrated offerings across the entire spectrum of pharmacy care, has a market capitalization of $87.09 billion. The company has a long-term estimated earnings growth rate of 4.5%.
Let’s delve deeper.
Tailwinds
Health Care Benefit Shows Potential: Following the colossal acquisition of health insurance giant Aetna, CVS Health has introduced its Health Care Benefits business arm.
Medical membership in the third quarter of 2023 grew to 25.7 million, an increase of 1.4 million members versus the prior year, reflecting growth across multiple product lines, including individual exchange, Medicare, and commercial. CVS Health demonstrated strong growth led by significant progress made in restoring its Medicare Advantage Star ratings. Medicare Advantage is a key strategic growth area for its business.
During the third quarter earnings update, the company stated that Aetna continues to be a leader in zero-dollar premium products and approximately 84% of Medicare eligibles will have access to Aetna plans in this category in 2024.
Health Services Business Gaining Traction: CVS Health continues to gain traction within Health Services (previously known as the Pharmacy segment) driven by pharmacy claims growth, specialty pharmacy and brand inflation.
Within Health Service, both Signify Health and Oak Street Health continue to deliver strong business performance consistent with expectations.
Image Source: Zacks Investment Research
As Oak Street expands to additional geographies, these opportunities to drive higher patient growth will continue to increase. By the end of 2023, CVS Health expects to have Oak Street clinics in 25 states, up from 21 at the close of the transaction. The company expects to build 50-60 clinics next year.
Strong Solvency and High Return to Investors: CVS Health ended third-quarter 2023 with cash and cash equivalents of $16.19 billion compared with $16.88 billion at the end of second-quarter 2023. Long-term debt came up to $59.78 billion compared with $61.41 billion at the end of second-quarter 2023.
Although the total year-end debt was much higher than the corresponding cash and cash equivalent level, the near-term payable debt is at $2.1 million, lower than the short-term cash level. This is positive news in terms of solvency level as, at least during the economic downturn, the company is holding sufficient cash for debt repayment.
Downsides
Competitive Landscape: In spite of significant new client wins in the course of a strong selling season, intense competition and harsh industry conditions are major impediments for CVS Health. Big competitors such as Walgreens, Target and Wal-Mart are expanding their pharmacy businesses.
Exposure to International Market Risks: CVS Health’s international operations present political, legal, compliance, operational, regulatory, economic and other risks. These risks vary widely by country and include several regional and geopolitical business conditions and demands, government intervention and censorship, discriminatory regulation, climate change regulation, nationalization or expropriation of assets and pricing constraints.
Estimate Trends
In the past 90 days, the Zacks Consensus Estimate for its fiscal 2023 earnings has moved down from $8.62 to $8.59 per share.
The Zacks Consensus Estimate for fiscal 2023 revenues is pegged at $352.9 billion, suggesting a 9.5% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2 (Buy), posted adjusted earnings per share (EPS) of $1.14 in third-quarter 2023, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2.
DexCom has a long-term estimated growth rate of 33.6%. DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%.
Integer Holdings reported adjusted EPS of $1.27 in third-quarter 2023, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
CVS Health Corporation (CVS) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Key Picks Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Key Picks Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30568.0 | 2023-11-13 00:00:00 UTC | Validea's Top Health Care Stocks Based On Peter Lynch - 11/13/2023 | ABT | https://www.nasdaq.com/articles/valideas-top-health-care-stocks-based-on-peter-lynch-11-13-2023 | nan | nan | The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ELEVANCE HEALTH INC (ELV) is a large-cap growth stock in the Insurance (Accident & Health) industry. The rating according to our strategy based on Peter Lynch is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefit, CarelonRx, Carelon Services, and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to individual, employer group risk-based, employer group fee-based, BlueCard, Medicare, Medicaid and federal employees health benefits (FEHB) program members. The CarelonRx segment includes its pharmacy business. CarelonRx markets and offers pharmacy services to affiliated health plan customers, as well as to external customers outside of the health plans. Carelon Services offers a broad array of healthcare-related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ELEVANCE HEALTH INC
ELV Guru Analysis
ELV Fundamental Analysis
PFIZER INC. (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company's primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of PFIZER INC.
PFE Guru Analysis
PFE Fundamental Analysis
DANAHER CORPORATION (DHR) is a large-cap growth stock in the Scientific & Technical Instr. industry. The rating according to our strategy based on Peter Lynch is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Danaher Corporation designs, manufactures and markets professional, medical, industrial, and commercial products and services. The Company's Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables and services that are used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. Its Life Sciences segment offers a range of instruments and consumables that are used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, and vaccines. Its Diagnostics segment offers clinical instruments, reagents, consumables, software that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of DANAHER CORPORATION
DHR Guru Analysis
DHR Fundamental Analysis
CIGNA GROUP (CI) is a large-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Peter Lynch is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: The Cigna Group is a global health services company. Its portfolio of offerings solves diverse challenges across the healthcare system. It offers a differentiated set of pharmacy, medical, behavioral, dental, and supplemental products, and services, primarily through two platforms: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes a range of coordinated and point solution health services and capabilities, as well as those from partners across the health care system, in pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions, which are provided to health plans, employers, government organizations and health care providers. Evernorth Health Services also offers MDLIVE virtual care platform. Cigna Healthcare includes the United States Commercial, United States Government, and International Health operating segments, which provide medical and coordinated solutions to clients and customers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of CIGNA GROUP
CI Guru Analysis
CI Fundamental Analysis
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is a global healthcare company. The Company's portfolio of technologies spans the spectrum of healthcare, with businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of CIGNA GROUP CI Guru Analysis CI Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. | Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Detailed Analysis of CIGNA GROUP CI Guru Analysis CI Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ELEVANCE HEALTH INC ELV Guru Analysis ELV Fundamental Analysis PFIZER INC. (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. | Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Detailed Analysis of CIGNA GROUP CI Guru Analysis CI Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Carelon Services offers a broad array of healthcare-related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs. | Detailed Analysis of CIGNA GROUP CI Guru Analysis CI Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. |
30569.0 | 2023-11-13 00:00:00 UTC | US STOCKS-Wall St falls as megacaps drag ahead of inflation data | ABT | https://www.nasdaq.com/articles/us-stocks-wall-st-falls-as-megacaps-drag-ahead-of-inflation-data | nan | nan | By Sruthi Shankar and Amruta Khandekar
Nov 13 (Reuters) - Wall Street's main indexes slipped on Monday as investors awaited a crucial inflation reading and other economic data this week that could shape expectations around how long the Federal Reserve will keep interest rates elevated.
Megacap growth stocks were a big drag, as the benchmark U.S. 10-year Treasury yield US10YT=RR rose. Shares of Microsoft MSFT.O, Amazon.com AMZN.O and Apple AAPL.O fell between 0.5% and 1.5% in early trade.
Eight of the 11 major S&P 500 sectors were in the red, with rate-sensitive real estate stocks .SPLRCRdown 1.2% and leading declines.
This week's economic data as well as speeches from Fed officials will provide clues on the trajectory of interest rates amid growing expectations that the Fed is done hiking borrowing costs.
A report on Tuesday is expected to show headline consumer prices eased to 3.3% in October from 3.7% in September. However, core prices are seen unchanged from the previous month.
"If the year-over-year (number) continues to show a decline, then that seals the fact that the Fed is not going to raise in December and most likely they're done with the hiking campaign," said Peter Cardillo, chief market economist at Spartan Capital Securities.
The major U.S. stock indexes have rebounded strongly this month, fueled by a stronger-than-expected earnings season and on hopes that U.S. interest rates are near their peak.
The benchmark S&P 500 .SPX closed at near eight-week highs on Friday, while the tech-heavy Nasdaq .IXIC hit a two-month peak.
Traders have priced in a nearly 86% chance that the Fed will hold interest rates in December, but have pushed back bets of rate cuts to June from May, according to the CME Group's FedWatch tool.
Adding to the cautious mood, Moody's lowered its outlook on the U.S. credit rating to "negative" from "stable", citing large fiscal deficits and a decline in debt affordability.
"With the absence of macro news and the strong rally that we had on Friday, the downgrade and the anticipation of the inflation data is inducing some selling this morning," Cardillo said.
U.S. House of Representatives Speaker Mike Johnson unveiled a Republican stopgap spending measure on Saturday aimed at averting a government shutdown on Friday, but the measure quickly ran into opposition from lawmakers from both parties in Congress.
At 9:41 a.m. ET, the Dow Jones Industrial Average .DJI was down 20.28 points, or 0.06%, at 34,262.82, the S&P 500 .SPX was down 19.10 points, or 0.43%, at 4,396.14, and the Nasdaq Composite .IXIC was down 96.40 points, or 0.70%, at 13,701.71. Medtech companies such as Dexcom DXCM.O, Abbott ABT.N and Insulet PODD.O rose between 2% and 5% as analysts said data for cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy is better than feared for the companies.
Cushioning the Dow, Boeing BA.N climbed 5.1% after Bloomberg News reported that China is considering resuming purchases of 737 Max aircraft.
The S&P index recorded 11 new 52-week highs and one new low, while the Nasdaq recorded 19 new highs and 82 new lows.
(Reporting by Sruthi Shankar and Amruta Khandekar in Bengaluru; Editing by Maju Samuel)
((sruthi.shankar@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 6182 2787;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Medtech companies such as Dexcom DXCM.O, Abbott ABT.N and Insulet PODD.O rose between 2% and 5% as analysts said data for cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy is better than feared for the companies. By Sruthi Shankar and Amruta Khandekar Nov 13 (Reuters) - Wall Street's main indexes slipped on Monday as investors awaited a crucial inflation reading and other economic data this week that could shape expectations around how long the Federal Reserve will keep interest rates elevated. "If the year-over-year (number) continues to show a decline, then that seals the fact that the Fed is not going to raise in December and most likely they're done with the hiking campaign," said Peter Cardillo, chief market economist at Spartan Capital Securities. | Medtech companies such as Dexcom DXCM.O, Abbott ABT.N and Insulet PODD.O rose between 2% and 5% as analysts said data for cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy is better than feared for the companies. By Sruthi Shankar and Amruta Khandekar Nov 13 (Reuters) - Wall Street's main indexes slipped on Monday as investors awaited a crucial inflation reading and other economic data this week that could shape expectations around how long the Federal Reserve will keep interest rates elevated. The S&P index recorded 11 new 52-week highs and one new low, while the Nasdaq recorded 19 new highs and 82 new lows. | Medtech companies such as Dexcom DXCM.O, Abbott ABT.N and Insulet PODD.O rose between 2% and 5% as analysts said data for cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy is better than feared for the companies. By Sruthi Shankar and Amruta Khandekar Nov 13 (Reuters) - Wall Street's main indexes slipped on Monday as investors awaited a crucial inflation reading and other economic data this week that could shape expectations around how long the Federal Reserve will keep interest rates elevated. This week's economic data as well as speeches from Fed officials will provide clues on the trajectory of interest rates amid growing expectations that the Fed is done hiking borrowing costs. | Medtech companies such as Dexcom DXCM.O, Abbott ABT.N and Insulet PODD.O rose between 2% and 5% as analysts said data for cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy is better than feared for the companies. By Sruthi Shankar and Amruta Khandekar Nov 13 (Reuters) - Wall Street's main indexes slipped on Monday as investors awaited a crucial inflation reading and other economic data this week that could shape expectations around how long the Federal Reserve will keep interest rates elevated. This week's economic data as well as speeches from Fed officials will provide clues on the trajectory of interest rates amid growing expectations that the Fed is done hiking borrowing costs. |
30570.0 | 2023-11-13 00:00:00 UTC | Medical device makers rise on relief after Wegovy obesity trial data | ABT | https://www.nasdaq.com/articles/medical-device-makers-rise-on-relief-after-wegovy-obesity-trial-data | nan | nan | Corrects syntax in paragraph 1
Nov 13 (Reuters) - Shares of U.S. medical device makers climbed in early trading on Monday as a potential hit from the cardiac benefits of Novo Nordisk's NOVOb.CO Wegovy was seen as more moderate than initially feared by investors.
"In our view, several bullets were dodged here," Jefferies analyst Matthew Taylor said in a note.
The heart protective benefits of Wegovy obesity treatment are due to more than weight loss alone, according to presented by Novo at a major medical meeting on Saturday.
Heart device maker Penumbra PEN.N was the biggest gainer, up 19%, after the data showed the reduction in risk of non-fatal stroke was not statistically significant over the length of the trial.
"Investors had feared a significant reduction in strokes. That didn't materialize," J.P. Morgan analyst Robbie Marcus said in a note.
Shares of diabetes care device makers Abbott Laboratories ABT.N, Dexcom DXCM.O, Insulet PODD.O, Tandem TNDM.O and Medtronic rose between 2% and 8%.
Inari Medical NARI.O, which also produces surgical equipment, were up 6% in morning trade.
The iShares US Medical Devices ETF IHI.P rose 2.3%, eyeing its biggest one-day percentage gain since April, days after the fund hit a more than three-year low.
(Reporting by Leroy Leo in Bengaluru; Editing by Sriraj Kalluvila)
((Leroy.Dsouza@thomsonreuters.com ; https://twitter.com/LeroyLeo7;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of diabetes care device makers Abbott Laboratories ABT.N, Dexcom DXCM.O, Insulet PODD.O, Tandem TNDM.O and Medtronic rose between 2% and 8%. Corrects syntax in paragraph 1 Nov 13 (Reuters) - Shares of U.S. medical device makers climbed in early trading on Monday as a potential hit from the cardiac benefits of Novo Nordisk's NOVOb.CO Wegovy was seen as more moderate than initially feared by investors. Heart device maker Penumbra PEN.N was the biggest gainer, up 19%, after the data showed the reduction in risk of non-fatal stroke was not statistically significant over the length of the trial. | Shares of diabetes care device makers Abbott Laboratories ABT.N, Dexcom DXCM.O, Insulet PODD.O, Tandem TNDM.O and Medtronic rose between 2% and 8%. Corrects syntax in paragraph 1 Nov 13 (Reuters) - Shares of U.S. medical device makers climbed in early trading on Monday as a potential hit from the cardiac benefits of Novo Nordisk's NOVOb.CO Wegovy was seen as more moderate than initially feared by investors. Heart device maker Penumbra PEN.N was the biggest gainer, up 19%, after the data showed the reduction in risk of non-fatal stroke was not statistically significant over the length of the trial. | Shares of diabetes care device makers Abbott Laboratories ABT.N, Dexcom DXCM.O, Insulet PODD.O, Tandem TNDM.O and Medtronic rose between 2% and 8%. Corrects syntax in paragraph 1 Nov 13 (Reuters) - Shares of U.S. medical device makers climbed in early trading on Monday as a potential hit from the cardiac benefits of Novo Nordisk's NOVOb.CO Wegovy was seen as more moderate than initially feared by investors. Heart device maker Penumbra PEN.N was the biggest gainer, up 19%, after the data showed the reduction in risk of non-fatal stroke was not statistically significant over the length of the trial. | Shares of diabetes care device makers Abbott Laboratories ABT.N, Dexcom DXCM.O, Insulet PODD.O, Tandem TNDM.O and Medtronic rose between 2% and 8%. Corrects syntax in paragraph 1 Nov 13 (Reuters) - Shares of U.S. medical device makers climbed in early trading on Monday as a potential hit from the cardiac benefits of Novo Nordisk's NOVOb.CO Wegovy was seen as more moderate than initially feared by investors. "In our view, several bullets were dodged here," Jefferies analyst Matthew Taylor said in a note. |
30571.0 | 2023-11-13 00:00:00 UTC | Quest Diagnostics (DGX) Introduces Mobile Phlebotomy Service | ABT | https://www.nasdaq.com/articles/quest-diagnostics-dgx-introduces-mobile-phlebotomy-service | nan | nan | Quest Diagnostics Incorporated DGX recently launched Quest Mobile — which enables patients nationwide to have a specimen collected for laboratory testing more easily and conveniently. By the end of 2023, Quest Mobile's 5,000 skilled mobile phlebotomists will be operating in 44 states.
The latest development is likely to broaden Quest Diagnostics' laboratory services offering.
More on Quest Mobile
The Quest Mobile service will be accessible in 44 states and is based on the most easily accessible mobile collecting healthcare network in the United States. Patients can request an appointment for at-home specimen collection with a trained Quest Mobile phlebotomist for a broad range of laboratory tests in the comfort of their homes.
Patients will be required to pay a $55 mobile collection fee at the time of scheduling and Quest Mobile does not bill health insurance. The business is actively arranging commercial pricing with healthcare systems, health insurance and providers to remove the need for patients to pay out-of-pocket.
Significance of Latest Launch
Healthcare, particularly lab testing, is becoming more and more centered around the patient's choice and convenience. People may now get important testing services on their own schedules and from a reputable provider of quality and customer care by using Quest Mobile. The service is a manifestation of Quest Diagnostics’ approach to advance and leverage its scale and expertise to cater to the changing demands of its clientele, which encompasses a growing need for at-home care services.
Quest Diagnostics’ network of 5,000 trained mobile phlebotomists is believed to be the largest in the industry. The new service complements the company's current service options, which include online appointment scheduling and walk-in visits at one of Quest's 2,100 patient service centers and in-office phlebotomy at some health provider sites.
With the launch of Quest Mobile, the company can offer patients and physicians a seamless connection to Quest Diagnostic's laboratory testing, allowing them to work together for a healthier world — one life at a time.
Industry Prospects
Per a report by Grand View Research, the global clinical laboratory service market size was estimated at $217.53 billion in 2022 and is expected to expand at a CAGR of 3.2% from 2023 to 2030. The industry is witnessing growth due to factors such as the increasing burden of chronic diseases and the growing demand for early diagnostic tests.
Progress Within Laboratory Business
In October 2023, Quest Diagnostics inked a strategic lab services agreement with Neway. The agreement aims to accelerate dialysis laboratory testing and reduce the laboratory costs of dialysis programs for patients with end-stage renal disease (ESRD).
Image Source: Zacks Investment Research
The same month, Quest Diagnostics was granted FDA Breakthrough Device Designation for its adeno-associated virus called AAV companion diagnostic (CDx), developed in collaboration with Sarepta Therapeutics for the Duchenne muscular dystrophy gene therapy. Per terms of the agreement, Diadem has licensed exclusive U.S. rights to the intellectual property of its AlzoSure Predict blood-based prognostic technology to Quest Diagnostics for the purpose of developing, validating and marketing a laboratory-developed test service for providers and patients in the United States.
Price Performance
In the past year, shares of DGX have declined 11.7% compared with the industry’s 3.2% fall.
Zacks Rank and Other Key Picks
Quest Diagnostics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2 (Buy), reported adjusted EPS of $1.14 in third-quarter 2023, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2.
DexCom has a long-term estimated growth rate of 33.6%. DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%.
Integer Holdings reported adjusted EPS of $1.27 in third-quarter 2023, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30572.0 | 2023-11-13 00:00:00 UTC | Abbott Says Aspirin-free Medication Regimen Benefits People With HeartMate 3 Heart Pump | ABT | https://www.nasdaq.com/articles/abbott-says-aspirin-free-medication-regimen-benefits-people-with-heartmate-3-heart-pump | nan | nan | (RTTNews) - Abbott's (ABT) new data show that an Aspirin-free medication regimen benefits people with its HeartMate 3 heart pump.
According to Abbott, the new late-breaking data show advanced heart failure patients living with its HeartMate 3 heart pump who didn't receive aspirin as part of their blood-thinning medication regimen experienced fewer complications from bleeding and were associated with reduced hospital visits compared to patients who took aspirin daily following their implant.
The data from the ARIES trial is the first to potentially shift how physicians manage their patients living with a HeartMate 3 heart pump.
The ARIES trial studied more than 600 patients and found that HeartMate 3 patients who didn't receive aspirin but continued using the standard post-implant vitamin-K antagonist (VKA) treatment regimen met the primary endpoint by showing non-inferiority of no aspirin to aspirin. The HeartMate 3 patients who did not take aspirin spent 47% fewer days in the hospital due to a nearly 40% decrease in bleeding events compared to patients who continued to take aspirin daily.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott's (ABT) new data show that an Aspirin-free medication regimen benefits people with its HeartMate 3 heart pump. According to Abbott, the new late-breaking data show advanced heart failure patients living with its HeartMate 3 heart pump who didn't receive aspirin as part of their blood-thinning medication regimen experienced fewer complications from bleeding and were associated with reduced hospital visits compared to patients who took aspirin daily following their implant. The data from the ARIES trial is the first to potentially shift how physicians manage their patients living with a HeartMate 3 heart pump. | (RTTNews) - Abbott's (ABT) new data show that an Aspirin-free medication regimen benefits people with its HeartMate 3 heart pump. According to Abbott, the new late-breaking data show advanced heart failure patients living with its HeartMate 3 heart pump who didn't receive aspirin as part of their blood-thinning medication regimen experienced fewer complications from bleeding and were associated with reduced hospital visits compared to patients who took aspirin daily following their implant. The data from the ARIES trial is the first to potentially shift how physicians manage their patients living with a HeartMate 3 heart pump. | (RTTNews) - Abbott's (ABT) new data show that an Aspirin-free medication regimen benefits people with its HeartMate 3 heart pump. According to Abbott, the new late-breaking data show advanced heart failure patients living with its HeartMate 3 heart pump who didn't receive aspirin as part of their blood-thinning medication regimen experienced fewer complications from bleeding and were associated with reduced hospital visits compared to patients who took aspirin daily following their implant. The ARIES trial studied more than 600 patients and found that HeartMate 3 patients who didn't receive aspirin but continued using the standard post-implant vitamin-K antagonist (VKA) treatment regimen met the primary endpoint by showing non-inferiority of no aspirin to aspirin. | (RTTNews) - Abbott's (ABT) new data show that an Aspirin-free medication regimen benefits people with its HeartMate 3 heart pump. According to Abbott, the new late-breaking data show advanced heart failure patients living with its HeartMate 3 heart pump who didn't receive aspirin as part of their blood-thinning medication regimen experienced fewer complications from bleeding and were associated with reduced hospital visits compared to patients who took aspirin daily following their implant. The ARIES trial studied more than 600 patients and found that HeartMate 3 patients who didn't receive aspirin but continued using the standard post-implant vitamin-K antagonist (VKA) treatment regimen met the primary endpoint by showing non-inferiority of no aspirin to aspirin. |
30573.0 | 2023-11-13 00:00:00 UTC | Medical device stocks rise in relief after Wegovy heart benefits data | ABT | https://www.nasdaq.com/articles/medical-device-stocks-rise-in-relief-after-wegovy-heart-benefits-data | nan | nan | Adds fresh analyst comments in paragraphs 3, 10; updates share movement
Nov 13 (Reuters) - Shares of U.S. medical device makers rose on Monday as a potential hit from the cardiac benefits of Novo Nordisk's NOVOb.CO weight-loss drug Wegovy was seen as more moderate for the battered sector than initially feared by investors.
To be sure, the full results presented on Saturday at a major medical meeting gave analysts even more confidence in the heart protective benefits of the hugely popular drug.
"We believe key findings could be seen as a marginal positive for some, but not all, verticals within MedTech, especially given currently depressed sentiment," said Baird analyst Jeff Johnson.
The data, for instance, showed the reduction in risk of non-fatal stroke was not statistically significant over the length of the trial.
That lifted shares of Penumbra PEN.N, which makes devices used in surgeries for stroke patients, 13% in morning trading.
Its shares have tumbled about 28% as of last close since Novo in August said Wegovy had also shown a clear cardiovascular benefit.
The $4.64 billion iShares US Medical Devices ETF IHI.P rose 2.3% on Monday, eyeing its biggest one-day percentage gain since April. The ETF is down about 13% this year, through Friday's close.
Shares of diabetes care device makers Abbott Laboratories ABT.N, Dexcom DXCM.O, Insulet PODD.O, Tandem TNDM.O and Medtronic MDT.N gained between 2% and 8%.
Monday's moves are the latest sign that investors across industries are closely looking at developments with the popular new class of weight-loss and diabetes drugs called GLP-1s such as Wegovy and Eli Lilly's LLY.N Mounjaro and Zepbound.
"The full detailed results ... do not shift our outlook that MedTech device stocks appear broadly oversold," said Leerink analyst Mike Kratky.
ANALYSIS-Healthcare companies counter investor worries over Wegovy effect
(Reporting by Leroy Leo and Medha Singh in Bengaluru; Editing by Sriraj Kalluvila)
((Leroy.Dsouza@thomsonreuters.com ; https://twitter.com/LeroyLeo7;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of diabetes care device makers Abbott Laboratories ABT.N, Dexcom DXCM.O, Insulet PODD.O, Tandem TNDM.O and Medtronic MDT.N gained between 2% and 8%. To be sure, the full results presented on Saturday at a major medical meeting gave analysts even more confidence in the heart protective benefits of the hugely popular drug. Monday's moves are the latest sign that investors across industries are closely looking at developments with the popular new class of weight-loss and diabetes drugs called GLP-1s such as Wegovy and Eli Lilly's LLY.N Mounjaro and Zepbound. | Shares of diabetes care device makers Abbott Laboratories ABT.N, Dexcom DXCM.O, Insulet PODD.O, Tandem TNDM.O and Medtronic MDT.N gained between 2% and 8%. Adds fresh analyst comments in paragraphs 3, 10; updates share movement Nov 13 (Reuters) - Shares of U.S. medical device makers rose on Monday as a potential hit from the cardiac benefits of Novo Nordisk's NOVOb.CO weight-loss drug Wegovy was seen as more moderate for the battered sector than initially feared by investors. The $4.64 billion iShares US Medical Devices ETF IHI.P rose 2.3% on Monday, eyeing its biggest one-day percentage gain since April. | Shares of diabetes care device makers Abbott Laboratories ABT.N, Dexcom DXCM.O, Insulet PODD.O, Tandem TNDM.O and Medtronic MDT.N gained between 2% and 8%. Adds fresh analyst comments in paragraphs 3, 10; updates share movement Nov 13 (Reuters) - Shares of U.S. medical device makers rose on Monday as a potential hit from the cardiac benefits of Novo Nordisk's NOVOb.CO weight-loss drug Wegovy was seen as more moderate for the battered sector than initially feared by investors. Monday's moves are the latest sign that investors across industries are closely looking at developments with the popular new class of weight-loss and diabetes drugs called GLP-1s such as Wegovy and Eli Lilly's LLY.N Mounjaro and Zepbound. | Shares of diabetes care device makers Abbott Laboratories ABT.N, Dexcom DXCM.O, Insulet PODD.O, Tandem TNDM.O and Medtronic MDT.N gained between 2% and 8%. Adds fresh analyst comments in paragraphs 3, 10; updates share movement Nov 13 (Reuters) - Shares of U.S. medical device makers rose on Monday as a potential hit from the cardiac benefits of Novo Nordisk's NOVOb.CO weight-loss drug Wegovy was seen as more moderate for the battered sector than initially feared by investors. To be sure, the full results presented on Saturday at a major medical meeting gave analysts even more confidence in the heart protective benefits of the hugely popular drug. |
30574.0 | 2023-11-13 00:00:00 UTC | US STOCKS-Wall Street wavers after rally, focus on inflation data | ABT | https://www.nasdaq.com/articles/us-stocks-wall-street-wavers-after-rally-focus-on-inflation-data | nan | nan | By Sinéad Carew and Sruthi Shankar
Nov 13 (Reuters) - Wall Street's three main stock indexes were making little progress in either direction on Monday as investors awaited a crucial inflation reading that could shape expectations around how long the U.S. Federal Reserve will keep interest rates elevated.
After the indexes enjoyed a rally on Friday investors turned their focus to Consumer Price Index (CPI) data, due out Tuesday morning. Economists expect a headline increase of 3.3% for October, easing from 3.7% in September. But core prices are expected to be unchanged from the previous month.
"Everyone's kind of in a holding pattern waiting to see what happens with the inflation data in morning," Michael O’Rourke, chief market strategist at JonesTrading in Stamford, Connecticut.
While the CPI reading was likely the biggest concern, O'Rourke said that investors were also still digesting Moody's weaker U.S. credit outlook issued after market close on Friday.
Friday Moody's lowered its outlook on the U.S. credit rating to "negative" from "stable", citing large fiscal deficits and a decline in debt affordability.
This added to investor reluctance to make big decisions ahead of a weekend deadline that could result in a U.S. government shutdown, O'Rourke said.
U.S. House of Representatives Speaker Mike Johnson unveiled a Republican stopgap spending measure on Saturday aimed at averting a shutdown, but the measure quickly met opposition from lawmakers from both parties in Congress.
The Dow Jones Industrial Average .DJI rose 52.18 points, or 0.15%, to 34,335.28, the S&P 500 .SPX lost 0.82 points, or 0.02%, to 4,414.42 and the Nasdaq Composite .IXIC dropped 12.31 points, or 0.09%, to 13,785.80.
The major U.S. stock indexes had rebounded so far this month, fueled by a stronger-than-expected earnings season and hopes that U.S. interest rates are near their peak.
Traders have priced in a nearly 86% chance that the Fed will hold interest rates in December, according to the CME Group's FedWatch tool.
Among the S&P 500's 11 major sectors energy .SPNY was the biggest gainer, up 0.7%, while utilities .SPLRCU was the biggest loser, down more than 1%.
While Tesla TSLA.O shares, up more than 4%, added some support to the consumer discretionary index .SPLRCD declines in heavyweight stocks such as Apple AAPL.O and Microsoft MSFT.O helped weigh down the S&P 500 technology index .SPLRCT.
Helping keep the Dow afloat, Boeing BA.N climbed 4.3% after Bloomberg News reported that China is considering resuming purchases of 737 Max aircraft.
And, Dubai's Emirates placed an order for 90 more Boeing 777X jets at the opening of the Dubai Airshow on Monday.
Medtech companies were rising with Dexcom DXCM.O adding 5%, Insulet PODD.O climbing more than 6% and Abbott ABT.N rising 2% as analysts commented on data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy.
Advancing issues outnumbered declining ones on the NYSE by a 1.08-to-1 ratio; on Nasdaq, a 1.02-to-1 ratio favored decliners.
The S&P 500 posted 23 new 52-week highs and 7 new lows; the Nasdaq Composite recorded 44 new highs and 199 new lows.
(Reporting by Sinéad Carew in New York, Sruthi Shankar and Amruta Khandekar in Bengaluru; Editing by Maju Samuel and Aurora Ellis)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Medtech companies were rising with Dexcom DXCM.O adding 5%, Insulet PODD.O climbing more than 6% and Abbott ABT.N rising 2% as analysts commented on data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy. By Sinéad Carew and Sruthi Shankar Nov 13 (Reuters) - Wall Street's three main stock indexes were making little progress in either direction on Monday as investors awaited a crucial inflation reading that could shape expectations around how long the U.S. Federal Reserve will keep interest rates elevated. "Everyone's kind of in a holding pattern waiting to see what happens with the inflation data in morning," Michael O’Rourke, chief market strategist at JonesTrading in Stamford, Connecticut. | Medtech companies were rising with Dexcom DXCM.O adding 5%, Insulet PODD.O climbing more than 6% and Abbott ABT.N rising 2% as analysts commented on data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy. By Sinéad Carew and Sruthi Shankar Nov 13 (Reuters) - Wall Street's three main stock indexes were making little progress in either direction on Monday as investors awaited a crucial inflation reading that could shape expectations around how long the U.S. Federal Reserve will keep interest rates elevated. After the indexes enjoyed a rally on Friday investors turned their focus to Consumer Price Index (CPI) data, due out Tuesday morning. | Medtech companies were rising with Dexcom DXCM.O adding 5%, Insulet PODD.O climbing more than 6% and Abbott ABT.N rising 2% as analysts commented on data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy. By Sinéad Carew and Sruthi Shankar Nov 13 (Reuters) - Wall Street's three main stock indexes were making little progress in either direction on Monday as investors awaited a crucial inflation reading that could shape expectations around how long the U.S. Federal Reserve will keep interest rates elevated. After the indexes enjoyed a rally on Friday investors turned their focus to Consumer Price Index (CPI) data, due out Tuesday morning. | Medtech companies were rising with Dexcom DXCM.O adding 5%, Insulet PODD.O climbing more than 6% and Abbott ABT.N rising 2% as analysts commented on data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy. By Sinéad Carew and Sruthi Shankar Nov 13 (Reuters) - Wall Street's three main stock indexes were making little progress in either direction on Monday as investors awaited a crucial inflation reading that could shape expectations around how long the U.S. Federal Reserve will keep interest rates elevated. Economists expect a headline increase of 3.3% for October, easing from 3.7% in September. |
30575.0 | 2023-11-13 00:00:00 UTC | US STOCKS-S&P 500 takes a pause ahead of U.S inflation data | ABT | https://www.nasdaq.com/articles/us-stocks-sp-500-takes-a-pause-ahead-of-u.s-inflation-data-0 | nan | nan | By Sinéad Carew and Sruthi Shankar
Nov 13 (Reuters) - The S&P 500 closed Monday's session slightly lower as investors held their breath before a crucial inflation reading that could provide clues as to how long the U.S. Federal Reserve will keep interest rates elevated.
After the indexes enjoyed a solid rally on Friday, the market turned its focus on Monday to Consumer Price Index (CPI) data, due out Tuesday morning. Economists expect a headline increase of 3.3% for October, easing from 3.7% in September. But core prices are expected to be unchanged from the previous month.
The CPI reading, along with labor market, "are clearly in the driver's seat for what matters to financial markets, because it dictates where Fed policy goes from here," said Matt Stucky, chief portfolio manager for equities at Northwestern Mutual Wealth Management Company in Milwaukee, Wisconsin.
"The market has the expectation the Fed is done with interest rate hikes and for that to be true, you need to have continued progress on the inflation front," along with labor market cooling, he said.
Traders have priced in a nearly 86% chance the Fed holds interest rates steady in December, according to the CME Group's FedWatch tool.
While the CPI reading was the key issue keeping investors "in a holding pattern" on Monday, Michael O’Rourke, chief market strategist at JonesTrading in Stamford, Connecticut said they were also digesting a weaker U.S. credit outlook issued.
Moody's late on Friday lowered its outlook on the U.S. credit rating to "negative" from "stable", citing large fiscal deficits and a decline in debt affordability.
This added to investor reluctance to make big decisions ahead of a weekend deadline that could potentially result in a U.S. government shutdown, O'Rourke said.
U.S. House of Representatives Speaker Mike Johnson unveiled a Republican stopgap spending measure on Saturday aimed at averting a shutdown, but the measure quickly met opposition from lawmakers from both parties in Congress.
However on Monday afternoon, top U.S. Senate Democrat Chuck Schumer expressed tentative support for Johnson's short-term funding bill that would keep the government open past the weekend.
The Dow Jones Industrial Average .DJI rose 54.77 points, or 0.16%, to 34,337.87, the S&P 500 .SPX lost 3.69 points, or 0.08%, to 4,411.55 and the Nasdaq Composite .IXIC dropped 30.37 points, or 0.22%, to 13,767.74.
The major U.S. stock indexes had rebounded so far this month, fueled by a stronger-than-expected earnings season and hopes that U.S. interest rates are near their peak.
Among the S&P 500's 11 major sectors energy .SPNY was the biggest gainer, ending up 0.7% while utilities .SPLRCU was the biggest loser, falling 1.2%.
Helping keep the Dow afloat, Boeing BA.N rallied 4% on Monday after Bloomberg News reported that China is considering resuming purchases of 737 Max aircraft.
And, Dubai's Emirates placed an order for 90 more Boeing 777X jets at the opening of the Dubai Airshow on Monday.
The S&P healthcare index .SPXHC was the benchmark's second biggest percentage gainer, adding 0.6%. It's biggest percentage gainer was dialysis company Davita Inc DVA.N, which rose 6.5%.
Other medtech companies rallying included Insulet PODD.O, which added 5.6% and Dexcom DXCM.O, up 4.6%, along with Abbott's ABT.N 1.9% gain as analysts reacted to data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy.
While Tesla TSLA.O shares, finishing up more than 4%, added some support to the consumer discretionary index .SPLRCD declines in heavyweight stocks such as Apple AAPL.O and Microsoft MSFT.O helped weigh down the S&P 500 technology index .SPLRCT.
Advancing issues outnumbered declining ones on the NYSE by a 1.08-to-1 ratio; on Nasdaq, a 1.03-to-1 ratio favored decliners.
The S&P 500 posted 24 new 52-week highs and 7 new lows; the Nasdaq Composite recorded 52 new highs and 227 new lows.
On U.S. exchanges 9.34 billion shares changed hands compared with the 10.97 billion after for the last 20 sessions.
(Reporting by Sinéad Carew in New York, Sruthi Shankar and Amruta Khandekar in Bengaluru; Editing by Maju Samuel and Aurora Ellis)
((sinead.carew@thomsonreuters.com; +13322191897;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other medtech companies rallying included Insulet PODD.O, which added 5.6% and Dexcom DXCM.O, up 4.6%, along with Abbott's ABT.N 1.9% gain as analysts reacted to data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy. By Sinéad Carew and Sruthi Shankar Nov 13 (Reuters) - The S&P 500 closed Monday's session slightly lower as investors held their breath before a crucial inflation reading that could provide clues as to how long the U.S. Federal Reserve will keep interest rates elevated. However on Monday afternoon, top U.S. Senate Democrat Chuck Schumer expressed tentative support for Johnson's short-term funding bill that would keep the government open past the weekend. | Other medtech companies rallying included Insulet PODD.O, which added 5.6% and Dexcom DXCM.O, up 4.6%, along with Abbott's ABT.N 1.9% gain as analysts reacted to data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy. After the indexes enjoyed a solid rally on Friday, the market turned its focus on Monday to Consumer Price Index (CPI) data, due out Tuesday morning. Traders have priced in a nearly 86% chance the Fed holds interest rates steady in December, according to the CME Group's FedWatch tool. | Other medtech companies rallying included Insulet PODD.O, which added 5.6% and Dexcom DXCM.O, up 4.6%, along with Abbott's ABT.N 1.9% gain as analysts reacted to data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy. By Sinéad Carew and Sruthi Shankar Nov 13 (Reuters) - The S&P 500 closed Monday's session slightly lower as investors held their breath before a crucial inflation reading that could provide clues as to how long the U.S. Federal Reserve will keep interest rates elevated. After the indexes enjoyed a solid rally on Friday, the market turned its focus on Monday to Consumer Price Index (CPI) data, due out Tuesday morning. | Other medtech companies rallying included Insulet PODD.O, which added 5.6% and Dexcom DXCM.O, up 4.6%, along with Abbott's ABT.N 1.9% gain as analysts reacted to data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy. The CPI reading, along with labor market, "are clearly in the driver's seat for what matters to financial markets, because it dictates where Fed policy goes from here," said Matt Stucky, chief portfolio manager for equities at Northwestern Mutual Wealth Management Company in Milwaukee, Wisconsin. "The market has the expectation the Fed is done with interest rate hikes and for that to be true, you need to have continued progress on the inflation front," along with labor market cooling, he said. |
30576.0 | 2023-11-13 00:00:00 UTC | US STOCKS-S&P 500 takes a pause ahead of U.S inflation data | ABT | https://www.nasdaq.com/articles/us-stocks-sp-500-takes-a-pause-ahead-of-u.s-inflation-data | nan | nan | By Sinéad Carew and Sruthi Shankar
Nov 13 (Reuters) - The S&P 500 closed Monday's session slightly down as investors held their breath before a crucial inflation reading that could provide clues as to how long the U.S. Federal Reserve will keep interest rates elevated.
After the indexes enjoyed a solid rally on Friday, the market turned its focus on Monday to Consumer Price Index (CPI) data, due out Tuesday morning. Economists expect a headline increase of 3.3% for October, easing from 3.7% in September. But core prices are expected to be unchanged from the previous month.
The CPI reading, along with labor market, "are clearly in the driver's seat for what matters to financial markets, because it dictates where Fed policy goes from here," said Matt Stucky, chief portfolio manager for equities at Northwestern Mutual Wealth Management Company in Milwaukee, Wisconsin.
"The market has the expectation the Fed is done with interest rate hikes and for that to be true, you need to have continued progress on the inflation front," along with labor market cooling, he said.
While the CPI reading was the key issue keeping investors "in a holding pattern" on Monday, Michael O’Rourke, chief market strategist at JonesTrading in Stamford, Connecticut said they were also digesting a weaker U.S. credit outlook issued.
Moody's late on Friday lowered its outlook on the U.S. credit rating to "negative" from "stable", citing large fiscal deficits and a decline in debt affordability.
This added to investor reluctance to make big decisions ahead of a weekend deadline that could potentially result in a U.S. government shutdown, O'Rourke said.
U.S. House of Representatives Speaker Mike Johnson unveiled a Republican stopgap spending measure on Saturday aimed at averting a shutdown, but the measure quickly met opposition from lawmakers from both parties in Congress.
According to preliminary data, the S&P 500 .SPX lost 4.03 points, or 0.09%, to end at 4,411.51 points, while the Nasdaq Composite .IXIC lost 30.36 points, or 0.22%, to 13,767.74. The Dow Jones Industrial Average .DJI rose 49.76 points, or 0.15%, to 34,332.86.
The major U.S. stock indexes had rebounded so far this month, fueled by a stronger-than-expected earnings season and hopes that U.S. interest rates are near their peak.
Among the S&P 500's 11 major sectors energy .SPNY was the biggest gainer during the session, while utilities .SPLRCU was the biggest loser.
Helping keep the Dow afloat, Boeing BA.N rallied on Monday after Bloomberg News reported that China is considering resuming purchases of 737 Max aircraft.
And, Dubai's Emirates placed an order for 90 more Boeing 777X jets at the opening of the Dubai Airshow on Monday.
Medtech companies including Dexcom DXCM.O, Insulet PODD.O and Abbott ABT.N rose as analysts discussed data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy.
(Reporting by Sinéad Carew in New York, Sruthi Shankar and Amruta Khandekar in Bengaluru; Editing by Maju Samuel and Aurora Ellis)
((sinead.carew@thomsonreuters.com; +13322191897;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Medtech companies including Dexcom DXCM.O, Insulet PODD.O and Abbott ABT.N rose as analysts discussed data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy. By Sinéad Carew and Sruthi Shankar Nov 13 (Reuters) - The S&P 500 closed Monday's session slightly down as investors held their breath before a crucial inflation reading that could provide clues as to how long the U.S. Federal Reserve will keep interest rates elevated. Moody's late on Friday lowered its outlook on the U.S. credit rating to "negative" from "stable", citing large fiscal deficits and a decline in debt affordability. | Medtech companies including Dexcom DXCM.O, Insulet PODD.O and Abbott ABT.N rose as analysts discussed data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy. By Sinéad Carew and Sruthi Shankar Nov 13 (Reuters) - The S&P 500 closed Monday's session slightly down as investors held their breath before a crucial inflation reading that could provide clues as to how long the U.S. Federal Reserve will keep interest rates elevated. After the indexes enjoyed a solid rally on Friday, the market turned its focus on Monday to Consumer Price Index (CPI) data, due out Tuesday morning. | Medtech companies including Dexcom DXCM.O, Insulet PODD.O and Abbott ABT.N rose as analysts discussed data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy. By Sinéad Carew and Sruthi Shankar Nov 13 (Reuters) - The S&P 500 closed Monday's session slightly down as investors held their breath before a crucial inflation reading that could provide clues as to how long the U.S. Federal Reserve will keep interest rates elevated. After the indexes enjoyed a solid rally on Friday, the market turned its focus on Monday to Consumer Price Index (CPI) data, due out Tuesday morning. | Medtech companies including Dexcom DXCM.O, Insulet PODD.O and Abbott ABT.N rose as analysts discussed data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy. By Sinéad Carew and Sruthi Shankar Nov 13 (Reuters) - The S&P 500 closed Monday's session slightly down as investors held their breath before a crucial inflation reading that could provide clues as to how long the U.S. Federal Reserve will keep interest rates elevated. After the indexes enjoyed a solid rally on Friday, the market turned its focus on Monday to Consumer Price Index (CPI) data, due out Tuesday morning. |
30577.0 | 2023-11-10 00:00:00 UTC | Hologic's (HOLX) Q4 Earnings Beat Estimates, Gross Margin Down | ABT | https://www.nasdaq.com/articles/hologics-holx-q4-earnings-beat-estimates-gross-margin-down | nan | nan | Hologic, Inc. HOLX reported adjusted earnings per share (EPS) of 89 cents in fourth-quarter fiscal 2023, up 8.5% year over year. The bottom line surpassed the Zacks Consensus Estimate by 4.7%.
The adjustments include charges and benefits related to the amortization of acquired intangible assets, restructuring and integration/consolidation costs, product line discontinuation and many others.
The company’s GAAP EPS were 37 cents in the quarter compared with the year-ago quarter’s EPS of 47 cents, down 27%.
Full year fiscal 2023 adjusted EPS was $3.96, down 34.2% from fiscal 2022 levels.
Revenues in Detail
Revenues totaled $945.3 million in the said quarter, down 0.8% year over year (down 1.5% at the constant exchange rate or CER). The metric surpassed the Zacks Consensus Estimate by 0.4%. Lower sales of COVID-19 assays dragged the top line.
Fiscal 2023 revenues were $4.03 billion, down 17.1% from fiscal 2022 levels.
Segments in Detail
In the fiscal fourth quarter, U.S. revenues totaled $715.5 million and dropped 1.8%. International revenues amounted to $229.8 million, rising 2.3% year over year and dropping 0.4% at CER.
Revenues in the Diagnostics segment declined 20.1% year over year (down 20.6% at CER) to $416.4 million in the quarter under review. Excluding COVID-19 revenues, Diagnostics revenues increased 10.2% on a reported and CER basis.
Hologic, Inc. Price, Consensus and EPS Surprise
Hologic, Inc. price-consensus-eps-surprise-chart | Hologic, Inc. Quote
Cytology & Perinatal revenues of $115.2 million were up 1.3% at CER. Molecular Diagnostics revenues of $291.9 million declined 27.5% at CER. Blood Screening revenues of $9.3 million rose 17.7% year over year at CER.
Revenues in the Breast Health segment rose 28.2% from the year-ago period’s (up 27.4% at CER) levels to $352.8 million, primarily due to higher capital equipment revenues compared with the prior-year period’s levels.
Revenues in the GYN Surgical business rose 11% year over year (up 10.6% at CER) to $148 million, primarily driven by strong results from MyoSure and Fluent Fluid Management.
Revenues at Skeletal Health increased 16.7% year over year (up 15.9% at CER) to $28 million.
Operational Update
In the fiscal fourth quarter, the company-provided adjusted gross margin contracted 210 basis points (bps) to 60.4%. According to the company, the downside in gross margin was primarily due to a year-over-year decline in COVID-19 assay sales.
The company’s adjusted operating margin was 28.3%, expanded 40 bps, primarily led by improved non-COVID base business performance and lower marketing expenses.
Financial Update
Hologic ended fourth-quarter fiscal 2023 with cash and cash equivalents of $2.72 billion compared with $2.34 billion in a year-ago period.
Total long-term debt (including the current portion) was $2.82 billion at the end of the fiscal fourth quarter, unchanged from the year-ago levels.
Net cash provided by operating activities at the end of the fiscal fourth quarter was $1.05 billion compared with $2.13 billion a year ago.
The Company repurchased 3.2 million shares of its stock for $238 million in the fourth quarter of fiscal 2023.
Guidance
Hologic issued the guidance for the first quarter of 2024 and updated the fiscal 2023 guidance.
For fiscal 2023, the company projects revenues within $3.92-$4.02 billion (previous guidance was $3.99-$4.03 billion), suggesting a year-over-year decline in the range of 2.7-0.3% on a reported basis, (2.3%)-0.2% at CER and (1.7%)-0.8% organically. The Zacks Consensus Estimate for fiscal 2023 revenues is pegged at $4.03 billion.
Adjusted EPS for fiscal 2023 are estimated to be $3.90-$4.12 (up from the previous guidance of $3.87-$3.94), with a projected growth of (1.5%)-3.5% year over year. The Zacks Consensus Estimate for fiscal 2023 EPS is pegged at $3.92.
For first-quarter fiscal 2024, the company projects revenues within $960-$985 million, suggesting a year-over-year decline in the range of 10.6-8.3% on a reported basis, 10.9-8.5% at CER and 10.7-8.3% organically. The Zacks Consensus Estimate for first-quarter fiscal 2024 revenues is pegged at $1.01 billion.
Adjusted EPS for the first quarter are estimated in the range of 92-97 cents, suggesting a decline of 14-9.3% year over year. The Zacks Consensus Estimate for first-quarter fiscal 2024 EPS is pegged at 85 cents.
Our Take
Hologic delivered better-than-expected revenues and earnings in fourth-quarter fiscal 2023. The company’s Breast Health segment registered strong growth, primarily due to higher capital equipment revenue. GYN Surgical business is driven by strong results from MyoSure and Fluent Fluid Management. The company's adjusted operating margin increased by 40 basis points, primarily driven by improved non-COVID base business performance and lower marketing expenses.
On a year-over-year basis, revenues were down. The decline in COVID-19 assay revenues dented total revenues. The company also reported a contraction in gross margins, which looks discouraging.
Zacks Rank and Key Picks
Hologic currently carries Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2 (Buy), reported adjusted EPS of $1.14 in third-quarter 2023, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2.
DexCom has a long-term estimated growth rate of 33.6%. DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%.
Integer Holdings reported adjusted EPS of $1.27 in third-quarter 2023, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Hologic, Inc. (HOLX) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30578.0 | 2023-11-09 00:00:00 UTC | Wall Street Analysts See a 25.28% Upside in Abbott (ABT): Can the Stock Really Move This High? | ABT | https://www.nasdaq.com/articles/wall-street-analysts-see-a-25.28-upside-in-abbott-abt%3A-can-the-stock-really-move-this-high | nan | nan | Abbott (ABT) closed the last trading session at $94.74, gaining 2.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $118.69 indicates a 25.3% upside potential.
The average comprises 16 short-term price targets ranging from a low of $103 to a high of $133, with a standard deviation of $10.14. While the lowest estimate indicates an increase of 8.7% from the current price level, the most optimistic estimate points to a 40.4% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.
But, for ABT, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.
Here's What You Should Know About Analysts' Price Targets
According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Here's Why There Could be Plenty of Upside Left in ABT
There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 0.9%, as 10 estimates have moved higher compared to no negative revision.
Moreover, ABT currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, while the consensus price target may not be a reliable indicator of how much ABT could gain, the direction of price movement it implies does appear to be a good guide.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed the last trading session at $94.74, gaining 2.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. But, for ABT, an impressive average price target is not the only indicator of a potential upside. Here's Why There Could be Plenty of Upside Left in ABT There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. | Abbott (ABT) closed the last trading session at $94.74, gaining 2.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. Here's Why There Could be Plenty of Upside Left in ABT There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. But, for ABT, an impressive average price target is not the only indicator of a potential upside. | You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much ABT could gain, the direction of price movement it implies does appear to be a good guide. Abbott (ABT) closed the last trading session at $94.74, gaining 2.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. But, for ABT, an impressive average price target is not the only indicator of a potential upside. | But, for ABT, an impressive average price target is not the only indicator of a potential upside. Abbott (ABT) closed the last trading session at $94.74, gaining 2.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. Here's Why There Could be Plenty of Upside Left in ABT There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. |
30579.0 | 2023-11-09 00:00:00 UTC | IVV, GOOG, XOM, ABT: ETF Inflow Alert | ABT | https://www.nasdaq.com/articles/ivv-goog-xom-abt%3A-etf-inflow-alert | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P 500 ETF (Symbol: IVV) where we have detected an approximate $812.4 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 812,050,000 to 813,900,000). Among the largest underlying components of IVV, in trading today Alphabet Inc (Symbol: GOOG) is down about 0.2%, Exxon Mobil Corp (Symbol: XOM) is up about 0.7%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.7%. For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average:
Looking at the chart above, IVV's low point in its 52 week range is $376.49 per share, with $461.88 as the 52 week high point — that compares with a last trade of $438.43. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
Also see:
AMTG Options Chain
BAM Options Chain
PLUS Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IVV, in trading today Alphabet Inc (Symbol: GOOG) is down about 0.2%, Exxon Mobil Corp (Symbol: XOM) is up about 0.7%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.7%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. | Among the largest underlying components of IVV, in trading today Alphabet Inc (Symbol: GOOG) is down about 0.2%, Exxon Mobil Corp (Symbol: XOM) is up about 0.7%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.7%. For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average: Looking at the chart above, IVV's low point in its 52 week range is $376.49 per share, with $461.88 as the 52 week high point — that compares with a last trade of $438.43. Click here to find out which 9 other ETFs had notable inflows » Also see: AMTG Options Chain BAM Options Chain PLUS Videos The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IVV, in trading today Alphabet Inc (Symbol: GOOG) is down about 0.2%, Exxon Mobil Corp (Symbol: XOM) is up about 0.7%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P 500 ETF (Symbol: IVV) where we have detected an approximate $812.4 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 812,050,000 to 813,900,000). For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average: Looking at the chart above, IVV's low point in its 52 week range is $376.49 per share, with $461.88 as the 52 week high point — that compares with a last trade of $438.43. | Among the largest underlying components of IVV, in trading today Alphabet Inc (Symbol: GOOG) is down about 0.2%, Exxon Mobil Corp (Symbol: XOM) is up about 0.7%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P 500 ETF (Symbol: IVV) where we have detected an approximate $812.4 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 812,050,000 to 813,900,000). For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average: Looking at the chart above, IVV's low point in its 52 week range is $376.49 per share, with $461.88 as the 52 week high point — that compares with a last trade of $438.43. |
30580.0 | 2023-11-09 00:00:00 UTC | Here's Why You Should Retain Boston Scientific (BSX) Now | ABT | https://www.nasdaq.com/articles/heres-why-you-should-retain-boston-scientific-bsx-now-2 | nan | nan | Boston Scientific Corporation BSX is well poised for growth in coming quarters, backed by the strong worldwide demand for its GI and pulmonary treatment options and traction in Europe for its next-generation WATCHMAN FLX. The 2023 guidance indicating strong growth over 2022 builds confidence in the stock. However, unfavorable currency movements and stiff competition are a concern.
In the past year, this Zacks Rank #3 (Hold) stock has gained 23.9% compared with the 4.9% fall of the industry and a 17.7% rise of the S&P 500.
The renowned manufacturer of medical devices and products has a market capitalization of $77.27 billion. The company’s long-term projected growth of 12.5% compares with the industry’s growth projection of 12.1%.
Let’s delve deeper.
Factors At Play
WATCHMAN, a Long-Term Growth Component: Boston Scientific’s structural heart programs are fast building momentum, banking on the strong performance of the WATCHMAN left atrial appendage closure device. WATCHMAN is the first device to offer a non-pharmacologic alternative to oral anti-coagulants that has been studied in a randomized clinical trial and is the leading device in percutaneous LAAC globally.
In the third quarter of 2023, WATCHMAN’s organic sales grew 23.3% year over year. The U.S. demand remained strong and international growth was led by China and Japan. Our estimate suggests a 21% improvement in the company's Watchman revenue in 2023.
Geographic Expansion Continues: Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States. In 2022, 40% of the company’s consolidated revenues came from international regions.
In Europe, Middle East and Africa (EMEA), Boston Scientific is expanding its base banking on its diverse portfolio, new launches and commercial execution with healthy underlying market demand. In the third quarter, EMEA sales rose 10.9% year over year on an operational basis, with double-digit growth in seven of the company’s eight business units. The company is excited about 2023 and expects to deliver double-digit growth within this region.
Upbeat Guidance: For the full year, net sales growth is expected to be approximately 11% on a reported and organic basis (earlier estimate was 10.5-11.5% reported growth and 10-11% organic growth).
Full-year adjusted earnings per share are expected in the range of $1.99-$2.02 (previous guided range was $1.96 to $2.00). The Zacks Consensus Estimate is currently pegged at $1.99.
Image Source: Zacks Investment Research
For the fourth quarter of 2023, revenue growth is projected in the range of 9-11% on a reported basis (up 8-10% organically). Adjusted earnings are expected in the range of 49-52 cents per share.
Downsides
Competitive Landscape: The presence of a large number of players has made the medical devices market highly competitive. The company participates in several markets, including Cardiovascular, CRM, Endosurgery and Neuromodulation, where it faces competition from large, well-capitalized companies such as Johnson & Johnson, Abbott, Medtronic, Stryker, Smith & Nephew and Edwards Lifesciences, apart from several other smaller companies.
Exposure to Currency Movement: With Boston Scientific recording 40% of its sales from the international market, it is highly exposed to currency fluctuations. Unfavorable currency movements have been a major dampener over the last few quarters, as in the case of other important MedTech players, too.
In 2023, the company expects an approximate 100 basis-point headwind from foreign exchange on revenues.
Estimate Trend
The Zacks Consensus Estimate for Boston Scientific’s 2023 earnings is pegged at $2.01 per share, indicating a 17.5% increase from the 2022 reported number.
The Zacks Consensus Estimate for 2023 revenues is pegged at $14.10 billion, suggesting an 11.2% rise from the 2022 figure.
Key Picks
Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2 (Buy), reported adjusted EPS of $1.14 in third-quarter 2023, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
Inari Medical, carrying a Zacks Rank #2, reported adjusted EPS of 4 cents in third-quarter 2023, beating the Zacks Consensus Estimate by 128.6%. Revenues of $119 million outpaced the consensus estimate by 2.3%.
Inari Medical has an estimated earnings growth rate of 725% for the following year. Inari Medical’s earnings surpassed estimates in all the trailing four quarters, the average being 66.8%.
Integer Holdings reported a third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
Inari Medical, Inc. (NARI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Key Picks Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Key Picks Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30581.0 | 2023-11-09 00:00:00 UTC | Alcon (ALC) Unveils New Progress in Presbyopia Correcting IOLs | ABT | https://www.nasdaq.com/articles/alcon-alc-unveils-new-progress-in-presbyopia-correcting-iols | nan | nan | Alcon Inc. ALC recently announced the availability of Clareon Vivity — the first and only non-diffractive extended depth of focus (EDOF) intraocular lens (IOL) on Alcon’s most advanced lens platform in Canada. The Clareon Vivity is intended to offer a superior halo profile compared to diffractive EDOF lenses.
The recent launch will fortify Alcon’s Vision Care segment.
More on the News
The Clareon Vivity IOL is a new addition to the Clareon Collection and is intended for individuals who want an increased vision range. To increase the depth of focus and provide a visual disturbance profile akin to a monofocal, Clareon Vivity uses a wavefront shaping optic principle, patented as X-WAVETM technology.
Clareon Vivity is equipped with wavefront-shaping X-WAVE technology. The X-WAVE technology employs proprietary transition elements to generate advanced and delayed wavefronts, resulting in an enlarged focal range that is continuous. Other significant advantages include the IOL's ability to stretch and modify the wavefront without splitting it, which boosts confidence in hitting refractive goals.
Significance of Latest Launch
With its similarity to a mono-focal visual disturbance profile, Clearon vivity has been a game changer for surgeons and their patients, providing some independence from spectacles. The Clareon Vivity IOL highlights proven results and high levels of patient satisfaction and is developed to offer a similar halo profile when compared to a monofocal IOL.
Image Source: Zacks Investment Research
Worldwide, cataracts are the most frequent cause of vision loss. Nonetheless, surgeons can now supply cataract patients with lenses like Clarion Vivity, which have been shown to have a visual disturbance profile similar to a monofocal IOL and are made to deliver excellent vision from a distance to a functional close-up.
Industry Prospects
Per Grand View Research, the global contact lenses market size was estimated at $17.14 billion in 2022 and is expected to grow at a CAGR of 8.9% by 2030. The increasing cases of refractive errors, such as myopia, hyperopia, presbyopia, and astigmatism, are the major factors driving the demand for contact lenses globally.
Progress in Optical Care Line
Alcon is registering solid growth in vision care, banking on strong sales of its contact lenses and ocular health products. In contact lenses, the company is successfully investing in fast-growing market segments with significant share opportunities. As a result, Alcon is outpacing market growth in every category where it has launched new products.
In October 2023, Alcon launched launched TOTAL30 Multifocal — the first and only monthly Water Gradient multifocal contact lens for Patients with Presbyopia. The lenses are now available in the United States and other international markets. The lenses use PRECISION PROFILE, the most popular multifocal optical design in the United States, giving wearers of the lenses clear, uninterrupted vision from close up to far away.
Alcon expanded the TOTAL30 family in the United States and Europe by launching its multifocal modality. In terms of Daily Lenses, the company benefits from the strong performance of Toric lenses, including Precision1 and DAILIES TOTAL1 Toric.
Price Performance
In the past year, shares of ALC have gained 27.6% against the industry’s 2.2% fall.
Zacks Rank and Other Key Picks
Alcon currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2, reported adjusted EPS of $1.14 in third-quarter 2023, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
Inari Medical, carrying a Zacks Rank #2, reported adjusted EPS of 4 cents in third-quarter 2023, beating the Zacks Consensus Estimate by a staggering 128.6%. Revenues of $119 million outpaced the consensus estimate by 2.3%.
Inari Medical has an estimated earnings growth rate of 725% for the following year. Inari Medical’s earnings surpassed estimates in all the trailing four quarters, the average being 66.8%.
Integer Holdings reported a third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Alcon (ALC) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
Inari Medical, Inc. (NARI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some other top-ranked stocks in the broader medical space are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Some other top-ranked stocks in the broader medical space are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30582.0 | 2023-11-09 00:00:00 UTC | Surmodics (SRDX) Q4 Earnings Top Estimates, Revenues Up Y/Y | ABT | https://www.nasdaq.com/articles/surmodics-srdx-q4-earnings-top-estimates-revenues-up-y-y | nan | nan | Surmodics, Inc. SRDX delivered adjusted earnings per share (EPS) of 53 cents in the fourth quarter of fiscal 2023 against the year-ago quarter’s loss of 26 cents per share. The metric topped the Zacks Consensus Estimate by a huge 231.3%.
GAAP EPS for the quarter was 47 cents against the year-earlier loss of $1.06 per share.
Full-year adjusted EPS was 16 cents against the loss of 95 cents per share at the end of the comparable fiscal 2022 period and the Zacks Consensus Estimate of a loss of 22 cents per share.
Revenues in Detail
Surmodics registered revenues of $27.9 million in the fiscal fourth quarter, up 7.6% year over year. The figure surpassed the Zacks Consensus Estimate by 7.6%.
The top line was boosted by solid year-over-year product sales growth from both the Medical Device and In Vitro Diagnostics (IVD) businesses.
Excluding SurVeil drug-coated balloon (DCB) license fee revenues, total revenues increased 12.6% year over year to $26.9 million.
Full-year revenues were $132.6 million, reflecting a 32.6% improvement from the comparable fiscal 2022 period. The figure surpassed the Zacks Consensus Estimate by 1.5%.
Segmental Analysis
Surmodics operates via two reportable segments — Medical Device and IVD.
In the reported quarter, sales in the Medical Device segment summed $21 million, up 7.9% from the year-ago quarter. Excluding SurVeil DCB license fee revenues, Medical Device revenues increased 14.9% to $20 million year over year.
Medical Device revenue growth was primarily driven by increased performance coating royalties and significant contributions to product sales from the Pounce thrombectomy device platform. However, this was partly offset by a decrease in proprietary specialty catheter product sales due to the completion of a customer development program. This figure compares to our Medical Device fiscal fourth-quarter revenue projection of $19.7 million.
In the quarter under review, IVD sales improved 6.8% to $6.9 million, primarily driven by strong customer demand for microarray slide/surface products and favorable order timing for distributed antigen products. This figure compares to our IVD fiscal fourth-quarter revenue projection of $6.3 million.
The company also derives revenues from three primary sources — Product sales, Royalties and license fees and Research, development and other fees.
In the quarter under review, Product sales were $15.4 million, up 6.7% from the prior-year quarter. This figure compares to our fiscal fourth-quarter revenue projection of $14.9 million.
Royalties and license fees revenues totaled $10.1 million, up 5.7% from the prior-year quarter. This figure compares to our fiscal fourth-quarter revenue projection of $11.1 million.
Research, development and other revenues were $2.6 million, up 22.6% year over year.
Surmodics, Inc. Price, Consensus and EPS Surprise
Surmodics, Inc. price-consensus-eps-surprise-chart | Surmodics, Inc. Quote
Margin Trend
In the quarter under review, Surmodics’ gross profit increased 2.6% to $20.9 million. However, the gross margin contracted 363 basis points to 74.8%.
We had projected 80.0% of gross margin for the fiscal fourth quarter.
Selling, general & administrative expenses declined 7.1% to $12.8 million. Research and development expenses declined 20.9% year over year to $9.7 million. Adjusted operating expenses of $22.5 million declined 13.6% year over year.
Adjusted operating loss totaled $1.6 million compared with the prior-year quarter’s adjusted operating loss of $5.6 million.
Financial Position
Surmodics exited fiscal 2023 with cash and cash equivalents of $41.4 million compared with $18.9 million at the end of fiscal 2022. Total debt (including short-term debt) at the end of fiscal 2023 was $29.4 million compared with $10 million at the fiscal 2022-end.
Cumulative net cash provided by operating activities at the end of fiscal 2023 was $10.5 million against cumulative net cash used in operating activities of $17.2 million a year ago.
Fiscal 2024 Guidance
Surmodics has initiated its financial outlook for fiscal 2024.
The company projects fiscal year 2024 revenues in the range of $116 million-$121 million, representing a decrease of 13-9% over the comparable prior-year period. The Zacks Consensus Estimate currently stands at $121.2 million.
Excluding SurVeil DCB license fee revenues, Surmodics expects fiscal 2024 total revenues between $112 million and $117 million, representing an increase of 9-14% compared to fiscal 2023.
Adjusted loss per share for fiscal 2024 is expected to be in the range of $1.32-97 cents. The Zacks Consensus Estimate currently stands at a loss of 67 cents per share.
Our Take
Surmodics exited the fourth quarter of fiscal 2023 with better-than-expected results. The solid uptick in the overall top line and bottom line was impressive. The company registered robust revenues from both segments and its primary sources, which was encouraging. During the quarter, Surmodics advanced the initial commercialization of its Pounce arterial thrombectomy and Sublime radial access platforms. This looks promising for the stock.
In October, Surmodics launched its Preside medical device coating technology, providing improved lubricity and durability to a broader range of complex device applications. This raises our optimism about the stock.
However, the gross margin contraction does not bode well for Surmodics. Its operation in a competitive and evolving field and reliance on third parties also raise our apprehension.
Zacks Rank and Other Key Picks
Surmodics currently sports a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2.
DexCom has a long-term estimated growth rate of 33.6%. DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%.
Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Surmodics, Inc. (SRDX) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30583.0 | 2023-11-09 00:00:00 UTC | BD (BDX) Q4 Earnings In-Line With Estimates, Margins Contract | ABT | https://www.nasdaq.com/articles/bd-bdx-q4-earnings-in-line-with-estimates-margins-contract | nan | nan | Becton, Dickinson and Company BDX, popularly known as BD, delivered adjusted earnings per share (EPS) of $3.42 in the fourth quarter of fiscal 2023, up 24.4% year over year. The figure was in line with the Zacks Consensus Estimate.
The adjustments include expenses related to purchase accounting adjustments and integration costs, among others.
GAAP EPS for the quarter was 53 cents, reflecting a decline of 42.4% from the year-earlier figure.
Full-year adjusted EPS was $12.21, up 7.6% compared with that at the end of the comparable fiscal 2022 period. The figure lagged the Zacks Consensus Estimate by 0.2%.
Revenues in Detail
BD registered revenues of $5.09 billion in the fiscal fourth quarter, up 6.8% year over year. The figure surpassed the Zacks Consensus Estimate by 1.4%.
At constant exchange rate (CER), revenues climbed 5.9%.
The top-line improvement primarily resulted from robust performances by BD’s segments.
Base revenues were $5.07 billion in the fiscal fourth quarter, up 7.3% year over year on a reported basis and 6.3% at CER.
Base organic revenue growth for the fiscal fourth quarter was 7% at CER.
Full-year revenues were $19.37 billion, reflecting a 2.7% improvement from the comparable fiscal 2022 period. The figure surpassed the Zacks Consensus Estimate by 0.4%.
Segment Details
BD’s operations consist of three worldwide business segments — BD Medical, BD Life Sciences and BD Interventional.
For the quarter under review, BD Medical reported worldwide revenues of $2.55 billion, up 7.5% from the year-ago quarter on a reported basis and 6.2% at CER. Per management, this upside can be attributed to strong double-digit growth in Medication Management Solutions and Pharmaceutical Systems (PS) business units. This compares to our projection of fiscal fourth-quarter segmental revenues of $2.45 billion.
Worldwide revenues in the BD Life Sciences segment totaled $1.33 billion, up 3.3% year over year on a reported basis and up 2.2% at CER. The segment’s performance reflected solid growth in the base business and an expected decline in COVID-only testing revenues. The fiscal fourth-quarter revenues compare to our estimate of $1.34 billion.
BD Interventional segment generated worldwide revenues of $1.20 billion, up 9.7% from the year-ago quarter on a reported basis and 9.6% at CER. This was owing to strong growth across the segment. The fiscal fourth-quarter revenues compare to our estimate of $1.22 billion.
Geographic Results
In the fourth quarter of fiscal 2023, revenues in the United States improved 6.3% to $2.88 billion. This compares to our estimate of $2.87 billion.
International revenues grossed $2.21 billion, up 7.6% from the year-ago quarter on a reported basis and 5.3% at CER. This compares to our estimate of $2.13 billion.
Becton, Dickinson and Company Price, Consensus and EPS Surprise
Becton, Dickinson and Company price-consensus-eps-surprise-chart | Becton, Dickinson and Company Quote
Margin Analysis
In the quarter under review, BD’s gross profit declined 18.1% to $1.70 billion. The gross margin contracted a huge 1017 basis points (bps) to 33.4%.
Selling and administrative expenses decreased 3.8% to $1.14 billion. Research and development expenses decreased 6.3% year over year to $281 million. Adjusted operating expenses of $1.42 billion declined 4.3% year over year.
Adjusted operating profit totaled $283 million, reflecting a 52.4% plunge from the year-ago quarter. The adjusted operating margin in the fiscal fourth quarter contracted 691 bps to 5.6%.
Financial Position
BD exited fiscal 2023 with cash and cash equivalents and short-term investments of $1.42 billion compared with $1.01 billion at the fiscal 2022-end. Total debt (including current debt obligations) at the end of fiscal 2023 was $15.88 billion compared with $16.07 billion at the fiscal 2022-end.
Cumulative net cash flow from continuing operating activities at the end of fiscal 2023 was $2.99 billion compared with $2.47 million a year ago.
Meanwhile, BD has a consistent dividend-paying history, with its five-year annualized dividend growth being 4.23%.
Fiscal 2024 Guidance
BD has initiated its financial outlook for fiscal 2024.
BD projects its full fiscal year revenues to be in the range of $20.1 billion-$20.3 billion. The Zacks Consensus Estimate is pegged at $20.32 billion.
For fiscal 2024, organic revenue growth is expected to be between 5.25% and 6.25%, while revenue growth at CER is expected to be in the range of 4.5-5.5%.
For the full fiscal year, adjusted EPS is anticipated in the range of $12.70-$13.00, representing growth of 4-6.5%. The Zacks Consensus Estimate is pegged at $13.49.
Our Take
BD exited the fourth quarter of fiscal 2023 with in-line earnings and better-than-expected revenues. Solid top-line and bottom-line results, along with improvements in the overall base revenues, were impressive. Robust performances by all its segments and both geographic regions were encouraging. Strength in BD’s segment’s business units during the reported quarter was also promising.
This month, BD’s Medication Delivery Solutions (MDS) business unit launched its next-generation needle-free blood draw technology, the new PIVO Pro Needle-free Blood Collection Device. In August, BD received the FDA’s 510(k) clearance for the BD Respiratory Viral Panel for the BD MAX System. These developments also raise our optimism.
However, lower COVID-only testing revenues in the quarter were discouraging from a business perspective. MDS unit’s softness in China, driven by market dynamics (including volume-based procurement) and the PS unit’s slowdown in China exports of anticoagulants, were also concerning. Rising product costs put pressure on the margins, leading to the contraction of both margins, which do not bode well.
Zacks Rank and Key Picks
BD currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2.
DexCom has a long-term estimated growth rate of 33.6%. DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%.
Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Becton, Dickinson and Company (BDX) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30584.0 | 2023-11-09 00:00:00 UTC | What's Next For Boston Scientific Stock After 5% Gains In A Week? | ABT | https://www.nasdaq.com/articles/whats-next-for-boston-scientific-stock-after-5-gains-in-a-week | nan | nan | Boston Scientific (NYSE: BSX) reported its Q3 results last month, with revenues and earnings beating the street estimates. However, we believe BSX stock has little room for growth, as discussed below. The company reported revenue of $3.5 billion and adjusted earnings of $0.50 per share, compared to the consensus estimates of $3.4 billion and $0.48, respectively. In this note, we discuss Boston Scientific’s stock performance, key takeaways from its recent results, and valuation.
BSX stock has seen extremely strong gains of 55% from levels of $35 in early January 2021 to around $55 now, vs. an increase of about 15% for the S&P 500 over this roughly 3-year period. BSX is one of a handful of stocks that have increased their value in each of the last three years, but that still wasn’t enough for it to consistently beat the market. Returns for the stock were 18% in 2021, 9% in 2022, and 14% in 2023 (YTD). In comparison, returns for the S&P 500 have been 27% in 2021, -19% in 2022, and 14% in 2023 (YTD) – indicating that BSX underperformed the S&P in 2021.
In fact, consistently beating the S&P 500 – in good times and bad – has been difficult over recent years for individual stocks; for heavyweights in the Health Care sector, including LLY, UNH, and JNJ, and even for the megacap stars GOOG, TSLA, and MSFT. In contrast, the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has outperformed the S&P 500 each year over the same period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index, less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.
Given the current uncertain macroeconomic environment with high oil prices and elevated interest rates, could BSX face a similar situation as it did in 2021 and underperform the S&P over the next 12 months – or will it see a strong jump? From a valuation perspective, BSX stock looks like it has little room for growth. We estimate Boston Scientific’s Valuation to be $58 per share, reflecting just a 10% upside from its current levels of $53. This represents a 29x P/E multiple for BSX based on adjusted earnings expectation of $2.00 per share in 2023. The 29x P/E ratio also aligns with the last four-year average for BSX.
Boston Scientific’s revenue of $3.5 billion in Q3 was up 11% y-o-y, primarily due to 12% growth in the Cardiovascular segment and an 11% rise in MedSurg sales. Boston Scientific’s acquisition of Apollo Endosurgery and a majority stake in Acotec has bolstered its top-line growth, a trend expected to continue. The company expects its full-year 2023 sales to be around $14.1 billion, up 11% y-o-y.
Boston Scientific’s operating margin expanded over 300 bps to 29% in Q3. Higher revenues and margin expansion resulted in adjusted earnings of $0.50 per share, up 16% y-o-y. The company raised its earnings outlook to be in the range of $1.99 and $2.02 versus its prior guidance of $1.96 to $2.00.
Looking forward, the company should continue to benefit from new product launches, including POLARx (Japan), Vercise, and XL valves. Furthermore, its recent acquisitions, including Baylis and Apollo, will further bolster its top-line growth. Its majority stake in Acotec will likely aid its future sales growth in China. That said, much of the positives appear to be priced in for Boston Scientific. It is already trading at 5.7x sales, close to its last five-year average of 5.9x.
While BSX stock looks like it has little room for growth, it is helpful to see how Boston Scientific’s Peers fare on metrics that matter. You will find other valuable comparisons for companies across industries at Peer Comparisons.
Returns Nov 2023
MTD [1] 2023
YTD [1] 2017-23
Total [2]
BSX Return 3% 14% 144%
S&P 500 Return 4% 14% 95%
Trefis Reinforced Value Portfolio 4% 22% 525%
[1] Month-to-date and year-to-date as of 11/7/2023
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In fact, consistently beating the S&P 500 – in good times and bad – has been difficult over recent years for individual stocks; for heavyweights in the Health Care sector, including LLY, UNH, and JNJ, and even for the megacap stars GOOG, TSLA, and MSFT. Given the current uncertain macroeconomic environment with high oil prices and elevated interest rates, could BSX face a similar situation as it did in 2021 and underperform the S&P over the next 12 months – or will it see a strong jump? Boston Scientific’s acquisition of Apollo Endosurgery and a majority stake in Acotec has bolstered its top-line growth, a trend expected to continue. | Boston Scientific (NYSE: BSX) reported its Q3 results last month, with revenues and earnings beating the street estimates. The company reported revenue of $3.5 billion and adjusted earnings of $0.50 per share, compared to the consensus estimates of $3.4 billion and $0.48, respectively. Boston Scientific’s acquisition of Apollo Endosurgery and a majority stake in Acotec has bolstered its top-line growth, a trend expected to continue. | Boston Scientific (NYSE: BSX) reported its Q3 results last month, with revenues and earnings beating the street estimates. While BSX stock looks like it has little room for growth, it is helpful to see how Boston Scientific’s Peers fare on metrics that matter. Total [2] BSX Return 3% 14% 144% S&P 500 Return 4% 14% 95% Trefis Reinforced Value Portfolio 4% 22% 525% [1] Month-to-date and year-to-date as of 11/7/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company reported revenue of $3.5 billion and adjusted earnings of $0.50 per share, compared to the consensus estimates of $3.4 billion and $0.48, respectively. In comparison, returns for the S&P 500 have been 27% in 2021, -19% in 2022, and 14% in 2023 (YTD) – indicating that BSX underperformed the S&P in 2021. That said, much of the positives appear to be priced in for Boston Scientific. |
30585.0 | 2023-11-09 00:00:00 UTC | Inspire Medical (INSP) Q3 Earnings Top Estimates, Revenues Lag | ABT | https://www.nasdaq.com/articles/inspire-medical-insp-q3-earnings-top-estimates-revenues-lag | nan | nan | Inspire Medical Systems, Inc. INSP delivered a loss of 29 cents per share in third-quarter 2023, narrower than the year-ago loss of 60 cents. The metric was also narrower than the Zacks Consensus Estimate of a loss of 53 cents.
Revenues in Detail
Inspire Medical registered revenues of $153.3 million in the third quarter, up 40.4% year over year. However, the figure lagged the Zacks Consensus Estimate by 1.8%.
Per management, the top-line growth was driven by higher utilization at existing sites. The addition of new implanting centers and U.S. sales territories also complimented the improvement. The top line also benefited from strength in U.S. revenues and revenues outside the United States (All other countries).
Segment Details
Inspire Medical’s operations consist of two geographic regions — the United States and All other countries.
For the quarter under review, U.S. revenues of $147.5 million reflected an increase of 38.8% from the year-ago quarter on a reported basis. Per management, this upside was primarily driven by higher utilization at existing centers. Other growth drivers included the addition of new implanting centers, Inspire Medical’s continuing direct-to-consumer marketing and a higher number of territory managers.
During the reported quarter, Inspire Medical activated 62 new U.S. centers, thus bringing the total to 1,107 U.S. medical centers providing Inspire therapy. The company also created 13 new U.S. sales territories in the quarter, bringing the total to 274 U.S. sales territories.
Revenues from outside the United States totaled $5.8 million, up 99% year over year on a reported basis.
Inspire Medical Systems, Inc. Price, Consensus and EPS Surprise
Inspire Medical Systems, Inc. price-consensus-eps-surprise-chart | Inspire Medical Systems, Inc. Quote
Margin Analysis
In the third quarter, Inspire Medical’s gross profit increased 44.2% to $128.9 million. The gross margin expanded 222 basis points to 84.1%.
Selling, general and administrative expenses jumped 32.3% to $113.2 million. Research and development expenses increased 38.8% year over year to $29.1 million. Operating expenses of $142.4 million increased 33.6% year over year.
Operating loss totaled $13.5 million compared with the prior-year quarter’s operating loss of $17.2 million.
Financial Position
INSP exited third-quarter 2023 with cash and cash equivalents and short-term investments of $464.2 million compared with $467.1 million at the second-quarter end.
Cumulative net cash provided by operating activities at the end of third-quarter 2023 was $7.4 million against cumulative net cash used in operating activities of $7.7 million a year ago.
Outlook
Inspire Medical has upped its revenue outlook for 2023.
The company now projects revenues in the range of $608 million-$612 million (reflecting growth of 49-50% from 2022 levels), up from the earlier projection of $600 million-$610 million (reflecting growth of 47-50% from 2022 levels). The Zacks Consensus Estimate is pegged at $612.3 million.
INSP continues to plan to activate 52-56 new U.S. medical centers providing Inspire therapy and add 12-14 new U.S. sales territories during the fourth quarter of 2023.
Our Take
Inspire Medical exited the third quarter of 2023 with narrower-than-expected loss per share. The robust improvement of the top line was impressive. Strength in year-over-year geographic results was promising. The gross margin expansion, despite rising product costs, also looks promising.
The activation of new U.S. centers and the creation of new U.S. sales territories during the reported quarter also look encouraging. Management’s expectations of activating more U.S. medical centers and adding new U.S. sales territories during the fourth quarter of 2023 also raise our optimism about the stock.
During the quarter, Inspire Medical’s management confirmed making significant progress with market access by expanding coverage policies with several large national health plans to include the company’s recently expanded indications. Management also stated that the company continued to make investments in its clinical research, as reflected by the PREDICTOR study results. These also look promising for the stock.
However, lower-than-expected revenues and dismal bottom-line results were disappointing. Rising operating costs weighed on the company’s performance and resulted in continued operating loss. This also raises apprehension.
Zacks Rank and Key Picks
Inspire Medical currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted earnings per share (EPS) of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2.
DexCom has a long-term estimated growth rate of 33.6%. DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%.
Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
Inspire Medical Systems, Inc. (INSP) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inspire Medical Systems, Inc. (INSP) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inspire Medical Systems, Inc. (INSP) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inspire Medical Systems, Inc. (INSP) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inspire Medical Systems, Inc. (INSP) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30586.0 | 2023-11-09 00:00:00 UTC | 2 No-Brainer Stocks to Buy for Forever Dividend Growth | ABT | https://www.nasdaq.com/articles/2-no-brainer-stocks-to-buy-for-forever-dividend-growth | nan | nan | No matter what the market is doing, dividend stocks offer you regular payments. Knowing this may help you sleep at night during times of market turmoil. And during better market times, these payments offer your portfolio an extra boost. So, owning dividend stocks really is a win-win situation.
But how can you be sure a particular stock will offer you dividend growth over the long term? After all, a company can suspend its dividend at any time or simply stop increasing it.
Nothing is 100% certain, of course, but you can increase your chances of long-term dividend growth by choosing companies with a track record of dividend increases. You'll find them in the list of Dividend Kings, companies that have increased their dividends for at least 50 consecutive years. This suggests rewarding shareholders is important to them, so it's likely they'll stick with that policy.
If the company also boasts solid free cash flow, you probably are looking at a dividend winner that you'll want in your portfolio. And I've got two that fit the bill. Let's check out these no-brainer stocks to buy for forever dividend growth.
Image source: Getty Images.
1. Coca-Cola
Coca-Cola (NYSE: KO) doesn't spend a lot of time talking about its dividend -- and it doesn't have to. Its track record speaks for itself. The world's biggest non-alcoholic beverage maker has raised its dividend for the past 61 years, and since 2010, it's paid out a total of more than $76 billion in dividends to shareholders. That's reason to be confident about its commitment to growing your passive income.
This classic dividend stock offers a total annual payment of $1.84 per share, which amounts to a dividend yield of 3.23% at the current share price. As for Coca-Cola's ability to continue lifting payouts, that looks good too. The company's free cash flow stands at more than $10 billion, and Coca-Cola pays out about 79% of that amount in the form of dividends.
But you won't want to buy Coca-Cola for its dividend alone. The company is also a buy thanks to its long track record of earnings growth and ability to keep growing even during tougher economic environments, like the current one. That's thanks to the company's brand strength, innovation, and solid distribution network. In the most recent quarter, Coca-Cola even lifted its full-year revenue guidance.
All this means Coca-Cola may offer you dividend and earnings growth as far as the eye can see.
2. Abbott Laboratories
Abbott Laboratories (NYSE: ABT) has also placed an important focus on dividends, lifting its payments for 51 straight years. Today, the healthcare giant pays investors an annual dividend of $2.04 per share, representing a yield of 2.15%. That beats the S&P 500 Index's dividend yield of 1.62%.
Like Coca-Cola, Abbott has grown its free cash flow into the billions of dollars over the years, and today it's reached about $4.4 billion. Meanwhile, Abbott has continued to increase revenue and net income over time, thanks to its four businesses: diagnostics, medical devices, established pharmaceuticals, and nutrition. So, Abbott has the financial power to continue along the path of dividend growth.
As with Coca-Cola, you'll want to buy this market giant not only for its dividend but also for its overall growth story. Abbott recently reported a dip in revenue due to declines in demand for coronavirus testing -- Abbott is a leading maker of test kits. But if you remove coronavirus testing from the equation and just look at Abbott's underlying business, revenue is climbing in the double digits -- both overall and for each of the individual businesses.
Finally, Abbott continues to launch new and innovative products. It also recently beefed up its presence in one of its areas of strength, diabetes management, with the acquisition of Bigfoot Biomedical. All this should spur more growth moving forward.
That means Abbott offers you the possibility of forever dividend growth -- and a whole lot more.
10 stocks we like better than Coca-Cola
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Coca-Cola wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of November 6, 2023
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends the following options: long January 2024 $47.50 calls on Coca-Cola. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) has also placed an important focus on dividends, lifting its payments for 51 straight years. The company's free cash flow stands at more than $10 billion, and Coca-Cola pays out about 79% of that amount in the form of dividends. The company is also a buy thanks to its long track record of earnings growth and ability to keep growing even during tougher economic environments, like the current one. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) has also placed an important focus on dividends, lifting its payments for 51 straight years. This classic dividend stock offers a total annual payment of $1.84 per share, which amounts to a dividend yield of 3.23% at the current share price. Today, the healthcare giant pays investors an annual dividend of $2.04 per share, representing a yield of 2.15%. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) has also placed an important focus on dividends, lifting its payments for 51 straight years. Nothing is 100% certain, of course, but you can increase your chances of long-term dividend growth by choosing companies with a track record of dividend increases. This classic dividend stock offers a total annual payment of $1.84 per share, which amounts to a dividend yield of 3.23% at the current share price. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) has also placed an important focus on dividends, lifting its payments for 51 straight years. But how can you be sure a particular stock will offer you dividend growth over the long term? The company is also a buy thanks to its long track record of earnings growth and ability to keep growing even during tougher economic environments, like the current one. |
30587.0 | 2023-11-09 00:00:00 UTC | Abbott India's Q2 profit climbs on strong sales | ABT | https://www.nasdaq.com/articles/abbott-indias-q2-profit-climbs-on-strong-sales | nan | nan | BENGALURU, Nov 9 (Reuters) - Abbott India ABOT.NS, the local unit of U.S. healthcare firm Abbott Laboratories ABT.N, reported a 17.7% rise in second-quarter profit on Thursday, driven by strong sales in its mainstay pharmaceuticals segment.
Profit for the company, which makes pain-reliever ibuprofen under the brand name Brufen, rose to 3.13 billion rupees ($37.6 million) in the three months to Sept. 30 from a year earlier.
For further earnings highlights, click
KEY CONTEXT
Waning price erosion in the U.S. market, which accounts for a significant share of Indian generic drug-makers' revenue, led to an 8.3% rise in Abbott's revenue, driving up profit.
Peers Cipla CIPL.NS and Dr Reddy's REDY.NS beat analysts' profit estimates while Gland Pharma GLAD.NS missed profit estimates.
Still, Abbott was hurt by production halts in Goa, where it has one of its two India plants, after customer complaints led to a voluntary recall of its antacid syrup starting August and left the company embroiled in a tussle with regulators in the state.
PEER COMPARISON
Valuation (next 12 months)
Estimates (next 12 months)
Analysts' sentiment
RIC
PE
EV/EBITDA
Revenue growth
profit growth
Mean rating*
# of analysts
Stock to price target**
Div yield (%)
Abbott India Ltd
ABOT.NS
43.18
31.48
12.63
17.51
Buy
7
1.05
0.74
Gland Pharma Ltd
GLAD.NS
25.72
16.30
25.47
16.49
Buy
16
1.00
-
Cipla Ltd
CIPL.NS
24.21
14.42
10.53
17.96
Buy
35
1.00
0.68
Dr Reddy's Laboratories Ltd
REDY.NS
17.72
10.95
8.03
7.18
Hold
37
0.97
0.73
* Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell
** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT
JULY-SEPT STOCK PERFORMANCE
-- All data from LSEG
-- $1 = 83.2540 Indian rupees
JULY-SEPTEMBER STOCK PERFORMANCE ABBOTT https://tmsnrt.rs/47ncOqi
(Reporting by Varun Vyas in Bengaluru; Editing by Janane Venkatraman)
((varunvyas.hebbalalu@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | BENGALURU, Nov 9 (Reuters) - Abbott India ABOT.NS, the local unit of U.S. healthcare firm Abbott Laboratories ABT.N, reported a 17.7% rise in second-quarter profit on Thursday, driven by strong sales in its mainstay pharmaceuticals segment. Profit for the company, which makes pain-reliever ibuprofen under the brand name Brufen, rose to 3.13 billion rupees ($37.6 million) in the three months to Sept. 30 from a year earlier. Still, Abbott was hurt by production halts in Goa, where it has one of its two India plants, after customer complaints led to a voluntary recall of its antacid syrup starting August and left the company embroiled in a tussle with regulators in the state. | BENGALURU, Nov 9 (Reuters) - Abbott India ABOT.NS, the local unit of U.S. healthcare firm Abbott Laboratories ABT.N, reported a 17.7% rise in second-quarter profit on Thursday, driven by strong sales in its mainstay pharmaceuticals segment. Peers Cipla CIPL.NS and Dr Reddy's REDY.NS beat analysts' profit estimates while Gland Pharma GLAD.NS missed profit estimates. Revenue growth profit growth Mean rating* # of analysts Stock to price target** Div yield (%) Abbott India Ltd | BENGALURU, Nov 9 (Reuters) - Abbott India ABOT.NS, the local unit of U.S. healthcare firm Abbott Laboratories ABT.N, reported a 17.7% rise in second-quarter profit on Thursday, driven by strong sales in its mainstay pharmaceuticals segment. Peers Cipla CIPL.NS and Dr Reddy's REDY.NS beat analysts' profit estimates while Gland Pharma GLAD.NS missed profit estimates. Revenue growth profit growth Mean rating* # of analysts Stock to price target** Div yield (%) Abbott India Ltd | BENGALURU, Nov 9 (Reuters) - Abbott India ABOT.NS, the local unit of U.S. healthcare firm Abbott Laboratories ABT.N, reported a 17.7% rise in second-quarter profit on Thursday, driven by strong sales in its mainstay pharmaceuticals segment. Peers Cipla CIPL.NS and Dr Reddy's REDY.NS beat analysts' profit estimates while Gland Pharma GLAD.NS missed profit estimates. 25.72 16.30 25.47 16.49 Buy 16 1.00 - Cipla Ltd |
30588.0 | 2023-11-09 00:00:00 UTC | BD beats quarterly revenue estimates on strong demand for medical devices | ABT | https://www.nasdaq.com/articles/bd-beats-quarterly-revenue-estimates-on-strong-demand-for-medical-devices | nan | nan | Nov 9 (Reuters) - Becton Dickinson BDX.N reported fourth-quarter revenue above Wall Street estimates on Thursday, helped by strong demand for its drug-delivery devices and surgical equipment.
The company manufactures and distributes medical and surgical products such as needles, syringes and sharps disposal units.
The company reported a 6.8% rise in quarterly revenue to $5.09 billion, marginally ahead of analysts' average estimate of $5.02 billion, according to LSEG data.
BD joined a list of companies that have benefited from a recent boost to medical technology businesses, including larger rivals Abbott Laboratories ABT.N and Boston Scientific BSX.N, as more people, especially older patients, opted for surgeries they put off during the pandemic.
Becton's largest unit, which makes devices to administer drugs, reported a 7.5% rise in sales to $2.55 billion, largely in line with analysts' average estimate.
The company's interventional unit, through which it offers surgical and critical care devices, recorded sales of $1.20 billion, beating estimates of $1.16 billion.
On an adjusted basis, the company reported a profit of $3.42 per share in the quarter ended Sept. 30, narrowly missing analysts' estimate of $3.43 per share.
The New Jersey-based company now expects an adjusted profit of $12.70 to $13.00 per share for the fiscal year 2024, compared with analysts' average expectation of $13.50 per share.
The company said its profit forecast includes impact from the divestiture of its surgical instrumentation platform which was sold to Steris STE.N in June.
(Reporting by Christy Santhosh in Bengaluru; Editing by Maju Samuel)
((Christy.Santhosh@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | BD joined a list of companies that have benefited from a recent boost to medical technology businesses, including larger rivals Abbott Laboratories ABT.N and Boston Scientific BSX.N, as more people, especially older patients, opted for surgeries they put off during the pandemic. Nov 9 (Reuters) - Becton Dickinson BDX.N reported fourth-quarter revenue above Wall Street estimates on Thursday, helped by strong demand for its drug-delivery devices and surgical equipment. Becton's largest unit, which makes devices to administer drugs, reported a 7.5% rise in sales to $2.55 billion, largely in line with analysts' average estimate. | BD joined a list of companies that have benefited from a recent boost to medical technology businesses, including larger rivals Abbott Laboratories ABT.N and Boston Scientific BSX.N, as more people, especially older patients, opted for surgeries they put off during the pandemic. The company reported a 6.8% rise in quarterly revenue to $5.09 billion, marginally ahead of analysts' average estimate of $5.02 billion, according to LSEG data. Becton's largest unit, which makes devices to administer drugs, reported a 7.5% rise in sales to $2.55 billion, largely in line with analysts' average estimate. | BD joined a list of companies that have benefited from a recent boost to medical technology businesses, including larger rivals Abbott Laboratories ABT.N and Boston Scientific BSX.N, as more people, especially older patients, opted for surgeries they put off during the pandemic. The company reported a 6.8% rise in quarterly revenue to $5.09 billion, marginally ahead of analysts' average estimate of $5.02 billion, according to LSEG data. The company's interventional unit, through which it offers surgical and critical care devices, recorded sales of $1.20 billion, beating estimates of $1.16 billion. | BD joined a list of companies that have benefited from a recent boost to medical technology businesses, including larger rivals Abbott Laboratories ABT.N and Boston Scientific BSX.N, as more people, especially older patients, opted for surgeries they put off during the pandemic. Nov 9 (Reuters) - Becton Dickinson BDX.N reported fourth-quarter revenue above Wall Street estimates on Thursday, helped by strong demand for its drug-delivery devices and surgical equipment. The company reported a 6.8% rise in quarterly revenue to $5.09 billion, marginally ahead of analysts' average estimate of $5.02 billion, according to LSEG data. |
30589.0 | 2023-11-08 00:00:00 UTC | Globus Medical (GMED) Q3 Earnings Top Estimates, Margins Down | ABT | https://www.nasdaq.com/articles/globus-medical-gmed-q3-earnings-top-estimates-margins-down | nan | nan | Globus Medical, Inc. GMED reported adjusted earnings per share (EPS) of 57 cents in the third quarter of 2023, beating the Zacks Consensus Estimate by 5.6%. The metric increased 14% year over year.
The adjusted EPS excludes certain non-recurring expenses and benefits like the amortization of intangibles, acquisition-related costs/licensing and provision for litigation, among others.
Without adjustments, the company registered a GAAP EPS of 1 cent, down from the year-ago EPS of 47 cents.
Revenues
Worldwide sales in the quarter under review totaled $383.6 million, up 50.9% year over year. The reported figure exceeded the Zacks Consensus Estimate by 42.4%.
Excluding business from the newly acquired NuVasive, worldwide net sales totaled $281.2 million, an increase of 10.7% year over year.
Quarterly Details
During the quarter under review, net sales generated in the United States increased 42.5% year over year to $309.3 million. Internationally, revenues surged 100.2% to $74.3 million, up 96% year over year at CER.
Through its product category, Musculoskeletal Solutions generated revenues of $347.5 million, up 51% year over year. Growth was led primarily by the company’s spine and trauma businesses’ performance.
Enabling Technologies' product revenues of $27.7 million in the quarter improved 14.8% from the prior-year figure. The continued uptake of EGPS and E3D systems drove the year-over-year surge.
Margin
Gross profit in the reported quarter rose 25.6% year over year to $248.2 million. However, gross margin contracted 1306 basis points (bps) to 64.7% on a 139.6% surge in the cost of goods sold to $135.4 million.
SG&A expenses in the reported quarter totaled $156.2 million, up 46.6% from the year-ago quarter’s levels. The increased spending is primarily reflective of additional sales compensation costs from higher volume, higher benefit costs and some additional bad debt expenses.
Globus Medical, Inc. Price, Consensus and EPS Surprise
Globus Medical, Inc. price-consensus-eps-surprise-chart | Globus Medical, Inc. Quote
Research and development expenses increased 56.8% to $29.3 million. According to Globus Medical, the increase in expenses was largely due to additional headcount, primarily in the Spine and Enabling Technologies businesses.
The quarter’s adjusted operating profit fell 13.3% to $62.7 million from the year-ago quarter’s figure. The adjusted operating margin contracted 1212 bps in the quarter to 16.3%.
Cash Position
Globus Medical exited the third quarter of 2023 with cash and cash equivalents and short-term marketable securities of $468.9 million compared with $612.8 million at the end of the second quarter.
Cumulative net cash provided by operating activities at the end of the third quarter was $138.3 million compared with the year-ago figure of $114.5 million.
2023 Guidance
The company updated its 2023 guidance.
The full-year net sales are projected to be $1.55 billion (up from previous guidance of $1.125 billion). The Zacks Consensus Estimate for the same is currently pegged at $1.13 billion.
The company’s adjusted EPS guidance for 2023 was reiterated at $2.30. The Zacks Consensus Estimate for the same is pegged at $2.29.
Our Take
Globus Medical exited the third quarter of 2023 on a bullish note with earnings and revenue beat. The third quarter of 2023 was a defining moment for Globus Medical, as it completed its planned merger with NuVasive to create the most innovative company in the spine industry. During the reported quarter, the legacy Globus business continues to drive share growth across its U.S. spine and trauma portfolios, while the Enabling Technologies business is benefiting from the continued uptake of EGPS and E3D systems. The company continues to witness strong international business growth, driven by further penetration of its focus countries, including Australia, Italy, Belgium, Poland, Austria and Ireland. The raised 2023 revenue outlook instills optimism.
However, escalating costs and expenses are exerting pressure on margins. The contraction of both margins is discouraging, too.
Zacks Rank and Key Picks
Globus Medical currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2 (Buy), reported adjusted EPS of $1.14 in third-quarter 2023, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
Inari Medical, carrying a Zacks Rank #2, reported adjusted EPS of 4 cents in third-quarter 2023, beating the Zacks Consensus Estimate by a staggering 128.6%. Revenues of $119 million outpaced the consensus estimate by 2.3%.
Inari Medical has an estimated earnings growth rate of 725% for the following year. Inari Medical’s earnings surpassed estimates in all the trailing four quarters, the average being 66.8%.
Integer Holdings reported a third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Globus Medical, Inc. (GMED) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
Inari Medical, Inc. (NARI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30590.0 | 2023-11-08 00:00:00 UTC | Analysts Anticipate USMV Will Reach $83 | ABT | https://www.nasdaq.com/articles/analysts-anticipate-usmv-will-reach-%2483 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares MSCI USA Min Vol Factor ETF (Symbol: USMV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $83.20 per unit.
With USMV trading at a recent price near $73.79 per unit, that means that analysts see 12.75% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of USMV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), American Financial Group Inc (Symbol: AFG), and Exxon Mobil Corp (Symbol: XOM). Although ABT has traded at a recent price of $94.80/share, the average analyst target is 25.20% higher at $118.69/share. Similarly, AFG has 24.37% upside from the recent share price of $111.23 if the average analyst target price of $138.33/share is reached, and analysts on average are expecting XOM to reach a target price of $129.44/share, which is 24.21% above the recent price of $104.21. Below is a twelve month price history chart comparing the stock performance of ABT, AFG, and XOM:
Below is a summary table of the current analyst target prices discussed above:
NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
iShares MSCI USA Min Vol Factor ETF USMV $73.79 $83.20 12.75%
Abbott Laboratories ABT $94.80 $118.69 25.20%
American Financial Group Inc AFG $111.23 $138.33 24.37%
Exxon Mobil Corp XOM $104.21 $129.44 24.21%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
Also see:
BDC Investor
PXD Past Earnings
TKR Stock Predictions
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | iShares MSCI USA Min Vol Factor ETF USMV $73.79 $83.20 12.75% Abbott Laboratories ABT $94.80 $118.69 25.20% American Financial Group Inc AFG $111.23 $138.33 24.37% Exxon Mobil Corp XOM $104.21 $129.44 24.21% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of USMV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), American Financial Group Inc (Symbol: AFG), and Exxon Mobil Corp (Symbol: XOM). Although ABT has traded at a recent price of $94.80/share, the average analyst target is 25.20% higher at $118.69/share. | Three of USMV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), American Financial Group Inc (Symbol: AFG), and Exxon Mobil Corp (Symbol: XOM). iShares MSCI USA Min Vol Factor ETF USMV $73.79 $83.20 12.75% Abbott Laboratories ABT $94.80 $118.69 25.20% American Financial Group Inc AFG $111.23 $138.33 24.37% Exxon Mobil Corp XOM $104.21 $129.44 24.21% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Although ABT has traded at a recent price of $94.80/share, the average analyst target is 25.20% higher at $118.69/share. | Three of USMV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), American Financial Group Inc (Symbol: AFG), and Exxon Mobil Corp (Symbol: XOM). Although ABT has traded at a recent price of $94.80/share, the average analyst target is 25.20% higher at $118.69/share. Below is a twelve month price history chart comparing the stock performance of ABT, AFG, and XOM: Below is a summary table of the current analyst target prices discussed above: | iShares MSCI USA Min Vol Factor ETF USMV $73.79 $83.20 12.75% Abbott Laboratories ABT $94.80 $118.69 25.20% American Financial Group Inc AFG $111.23 $138.33 24.37% Exxon Mobil Corp XOM $104.21 $129.44 24.21% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of USMV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), American Financial Group Inc (Symbol: AFG), and Exxon Mobil Corp (Symbol: XOM). Although ABT has traded at a recent price of $94.80/share, the average analyst target is 25.20% higher at $118.69/share. |
30591.0 | 2023-11-08 00:00:00 UTC | Here's Why You Should Retain Align Technology (ALGN) Stock Now | ABT | https://www.nasdaq.com/articles/heres-why-you-should-retain-align-technology-algn-stock-now | nan | nan | Align Technologies ALGN is well-poised for growth in the coming quarters, backed by its expanding its global presence to address the vast untapped demand in the malocclusion space. The company launched its first subscription-based clear aligner program DSP worldwide, which looks encouraging.
Mounting expenses are putting pressure on margins. Strong FX headwind impedes growth.
In the past year, this Zacks Rank #3 (Hold) stock has increased 13.1% compared with the 16.1% rise of the industry and 17.3% growth of the S&P 500 composite.
The renowned medical device company has a market capitalization of $15.13 billion. ALGN projects a long-term estimated earnings growth rate of 17.5% compared with 12.6% of the industry.
Let’s delve deeper.
Upsides
Invisalign’s Untapped Potential: Align Technology is strategically capturing the growing malocclusion market, one of the most prevalent clinical dental conditions in the world. Annually, only 21 million people globally elect treatment by orthodontists. This suggests that a large portion of the patient base is unattended. ALGN also noticed that 90% of this patient base could be treated with Invisalign Clear Aligner.
Align Technology’s Invisalign Clear Aligner received positive feedback so far. Till the end of 2022, over 14 million people worldwide have been treated with the Invisalign System. During the third quarter, Clear Aligner volume for teens increased 9.9% sequentially and increased 8.4% year over year to 221.8 thousand cases, driven by continued strength from Invisalign First.
Invisalign Portfolio Expansion: Align Technology’s Invisalign portfolio offers orthodontic treatment to straighten teeth without metal braces.
In the past couple of years, the company has successfully launched its first subscription-based clear aligner program, the Doctor Subscription Program (“DSP”), worldwide. It introduced DSP in the United States and Canada in 2021 and expanded it to Spain and the Nordic countries in the second quarter of 2023. Align Technology plans to launch DSP in France and the U.K. in the second half of 2023.
Strategic Alliances: Align Technology's slew of strategic alliances looks impressive. The company has well-established relationships with many DSOs, especially in the United States and is continuously exploring collaboration with others that drive the adoption of digital dentistry.
Image Source: Zacks Investment Research
In 2023, in the Americas, Align Technology is focused on reaching young adults as well as teens and their parents through influencer and creator-centric campaigns partnering with leading smile squad creators, including Marshall Martin, Rally Shaw and Jeremy Lin. Each of these creators shared their personal experiences with Invisalign treatment and why they chose to transform their smile with Invisalign aligners.
Downsides
Currency Headwinds: Foreign exchange is a major headwind for Align Technology due to a considerable percentage of its revenues coming from outside the United States (in 2022, 44% of the company’s consolidated revenues came from international regions). Through the first nine months of 2023, the strengthening of the U.S. dollar against nearly every other major currency hampered Align Technology’s revenues in the international markets. This was mainly due to the Fed’s 10 consecutive aggressive hikes in interest rates to tackle inflation since March 2022.
Competitive Landscape: Align Technology faces significant competition from traditional orthodontic appliance (or wires and brackets) players such as 3M’s Unitek, Danaher Corporation’s Sybron Dental Specialties and Dentsply International. The company also competes with products similar to Invisalign Technology, such as the ones from Ormco Orthodontics, a division of Sybron Dental Specialties.
Estimate Trend
The Zacks Consensus Estimate for Align Technologies’ 2023 earnings per share (EPS) has declined from $8.76 to $8.38 in the past 90 days.
The Zacks Consensus Estimate for the company’s 2023 revenues is pegged at 3.86 billion. The projection suggests a 3.3% rise from the year-ago reported number.
Other Key Picks
Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2 (Buy), reported adjusted earnings per share (EPS) of $1.14 in third-quarter 2023, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
Inari Medical, carrying a Zacks Rank #2, reported adjusted EPS of 4 cents in third-quarter 2023, beating the Zacks Consensus Estimate by a staggering 128.6%. Revenues of $119 million outpaced the consensus estimate by 2.3%.
Inari Medical has an estimated earnings growth rate of 725% for the following year. Inari Medical’s earnings surpassed estimates in all the trailing four quarters, the average being 66.8%.
Integer Holdings reported a third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Align Technology, Inc. (ALGN) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
Inari Medical, Inc. (NARI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other Key Picks Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Align Technology, Inc. (ALGN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. | Other Key Picks Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Align Technology, Inc. (ALGN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Align Technology, Inc. (ALGN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. Other Key Picks Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Other Key Picks Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Align Technology, Inc. (ALGN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30592.0 | 2023-11-08 00:00:00 UTC | Inogen (INGN) Q3 Earnings Miss Estimates, Revenues Down Y/Y | ABT | https://www.nasdaq.com/articles/inogen-ingn-q3-earnings-miss-estimates-revenues-down-y-y | nan | nan | Inogen, Inc. INGN incurred an adjusted loss per share of 36 cents for third-quarter 2023, wider than the adjusted loss per share of 18 cents in the year-ago period. The Zacks Consensus Estimate was pegged at a loss of 57 cents per share.
GAAP loss per share for the quarter was $1.97, wider than the year-earlier loss of 42 cents per share.
Revenues in Detail
Inogen registered revenues of $83.9 million for the third quarter, down 20.3% year over year. The figure surpassed the Zacks Consensus Estimate by 3.8%.
On a constant-currency basis, total revenues for the reported quarter decreased 21.5%.
Per management, the year-over-year decrease in the top line primarily resulted from lower domestic business-to-business sales and lower direct-to-consumer revenues. However, this was partially offset by strong growth in rental and international business-to-business sales.
Segmental Details
Inogen derives revenues from two sources — rental and sales.
Rental revenues for the reported quarter grossed $15.9 million, up 8.7% from the year-ago period. Per management, an increase in the total number of rental patients on service resulted in the upside. This figure compares to our Rental revenues’ third-quarter projection of $13.1 million.
Sales revenues were $67.9 million, down 25% from the prior-year quarter. This figure compares to our Sales revenues’ third-quarter projection of $67.2 million.
Revenues by Region & Category
Domestic business-to-business sales for third-quarter 2023 amounted to $17.3 million, down 59.4% on a year-over-year basis. Our projection for the same was $34.7 million.
International business-to-business sales for the reported quarter amounted to $25.6 million, up 69.8% year over year on a reported basis and up 62% on a constant-currency basis. Our model estimate for the metric was $15.2 million.
Domestic direct-to-consumer sales decreased 24.1% year over year to $25.1 million for the quarter. Our estimate for the same was $17.3 million.
Inogen, Inc Price, Consensus and EPS Surprise
Inogen, Inc price-consensus-eps-surprise-chart | Inogen, Inc Quote
Margins
For the quarter under review, Inogen’s adjusted gross profit fell 18.6% from the year-ago period to $37.1 million. However, the adjusted gross margin expanded 96 basis points to 44.2%.
Sales and marketing expenses decreased 22.7% from the year-ago quarter to $26.1 million. Research and development expenses decreased 2% year over year to $4.5 million, while general and administrative expenses increased 15.1% to $17 million. Adjusted operating expenses of $47.6 million decreased 10.4% year over year.
Adjusted operating loss totaled $10.5 million compared with the prior-year quarter’s adjusted operating loss of $7.5 million.
Financial Position
Inogen exited third-quarter 2023 with cash and cash equivalents of $124.6 million compared with $167.7 million at the second-quarter end.
The company ended the quarter with no debt on its balance sheet.
Cumulative net cash used in operating activities at the end of third-quarter 2023 was $0.1 million compared with $22.1 million a year ago.
Guidance
Inogen has reiterated its revenue outlook for the full year.
The company continues to expect its total revenues between $315 million and $320 million. The Zacks Consensus Estimate currently stands at $317.7 million.
Our Take
Inogen exited the third quarter of 2023 with better-than-expected revenues. The robust year-over-year uptick in rental revenues and international business-to-business sales was impressive. The expansion of the adjusted gross margin also bodes well.
In September, Inogen completed the acquisition of Physio-Assist SAS, which expanded its global respiratory care presence by addressing a sizeable, growing and underserved airway clearance market opportunity. On theearnings call management confirmed that it secured the reimbursement approval for Rove 6 in France in August. Inogen is currently focused on introducing Rove 6 to key customers in that market. These developments look promising for the stock.
Yet, wider-than-expected loss per share and dismal year-over-year top-line and bottom-line performances were worrying. A decline in domestic business-to-business and domestic direct-to-consumer sales was concerning as well. Inogen continued to incur operating losses for the third quarter, which did not bode well.
Zacks Rank and Key Picks
Inogen currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted earnings per share (EPS) of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2.
DexCom has a long-term estimated growth rate of 33.6%. DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%.
Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Inogen, Inc (INGN) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Inogen, Inc (INGN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Inogen, Inc (INGN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Inogen, Inc (INGN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Inogen, Inc (INGN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30593.0 | 2023-11-08 00:00:00 UTC | Masimo (MASI) Q3 Earnings Beat Estimates, Margins Fall | ABT | https://www.nasdaq.com/articles/masimo-masi-q3-earnings-beat-estimates-margins-fall | nan | nan | Masimo Corporation MASI delivered adjusted earnings per share (EPS) of 63 cents in the third quarter of 2023, down 37% year over year. The figure beat the Zacks Consensus Estimate by 6.78%.
uThe adjustments include acquisition, integration and related costs, and litigation-related expenses, settlements and awards, among others.
GAAP EPS for the quarter was 20 cents, down 71.4% from the year-earlier figure.
Revenues in Detail
Masimo registered revenues of $478.9 million in the third quarter, down 12.8% year over year on a reported basis. The figure missed the Zacks Consensus Estimate by 4.67%.
The year-over-year decline in the top line primarily resulted from lower revenues from the company’s healthcare and non-healthcare segments.
Per management, shipments of non-invasive technology boards and instruments, excluding handheld and fingertip pulse oximeters, totaled 63,100 in the third quarter of 2023.
Segmental Details
Masimo derives its revenues from two business sources — Healthcare and Non-healthcare.
Healthcare revenues in the third quarter totaled $307.8 million, indicating a decline of 5.9% on a reported basis and 6.1% at constant exchange rate (CER).
Non-healthcare revenues in the third quarter amounted to $171.1 million, implying a decline of 23% on a reported basis and 23.6% at CER.
Margin Analysis
In the quarter under review, Masimo’s gross profit decreased 16.9% year over year to $234.8 million. The gross margin contracted 240 basis points (bps) to 49%.
Selling, general & administrative expenses decreased 10.6% to $156.1 million. Research and development expenses declined 12.4% year over year to $46.5 million. Total operating expenses of $209.6 million decreased 7.9% on a year-over-year basis.
Total operating profit was $25.2 million, indicating a decline of 54% from the prior-year quarter’s level. The operating margin in the third quarter contracted 480 bps to 5.2%.
Financial Position
Masimo exited third-quarter 2023 with cash and cash equivalents of $124.4 million compared with $150.7 million at the end of the second quarter. Long-term debt at the end of third-quarter 2023 was $910.1 million compared with $888.8 million in the previous quarter.
Cumulative net cash flow from operating activities at the end of third-quarter 2023 was $27 million compared with $36 million a year ago.
Guidance
Masimo has provided its outlook for the fourth quarter and revised the same for 2023.
For the fourth quarter, total revenues are projected to be in the range of $526-$576 million. The Zacks Consensus Estimate for the same is currently pegged at $622.64 million.
Healthcare revenues are expected to be between $320 million and $345 million (indicating a decline of 2-9% on both reported basis and at CER), while Non-healthcare revenues are anticipated in the range of $206-$231 million.
Adjusted EPS for the fourth quarter is projected to be in the band of 74-94 cents. The Zacks Consensus Estimate for the same is pegged at $1.36.
For the full year, total revenues are now estimated to be in the range of $2,025-$2,075 million, down from the previous band of $2,100-$2,200 million. The Zacks Consensus Estimate for the same is currently pegged at $2.15 billion.
Healthcare revenues are now expected to be in the $1,255-$1,280 million range (implying a decline of 4-6% on both reported basis and at CER), down from the previous guidance of $1,300-$1,350 million.
Non-healthcare revenues for the year are now expected to be in the band of $770-$795 million compared with the previous guided range of $800-$850 million.
Adjusted EPS for 2023 is now projected in the $2.85-$3.05 range, down from the previously estimated band of $3.35-$3.55. The Zacks Consensus Estimate for the same is pegged at $3.45.
Masimo Corporation Price, Consensus and EPS Surprise
Masimo Corporation price-consensus-eps-surprise-chart | Masimo Corporation Quote
Our Take
Masimo exited the third quarter of 2023 with better-than-expected revenues. The expansion of the company’s installed base was impressive. Management confirmed that the company gained new hospital customers during the quarter, which was encouraging.
On the flip side, lower-than-expected top and bottom-line projections were disappointing. The decline in its Healthcare and Non-healthcare segmental revenues was worrying. The contraction of both margins in the quarter raises concern.
Zacks Rank & Stocks to Consider
Masimo currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR.
Abbott, carrying a Zacks Rank #2 (Buy) at present, reported third-quarter 2023 adjusted EPS of $1.14, which beat the Zacks Consensus Estimate by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Revenues of $10.14 billion outpaced the consensus mark by 3.6%.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%.
DexCom reported third-quarter 2023 adjusted EPS of 50 cents, which beat the Zacks Consensus Estimate by 47.1%. Revenues of $975 million beat the Zacks Consensus Estimate by 4%. The company currently carries a Zacks Rank #2.
DXCM has a long-term estimated growth rate of 33.6%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 36.43%.
Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27 and revenues of $405 million, which beat their respective Zacks Consensus Estimate by 21% and 8.7%. It currently carries a Zacks Rank #2.
ITGR has a long-term estimated growth rate of 15.8%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.98%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Masimo Corporation (MASI) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Masimo Corporation (MASI) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Masimo Corporation (MASI) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Masimo Corporation (MASI) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Masimo Corporation (MASI) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30594.0 | 2023-11-08 00:00:00 UTC | 2 Medical Device Companies Experiencing Strong Demand Even as Weight-Loss Drugs Rise in Popularity | ABT | https://www.nasdaq.com/articles/2-medical-device-companies-experiencing-strong-demand-even-as-weight-loss-drugs-rise-in | nan | nan | There's a growing fear among investors that weight-loss drugs and treatments such as Ozempic could negatively impact many businesses, from food companies to healthcare businesses. But there are a couple of medical device makers that are still seeing strong demand for their products even amid the rising popularity of weight-loss treatments.
DexCom (NASDAQ: DXCM) and Abbott Laboratories (NYSE: ABT) are two businesses that are still doing well. Here's why they could continue to be good buys for the foreseeable future.
1. DexCom
DexCom makes continuous glucose monitoring (CGM) devices that help people with diabetes track their glucose levels. But investors have been concerned that with the rising popularity of drugs that can help with weight loss, including Wegovy and Ozempic, there will be less of a need for CGMs, and that will hurt the growth prospects of a company like DexCom.
But the numbers don't suggest that at all. DexCom reported its third-quarter numbers last month, and revenue of $975 million for the period ended Sept. 30 was up 27% year over year. For the full year, DexCom anticipates that its top line will come in around $3.6 billion, which would represent a year-over-year increase of approximately 24%. It also projects that its adjusted operating margin will be a fairly healthy 19% of revenue.
On the company's earnings call, CEO Kevin Sayer also indicated that a rise in weight-loss drugs that help to curb appetite (also known as GLP-1 drugs) isn't hurting business. "The data clearly show that CGM usage grows faster in GLP-1 users than those who are not on therapy." Whether this pattern continues is the big question, but for now weight-loss drugs may be helping to encourage people to track their glucose levels.
DexCom is down more than 30% from its 52-week high. Now could be a potentially good time for investors to buy shares of this healthcare stock.
2. Abbott Laboratories
A big rival for DexCom is Abbott Laboratories, which also makes CGMs. The company's medical device segment, specifically diabetes care products, is a key source of growth. For the period ended Sept. 30, Abbott reported revenue of $4.2 billion in its medical device segment, which grew at a rate of nearly 17% -- the highest among all of its segments. Sales of its FreeStyle Libre CGM devices were especially strong, coming in at $1.4 billion and growing at a rate of 31%.
Abbott's management sees a similar to trend with respect to CGMs and weight-loss treatment: They are going hand-in-hand with one another. CEO Robert Ford said on the company's earnings call last month that "a recent analysis of our U.S. user base showed that a growing number of Libre users are using Libre in combination with GLP-1 medications as part of a companion therapy approach for managing their diabetes."
The early signs are encouraging for both DexCom and Abbott, indicating that perhaps GLP-1 treatments aren't going to bad news for their respective businesses. But with both stocks down more than 13% this year, investors don't appear to be convinced just yet.
Which stock is the better option for investors?
Trading at 33 times its trailing earnings, Abbott is the more modestly priced stock of the two right now -- DexCom's price-to-earnings multiple is at more than 100, but that should come down as the business continues to grow over the years. Abbott is also the more diversified of the two businesses, with pharmaceutical, nutritional products, diagnostics, and other medical devices also contributing to its top line.
Both stocks could make for good long-term investments, but if you prefer a more pure-play diabetes stock, then DexCom may be the better buy. However, if you want a more diversified healthcare investment, then Abbott could be the optimal choice for your long-term investing strategy.
10 stocks we like better than DexCom
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of November 6, 2023
David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | DexCom (NASDAQ: DXCM) and Abbott Laboratories (NYSE: ABT) are two businesses that are still doing well. But there are a couple of medical device makers that are still seeing strong demand for their products even amid the rising popularity of weight-loss treatments. But investors have been concerned that with the rising popularity of drugs that can help with weight loss, including Wegovy and Ozempic, there will be less of a need for CGMs, and that will hurt the growth prospects of a company like DexCom. | DexCom (NASDAQ: DXCM) and Abbott Laboratories (NYSE: ABT) are two businesses that are still doing well. DexCom DexCom makes continuous glucose monitoring (CGM) devices that help people with diabetes track their glucose levels. Abbott Laboratories A big rival for DexCom is Abbott Laboratories, which also makes CGMs. | DexCom (NASDAQ: DXCM) and Abbott Laboratories (NYSE: ABT) are two businesses that are still doing well. DexCom DexCom makes continuous glucose monitoring (CGM) devices that help people with diabetes track their glucose levels. Trading at 33 times its trailing earnings, Abbott is the more modestly priced stock of the two right now -- DexCom's price-to-earnings multiple is at more than 100, but that should come down as the business continues to grow over the years. | DexCom (NASDAQ: DXCM) and Abbott Laboratories (NYSE: ABT) are two businesses that are still doing well. There's a growing fear among investors that weight-loss drugs and treatments such as Ozempic could negatively impact many businesses, from food companies to healthcare businesses. But with both stocks down more than 13% this year, investors don't appear to be convinced just yet. |
30595.0 | 2023-11-08 00:00:00 UTC | DaVita (DVA) Q3 Earnings & Revenues Top Estimates, Margins Up | ABT | https://www.nasdaq.com/articles/davita-dva-q3-earnings-revenues-top-estimates-margins-up | nan | nan | DaVita Inc. DVA delivered adjusted earnings per share (EPS) of $2.85 in the third quarter of 2023, up 37% sequentially. The figure topped the Zacks Consensus Estimate by 48.4%.
GAAP EPS for the quarter was $2.62, reflecting a surge of 131.9% year over year.
Revenues in Detail
Revenues of $3.12 billion in the third quarter were up by 5.9% year over year. The figure surpassed the Zacks Consensus Estimate by 3.7%.
The top line was driven by solid performances of DaVita’s dialysis patient service revenues and Other revenues.
Segment Details
The company’s dialysis patient service revenues were $2.95 billion, up by 3.7% year over year. This figure compares to our dialysis patient service revenues’ third-quarter projection of $2.89 billion.
Other revenues were $169.4 million, up 65.7% from the year-ago quarter’s figure. This figure compares to our third-quarter projection of $111.9 million.
Per management, the total U.S. dialysis treatments for the third quarter were 7,306,948 or 92,493 per day, on average. This represents a per-day decrease of 0.2% on a sequential basis. Normalized non-acquired treatment growth in the third quarter of 2023 was 0.5% year over year.
As of Sep 30, 2023, DaVita provided dialysis services to around 249,100 patients at 3,053 outpatient dialysis centers, of which 2,694 were U.S. centers while 359 were located across 11 other countries.
During the third quarter of 2023, the company opened a total of five new dialysis centers and closed 15 dialysis centers in the United States. It also acquired two dialysis centers and opened four new dialysis centers outside the United States in the same period.
DaVita Inc. Price, Consensus and EPS Surprise
DaVita Inc. price-consensus-eps-surprise-chart | DaVita Inc. Quote
Margin Details
In the quarter under review, DaVita’s gross profit rose 22.1% to $1.05 billion. The gross margin expanded 450 basis points (bps) to 33.8%.
We had projected 31.9% of gross margin for the third quarter.
General & administrative expenses climbed 3.1% to $376.9 million.
Adjusted operating profit totaled $677.1 million, reflecting a 36.1% uptick from the prior-year quarter’s level. Adjusted operating margin in the third quarter expanded 482 bps to 21.7%.
Financial Position
DaVita exited the third quarter of 2023 with cash and cash equivalents and short-term investments of $461.2 million compared with $339.9 million at the second-quarter end. Total debt (including the current portion) at the end of third-quarter 2023 was $8.39 billion compared with $8.69 billion at the second-quarter end.
Cumulative net cash flow from operating activities at the end of third-quarter 2023 was $1.57 billion compared with $1.22 billion a year ago.
2023 Guidance
DaVita has raised its adjusted EPS outlook for 2023.
Adjusted EPS from continuing operations for the full year is now projected to be in the range of $7.80-$8.30, up from the prior outlook of $7.00-$7.80. The Zacks Consensus Estimate currently stands at $7.39.
Our Take
DaVita ended the third quarter of 2023 with better-than-expected results. The uptick in the company’s overall top line and dialysis patient service and Other revenues during the period was impressive. The sequential improvement of DaVita’s bottom line was also encouraging. The opening of several dialysis centers within the United States and overseas was promising. The expansion of both margins bodes well for the stock. DaVita raising its EPS outlook for the year also raises our optimism.
However, the decline in total U.S. dialysis treatments during the quarter due to a decrease in hospital inpatient revenues was discouraging. The company faced continued cost inflationary pressure, a tight labor market and low unemployment during the reported quarter, which was further concerning.
Zacks Rank and Other Key Picks
DaVita currently carries a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2.
DexCom has a long-term estimated growth rate of 33.6%. DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%.
Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
DaVita Inc. (DVA) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. | A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30596.0 | 2023-11-08 00:00:00 UTC | Accuray (ARAY) Q1 Earnings In-Line With Estimates, Revenues Top | ABT | https://www.nasdaq.com/articles/accuray-aray-q1-earnings-in-line-with-estimates-revenues-top | nan | nan | Accuray Incorporated ARAY reported loss per share of 3 cents for the first quarter of fiscal 2024, narrower than the year-ago period’s loss of 6 cents per share. The metric was in line with the Zacks Consensus Estimate.
Revenues in Detail
Accuray registered revenues of $ 103.9 million in the first quarter of fiscal 2024, up 7.7% year over year. The figure topped the Zacks Consensus Estimate by 6.3%.
The overall top-line growth was aided by robust Products revenues.
At constant exchange rate (CER), net revenues were $102.7 million, representing a 6.5% increase from the prior-year period.
Segmental Details
Accuray derives revenues from two sources — Products and Services.
In the fiscal first quarter, Product revenues improved 19.6% from the year-ago quarter to $53.4 million. This figure compares to our Product revenues’ fiscal first-quarter projection of $50.6 million.
At CER, Product revenues improved 15%.
Services revenues declined 2.6% from the year-ago quarter to $50.5 million. This figure compares to our Services revenues’ fiscal first-quarter projection of $47 million.
At CER, Services revenues were down 1%.
Gross product orders totaled $63.7 million, down 8.8% year over year. This figure compares to our gross orders’ fiscal first-quarter projection of $76.2 million.
Accuray Incorporated Price, Consensus and EPS Surprise
Accuray Incorporated price-consensus-eps-surprise-chart | Accuray Incorporated Quote
Margin Trend
In the quarter under review, Accuray’s gross profit rose 14.2% to $39.5 million. Gross margin expanded 216 basis points to 38%.
Selling and marketing expenses fell 5.1% to $10.2 million. Research and development expenses fell 0.6% year over year to $14 million, while general and administrative expenses went up 9.5% year over year to $13 million. Total operating expenses of $37.3 million increased 1.4% year over year.
Operating profit totaled $2.2 million in the fiscal first quarter against the prior-year quarter’s operating loss of $2.2 million.
Financial Position
Accuray exited first-quarter fiscal 2024 with cash and cash equivalents of $76.9 million compared with $89.4 million at the end of fiscal 2023. Total debt (including short-term debt) at the end of first-quarter fiscal 2024 was $176 million compared with $177.3 million at the fiscal 2023-end.
Cumulative net cash used in operating activities at the end of third-quarter 2023 was $8.6 million against cumulative net cash provided by operating activities of $0.1 million a year ago.
FY24 Guidance
Accuray has reiterated its outlook for fiscal 2024 based on current expectations.
The company continues to expect its fiscal year revenues to be $460 million-$470 million, reflecting year-over-year growth of 3-5%. The Zacks Consensus Estimate is pegged at $465.7 million.
Our Take
Accuray ended the first quarter of fiscal 2024 with an in-line loss per share and better-than-expected revenues. The company’s solid overall top-line results and robust Product revenues were encouraging. Geographically, Accuray’s performance was strong in EIMEA (Europe, India, the Middle East and Africa), China and Japan, which was impressive. The expansion in the global installed base also looks promising. Continued strong demand for Accuray’s CyberKnife, Radixact and TomoTherapy platforms buoy optimism. The gross margin expansion also bodes well.
On theearnings call management confirmed that with the addition of Cenos, the Radixact system will likely ensure that treatments change per the requirement to minimize dose to healthy tissue and personalize treatment. Management also stated that in early October Accuray gained regulatory clearance for its domestic manufactured Tomo C platform focused on the Type B segment in China. These look promising for the stock.
However, dismal bottom-line performances and a decline in gross orders were disappointing. The fall in revenues from the Americas and Asia Pacific (excluding China) and Services revenues were also worrying. The current global geopolitical and inflationary pressure are other challenges the company is navigating through, which is another concern.
Zacks Rank and Stocks to Consider
Accuray currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted earnings per share (EPS) of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2.
DexCom has a long-term estimated growth rate of 33.6%. DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%.
Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Accuray Incorporated (ARAY) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Accuray Incorporated (ARAY) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Accuray Incorporated (ARAY) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Accuray Incorporated (ARAY) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Accuray Incorporated (ARAY) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30597.0 | 2023-11-07 00:00:00 UTC | Medical device maker Zimmer cuts revenue growth forecast as profit beats | ABT | https://www.nasdaq.com/articles/medical-device-maker-zimmer-cuts-revenue-growth-forecast-as-profit-beats | nan | nan | Adds comments from conference call in paragraphs 3,4
Nov 7 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N on Tuesday trimmed its annual revenue growth forecast due to a stronger dollar after topping analysts' estimates for third-quarter profit on robust performance in the medical device maker's knee unit.
Shares of the company fell 3.8% in morning trading after declining about 7% in October on industry-wide concerns over the impact of the soaring popularity of weight-loss drugs.
However, Zimmer played down such concerns and echoed comments from larger peers like Johnson & Johnson JNJ.N that the weight-loss drugs, known as GLP-1s, could help more patients become eligible for orthopedic surgeries in the longer term.
"Once the (knee) cartilage is damaged, there is no recovery...And a drop in weight is not going to cure osteoarthritis," CEO Ivan Tornos said on anearnings call
On an adjusted basis, the company reported a profit of $1.65 per share, compared with analysts' average estimate of $1.60, according to LSEG data.
Larger peers Abbott LaboratoriesABT.N and Boston Scientific BSX.N had also topped quarterly profit estimates on easing staffing shortages and a surge in hospital admissions for elective procedures deferred during the pandemic.
Sales at Zimmer's knees unit rose 7.5% to $706.3 million, compared to analysts' estimate of $702.9 million. That helped cushion a miss at its hips unit, where sales of $465.3 million compared with estimates of $481.7 million.
The Indiana-based company's third-quarter revenue rose 5% to $1.75 billion, in line with analysts' average estimates.
Zimmer had said earlier that it expects second- and third-quarter revenue to be a "little bit lighter" compared to the first quarter.
The hip and knee implant maker cut its full-year reported revenue forecast to a growth of 6% to 6.5% from 6.5% to 7.0% earlier while backing its full-year profit forecast of $7.47 to $7.57 per share.
(Reporting by Christy Santhosh in Bengaluru; Editing by Sriraj Kalluvila)
((Christy.Santhosh@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Larger peers Abbott LaboratoriesABT.N and Boston Scientific BSX.N had also topped quarterly profit estimates on easing staffing shortages and a surge in hospital admissions for elective procedures deferred during the pandemic. Adds comments from conference call in paragraphs 3,4 Nov 7 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N on Tuesday trimmed its annual revenue growth forecast due to a stronger dollar after topping analysts' estimates for third-quarter profit on robust performance in the medical device maker's knee unit. "Once the (knee) cartilage is damaged, there is no recovery...And a drop in weight is not going to cure osteoarthritis," CEO Ivan Tornos said on anearnings call On an adjusted basis, the company reported a profit of $1.65 per share, compared with analysts' average estimate of $1.60, according to LSEG data. | Larger peers Abbott LaboratoriesABT.N and Boston Scientific BSX.N had also topped quarterly profit estimates on easing staffing shortages and a surge in hospital admissions for elective procedures deferred during the pandemic. "Once the (knee) cartilage is damaged, there is no recovery...And a drop in weight is not going to cure osteoarthritis," CEO Ivan Tornos said on anearnings call On an adjusted basis, the company reported a profit of $1.65 per share, compared with analysts' average estimate of $1.60, according to LSEG data. Sales at Zimmer's knees unit rose 7.5% to $706.3 million, compared to analysts' estimate of $702.9 million. | Larger peers Abbott LaboratoriesABT.N and Boston Scientific BSX.N had also topped quarterly profit estimates on easing staffing shortages and a surge in hospital admissions for elective procedures deferred during the pandemic. Adds comments from conference call in paragraphs 3,4 Nov 7 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N on Tuesday trimmed its annual revenue growth forecast due to a stronger dollar after topping analysts' estimates for third-quarter profit on robust performance in the medical device maker's knee unit. "Once the (knee) cartilage is damaged, there is no recovery...And a drop in weight is not going to cure osteoarthritis," CEO Ivan Tornos said on anearnings call On an adjusted basis, the company reported a profit of $1.65 per share, compared with analysts' average estimate of $1.60, according to LSEG data. | Larger peers Abbott LaboratoriesABT.N and Boston Scientific BSX.N had also topped quarterly profit estimates on easing staffing shortages and a surge in hospital admissions for elective procedures deferred during the pandemic. Adds comments from conference call in paragraphs 3,4 Nov 7 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N on Tuesday trimmed its annual revenue growth forecast due to a stronger dollar after topping analysts' estimates for third-quarter profit on robust performance in the medical device maker's knee unit. Sales at Zimmer's knees unit rose 7.5% to $706.3 million, compared to analysts' estimate of $702.9 million. |
30598.0 | 2023-11-07 00:00:00 UTC | OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top | ABT | https://www.nasdaq.com/articles/opko-health-opk-q3-earnings-lag-estimates-revenues-top-0 | nan | nan | OPKO Health, Inc. OPK delivered a loss per share of 11 cents in the third quarter of 2023, flat compared with the year-ago period’s loss per share. However, the figure was wider than the Zacks Consensus Estimate of a loss of 9 cents per share.
Revenues in Detail
OPKO Health registered revenues of $178.6 million in the third quarter, down 0.6% year over year. The figure, however, surpassed the Zacks Consensus Estimate by 2.1%.
Lower revenues from services dragged the overall top line.
Segmental Revenues
OPKO Health manages its operations through two reportable segments – Diagnostics and Pharmaceuticals.
Within the Diagnostics arm, revenues from services amounted to $131.7 million in the reported quarter, down 7.8% year over year, primarily due to lower COVID-19 testing volume and reimbursement. Clinical test reimbursement also decreased due to the mix of testing ordered, partially offset by an increase in clinical test volume. This compares to our projection of $131.3 million from services revenues in the third quarter.
Within the Pharmaceuticals arm, revenues from products rose 25.6% to $40.7 million, primarily on the back of higher sales in OPKO Health’s international operating companies and increased revenues from RAYALDEE sales. This compares to our projection of $41.6 million from product revenues in the third quarter.
Revenues from sales of RAYALDEE in the third quarter of 2023 were $7.3 million, up 5.8% from the prior-year period.
Revenues from the transfer of intellectual property and other totaled $6.2 million, up 37.8% from the prior-year period. This compares to our projection of $8 million of revenues from the transfer of intellectual property and other in the third quarter.
OPKO Health, Inc. Price, Consensus and EPS Surprise
OPKO Health, Inc. price-consensus-eps-surprise-chart | OPKO Health, Inc. Quote
Margin Analysis
In the quarter under review, OPKO Health’s gross profit rose 52.4% to $47.7 million. The gross margin expanded by a huge 929 basis points to 26.7%.
Selling, general and administrative expenses fell 9.3% to $72.3 million. Research and development expenses climbed 3.2% year over year to $19.4 million. Adjusted operating expenses of $91.7 million decreased 6.9% year over year.
Adjusted operating loss totaled $44 million compared with the prior-year quarter’s adjusted operating loss of $67.2 million.
Financial Position
OPKO Health exited third-quarter 2023 with cash and cash equivalents of $138.6 million compared with $108.1 million at the second-quarter end.
Cumulative net cash provided by operating activities at the end of third-quarter 2023 was $10.1 million against cumulative net cash used in operating activities of $63.6 million a year ago.
Guidance
OPKO Health has provided its financial outlook for the fourth quarter of 2023.
For the fourth quarter, it expects total revenues between $170 million and $180 million. The Zacks Consensus Estimate currently stands at $191.3 million.
OPKO Health expects its revenues from services to lie between $126 million and $132 million and revenues from product sales to be in the range of $33 million-$36 million. Other revenues are expected to be between $8 million and $12 million, inclusive of the estimated Pfizer gross profit share of $8 million to $10 million.
Our Take
OPKO Health exited the third quarter of 2023 with better-than-expected revenues. OPKO Health’s confirmation that NGENLA (somatrogon) has been approved in 48 markets, including the United States, Japan, EU Member States, Canada and Australia, looks promising. Also, its continued sales by Pfizer in more than 23 countries, including all priority global markets, raises our optimism about OPKO Health.
In September, BARDA awarded a contract to OPKO Health’s company, ModeX Therapeutics Inc., to advance a platform and specific therapeutic candidates designed to address a range of public health threats in viral infectious diseases. The same month, OPKO Health’s subsidiary, OPKO Biologics, Inc., entered into a Research Collaboration Agreement with Entera Bio Ltd. to develop oral peptide tablet formulations for obesity and intestinal malabsorption syndromes.
During the quarter, ModeX advanced its pipeline of antiviral and immune-oncology programs utilizing its next-generation multispecific antibodies. This month, OPKO Health presented positive late-breaking clinical data on RAYALDEE extended-release calcifediol. These look promising for the stock.
Robust results from the Pharmaceuticals segment, with solid sales of RAYALDEE, are impressive. The company’s continued strength in its oncology business and management’s confirmation that it has finalized new service agreements with several new-launch clients starting in the fourth quarter also augur well. The expansion of the gross margin bodes well.
However, the wider-than-expected loss per share and dismal top-line and bottom-line performances were concerning. Lower Diagnostics revenues were also worrying. The persistent operating loss for OPKO Health also does not bode well for the company.
Zacks Rank and Key Picks
OPKO Health currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
DexCom reported third-quarter 2023 adjusted EPS of 50 cents, beating the Zacks Consensus Estimate by 47.1%. Revenues of $975 million surpassed the Zacks Consensus Estimate by 4%. It currently carries a Zacks Rank #2.
DexCom has a long-term estimated growth rate of 33.6%. DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%.
Integer Holdings reported third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
OPKO Health, Inc. (OPK) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report OPKO Health, Inc. (OPK) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report OPKO Health, Inc. (OPK) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report OPKO Health, Inc. (OPK) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report OPKO Health, Inc. (OPK) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30599.0 | 2023-11-07 00:00:00 UTC | Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q3 | ABT | https://www.nasdaq.com/articles/myriad-genetics-mygn-posts-narrower-than-estimate-loss-in-q3 | nan | nan | Myriad Genetics, Inc. MYGN reported an adjusted loss of 3 cents per share in the third quarter of 2023 compared with the year-ago quarter’s loss of 19 cents. The metric was narrower than the Zacks Consensus Estimate of a loss of 8 cents.
The quarter’s adjustments exclude amortization expenses from acquired intangible assets, transitory costs related to transformation initiatives and equity compensations.
The GAAP loss was 75 cents compared with the prior-year quarter’s loss of 43 cents.
Revenues
Total revenues rose 22.7% year over year to $191.9 million in the quarter under review. The figure topped the Zacks Consensus Estimate by 6.3%.
Testing volumes rose 18% year over year, excluding contributions from the SneakPeek Early Gender DNA Test.
Quarter in Detail
Hereditary Cancer testing revenues rose 23% year over year to $86.5 million.
Pharmacogenomics testing revenue es were $35.7 million, up 8% year over year.
Tumor Profiling testing revenues were down 2% year over year to $30.2 million.
Prenatal testing revenues came in at $39.5 million, up 79% year over year.
Margin Trends
The gross margin in the quarter under review expanded 221 basis points (bps) to 70%.
Research and development expenses rose 17.1% year over year to $24 million. SG&A expenses increased 4.3% to $136.1 million in the reported quarter.
Myriad Genetics, Inc. Price, Consensus and EPS Surprise
Myriad Genetics, Inc. price-consensus-eps-surprise-chart | Myriad Genetics, Inc. Quote
The adjusted operating loss in the quarter was $25.8 million compared with the adjusted operating loss of $45 million in the year-ago quarter.
Financial Position
Myriad Genetics exited the third quarter of 2023 with cash and cash equivalents of $76 million compared with $56.9 million at the end of the second quarter of 2023. At the end of the third quarter, the long-term debt was $38.5 million compared with $38.4 million in the second quarter.
The cumulative net cash used in operating activities at the end of the third quarter was $56.2 million compared with the year-ago cumulative net operating cash outflow of $99 million.
2023 Guidance
Myriad Genetics updated its full-year 2023 guidance.
For 2023, the company now expects revenues in the range of $747 -$753 million (up from the earlier guidance of $730-$750 million). This indicates the projected annual growth of 10-11% over 2022. The Zacks Consensus Estimate for the same is pegged at $739.5 million.
The adjusted earnings per share (EPS) is expected to be in the range of a loss of 33-28 cents (the previous guidance was 36-24 cents). The Zacks Consensus Estimate for the metric is pegged at a loss of 31 cents per share.
2024 Guidance
Myriad Genetics introduces its 2024 revenue guidance, which is expected in the range of $815-$835 million (suggesting a 9-11% growth over the mid-point of the 2023 revenue guidance). The Zacks Consensus Estimate for the same is pegged at $803.1 million.
Our Take
Myriad Genetics exited the third quarter of 2023 with better-than-expected earnings and revenues. The company witnessed a strong testing volume improvement across all its businesses, with the Hereditary cancer testing franchise registering a 23% year-over-year increase — the fifth consecutive quarter of double-digit growth year over year.
In the third quarter, Myriad Genetics added approximately 4,000 clinicians who ordered GeneSight for the first time. In collaboration with Onsite Women’s Health, a leading national provider of breast health services, Myriad Genetics announced the launch of a new breast cancer risk assessment program to help more women understand their breast cancer risk. Expansion of gross margin is encouraging, too. The raised 2023 revenue guidance raises optimism.
The company registered operating loss due to mounting costs and expenses. Foreign exchange headwinds and stiff competition remain a concern.
Zacks Rank and Key Picks
Myriad Genetics currently carries Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR.
Abbott, carrying a Zacks Rank of 2 (Buy), reported adjusted EPS of $1.14 in third-quarter 2023, beating the Zacks Consensus Estimate by 3.6%. Revenues of $10.14 billion outpaced the consensus mark by 3.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term estimated growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%.
Inari Medical, carrying a Zacks Rank #2, reported adjusted EPS of 4 cents in third-quarter 2023, beating the Zacks Consensus Estimate by a staggering 128.6%. Revenues of $119 million outpaced the consensus estimate by 2.3%.
Inari Medical has an estimated earnings growth rate of 725% for the following year. Inari Medical’s earnings surpassed estimates in all the trailing four quarters, the average being 66.8%.
Integer Holdings reported a third-quarter 2023 adjusted EPS of $1.27, beating the Zacks Consensus Estimate by 20.9%. Revenues of $404.7 million surpassed the Zacks Consensus Estimate by 8.7%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 15.8%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 11.9%.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Myriad Genetics, Inc. (MYGN) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
Inari Medical, Inc. (NARI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Myriad Genetics, Inc. (MYGN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Myriad Genetics, Inc. (MYGN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Myriad Genetics, Inc. (MYGN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Myriad Genetics, Inc. (MYGN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.